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INTRODUCTION
Ronnie received the hepatitis B (hepB) shot the day before Halloween. He al-
most died by Christmas. He was diagnosed with a rare and life-threatening
form of arthritis. It was not long before Ronnie's parents suspected that the
shot they gave to their son to protect him had exposed and would subject him
to a life of chemotherapy, pain and suering. While his arthritis is currently
stabilized, Ronnie will need medication as long as he lives and his parents must
live with the uncertainty as to whether their son's deterioration will continue.1
120/20: Who's Calling the Shots (ABC television broadcast, Jan. 22, 1999) (ABC tran-
script number 1898).
3At six years of age, Katherine lies in a bed in Skokie Illinois, unable to lift
her head o her pillow or walk to the bathroom. Thirteen weeks before, this
boundlessly energetic ice skater had a dream of going to the Olympics. While
her mother did not want her vaccinated, her pediatrician advised her that it
would be soon mandated. Katherine received the hepB vaccine. Now, she may
never skate again. While her pediatrician, her state health department, the
Centers for Disease Control (CDC) and the American Academy of Pediatrics
(AAP) all recommended that Katherine be vaccinated, none of these entities
will be required to help Katherine's mother carry her daughter up the stairs so
that she can use the bathroom or pay for her medical care when her insurance
runs out.2
Lyla Rose Belkin was a lively and alert ve week old baby when her mother last
held her in her arms. Her mother never imagined that her daughter would die
within hours after receiving a hepB shot. Lyla had received her rst hepB shot
at 6 days old. Soon after her second shot, one month later, Lorna Belkin found
her daughter pale and cold. At her nal feeding that night, she was agitated
and feisty. Sixteen hours after the vaccination, she fell asleep never to wake up
again. The autopsy of her body ruled out choking as the cause of death and her
swollen brain was the only abnormal nding. Lyla Belkin's death was attributed
to Sudden Infant Death Syndrome (SIDS), a broad category or catch-all diag-
nosis when unexplainable childhood mortality takes away an otherwise healthy
baby. The most abused diagnosis in pediatric pathology, SIDS is virtually un-
2Barbara Loe Fisher, Co-Founder & President, National Vaccine Information Center, State-
ment made to the Illinois Board of Health , in a hearing, titled, \Hearing on Immunization
Rules and Proposed Changes" (March 26, 1998) [hereinafter Fisher Statement].
4heard of when the infant is younger than one year of age.3
As Lyla's, Katherine's and Ronnie's parents agonize over what they could have
done dierently, their parental instincts keep on returning to the medical event
which preceded the death of their children. While doctors scoed at Michael
Belkin's hypothesis of what may have caused the shocking death of his inno-
cent and healthy daughter, Michael's internal voice found support in substantial
research present on the Internet and Medline. He discovered that hepatitis B
mainly infects intravenous drug users, homosexuals, prostitutes and promiscu-
ous individuals because it is most commonly transmitted by blood, promiscuous
behavior or dirty needles. As a result of self-motivated investigation, Michael
Belkin and several similarly aected parents are beginning to question how a
newborn baby could possibly contract hepatitis B if the mother was screened
and tested negative, as Michael's wife was. Unless it is possible for a newborn
child to have unprotected sex or share needles with an infected junkie, Michael
learned that it is extremely unlikely for a newborn, like Lyla, to get the disease.
Through the tribulations of experience, many parents, like Michael, wish that
they had not followed the CDC's endorsement and state wide mandates of hepB
vaccination in newborns and young children and had known that their children
had a.001% chance risk of contracting the disease against which they had vacci-
nated their children. While these wishes come too late for protecting the health
of their own children, these parents are determined to realize their wishes in the
promising lives of other parents' children by questioning the safety of the hepB
3Michael Belkin, Mindless Vaccination Bureaucracy, at
<http://www.909shot/com/belkin.html> [hereinafter Belkin].
5vaccine.
Every day, in clinics and doctor oce's nationwide, children are being vaccinated
to protect them from disease. Parents trust that these immunizations and the
health bureaucracy endorsing them will save their children's lives, not curtail or
destroy them. Public health campaigns to control hepatitis B through manda-
tory childhood vaccination programs have instigated a vocal backlash from par-
ents and victims who believe that the vaccine is causing more harm than science
knows or public authorities will admit. Because of conicting reports as to the
actual incidence of hepatitis B in the United States and because the vaccine
was developed for those engaging in high risk behaviors, including drug users
and sexually promiscuous individuals, eorts to require administration of the
vaccine to most, if not all, of the U.S. population has become controversial. The
controversy has been intensied by an increasing number of adverse reactions,
particularly autoimmune in nature, reported in connection with the vaccine and
the increasing number of states which have mandated childhood vaccination as
a condition for school admission. Recently, an alliance of 15,000 anti-vaccine
activists and injured patients in France led a lawsuit against the French gov-
ernment and vaccine manufacturers, accusing them of understating the risks and
exaggerating the benets of the vaccine for the average person. While health
authorities in France, responding to concerns, have ended their mandatory hep-
atitis B vaccination program for eleven and twelve year old children, the CDC
continues to call for the universal immunization of children up to eighteen years
of age. Moreover, the U.S. federal health bureaucracy is currently devoting
6much of its resources to expanding and enforcing its mass vaccination policies,
rather than to eectively evaluating the adverse cases reported or genetic groups
possibly at risk for responding adversely to the hepB vaccine.
If the vaccine is causing the adverse events which are being notoriously as-
cribed to it, then it had made a grave error in choosing to victimize Bohn
Dunbar, brother of Bonnie Dunbar, professor of Cell Biology at Baylor College
of Medicine in Texas. Contrary to being an anti-vaccine advocate, Dr. Dun-
bar has devoted and continues to devote her life's work to developing vaccines.
She is a research scientist and medical professor who has a distinguished 25
year career in academic and laboratory science and has specialized in areas of
autoimmunity and vaccine development. Honored in 1994 by the National Insti-
tutes of Health as the \First Margaret Pittman" lecturer for her pioneering work
in contraceptive vaccine development, this pioneer has ignited a growing spark
among a number of scientists to join consumer advocates, patient-rights groups
and undiagnosed patients in a crusade against the hepB vaccine. Together they
are searching for answers to questions looming over the vaccine's safety, which
they contend is given to so many children in the dark without adequate study
and understanding. Though a developer of contraceptive vaccines herself, Dr.
Dunbar is a forceful critic. Her skepticism, like that of many others, was induced
through personal experience with the vaccine's possible consequences.
Dr. Dunbar began investigating the safety of the hepB vaccine after both her
brother and research assistant developed autoimmune and neurological dysfunc-
tions following the hepatitis B vaccinations they were required to obtain. These
7two individuals remain permanently debilitated from autoimmune side eects
allegedly caused by this vaccine. Knowing her brother's complete health his-
tory, she watched her once active and healthy brother transform into someone
she had never known. Following his hepB vaccination, he began suering from
serious rashes, joint pain, chronic fatigue, and multiple sclerosis like symptoms.
He has now been armatively diagnosed with POTS (an autoimmune cardio-
vascular neurological problem). His problems have been attributed to the hepB
vaccine by over ten dierent specialists of unquestionable medical authority. At
about the same time, a twenty-one year old medical student beginning work in
Dr. Dunbar's lab was required to receive the vaccine. She experienced fever and
fatigue after her rst injection. Three weeks following her second injection, she
lost vision in one eye. While she regained most of her vision six months later,
she had to revisit the hospital for two months after receiving the third dose of
the vaccine. Assured by her doctor that she was given the safest of all vaccines,
her aspirations for pursuing her life long dream of becoming a doctor have now
grown dim as she remains completely blinded in one eye.4
An expert in this area, Dr. Dunbar was astonished by how two previously active
and healthy individuals working in her laboratory developed autoimmune syn-
dromes at the same prolonged immunological time frame following their booster
injections to the hepB vaccine. These personal contacts with the health risks as-
sociated with the hepB vaccine have incited her to delve deeper into the trenches
4Dr. Bonnie Dunbar, Molecular Biologist, Baylor College of Medicine, Tes-
timony before the Subcommittee on Criminal Justice, Drug Policy and Hu-
man Resources Committee on Government Reform (May 18,1999), available at
<http://www/house.gov/reform/cj/hearings/5.18.99/Dunbar.htm> [hereinafter Dunbar's
Testimony].
8of the vaccine's possible dangers. Consequently, Dr. Dunbar has been collecting
data on the hepatitis B vaccine for the past few years, including investigating
the more than 20,000 reports of adverse reactions led with the FDA's Vaccine
Adverse Event Reporting System (VAERS). During the course of her research,
Dr. Dunbar has also been contacted by hundreds of doctors and patients around
the world who have reported severe autoimmune and neurological complications
to the hepatitis B vaccine in previously healthy children and adults, especially of
Caucasian origin. Such reactions have included serious rashes, fever, joint pain,
chronic fatigue, MS, lupus like symptoms, rheumatoid arthritis and neurological
dysfunctions. Dr. Dunbar and other scientists hypothesize that genetic factors
are implicated in the reactions reported to the vaccine. In investigating this
hypothesis she, and many others following in her inquisitive path, have found
that pre-licensure studies on the vaccine's safety were inadequate as have been
the long term follow up clinical trials heretofore conducted. Moreover, all of
the studies to date that have been touted for the vaccine's long term safety
have been in genetic population groups and for a duration of time for which one
would not expect to nd the ominous autoimmune side eects allegedly caused
by this vaccine. Interestingly, the side eects reported as a consequence of this
vaccine are similar in nature, if not identical, to those pervading vaccine pack-
age warning inserts often not disclosed to patients.5 Dr. Dunbar and others
regard these ndings, rather than the temporal relationship between the hepB
vaccine and adverse reactions following its administration, to be an \amazing
5Id.
9coincidence."
Although the stakes are always signicant in vaccination disputes, the hepatitis
B vaccine controversy has an added importance. The vaccine is the rst to
implement recombinant DNA technology so as to produce a vaccine containing
a surface protein of the virus molecule it is administered to protect against. Pa-
tients who have the hepatitis B disease or respond adversely to the vaccine show
similar reactions. New theories and experiments have been developed that could
explain the autoimmune reactions purportedly caused by this virus or the viral
protein used in the vaccine. Given the severe nature of reactions reported to
this vaccine, their rarity in the population at large, and their increasing preva-
lence among specic genetic population groups vaccinated, Dr. Dunbar has
proposed to study the mechanisms of post-vaccination autoimmune responses
and to identify autoantibodies that might be held in common among vaccine
recipients. She intends to determine possible diagnostic as well as therapeutic
strategies for those likely to be or are already responding adversely to the hepB
vaccine.6
Charging by Dr. Dunbar's side in this morally questionable national exper-
iment is Barbara Loe Fisher, president of the National Vaccine Information
6Dr. Dunbar's Proposal to the NIH for funding. Proposal obtained from Dr. Dunbar, but
is available at http://webpages.netlink.co.nz/ias/dunabar.htm> citations omitted [here-
inafter Dunbar's Proposal]. The studies outlined in her proposal would address her hypothesis
that recombinant HBsAg (the surface protein of the HBV contained in the vaccine) can act as
a molecular mimic to induce severe autoimmune reactions in genetically susceptible hepB vac-
cinated individuals or can generate anti-idiotypic antibodies with similar eects. Her research
would also provide new insights into the predictability of adverse side reactions to the hepB
vaccine in individuals of specic histocompatibility subtypes. Her studies would be unique in
following the onset of human autoimmune disorders for the further identication of specic
autoantibodies to \self" epitopes that could provide a mechanism for specic immunotherapy
in patients who have been adversely aected by this vaccine or who are suering from other
autoimmune diseases.
10Center (NVIC) child advocacy group. Her once healthy son was diagnosed with
immune system dysfunction, multiple learning disabilities and attention decit
disorder soon after receiving the DPT (Diptheria-Pertussis-Tetanus) vaccine.
Armed with federal statistics and personal stories of thousands of adverse reac-
tions reportedly caused by this vaccine, Barbara Fisher and many of her sup-
porters are demanding that parents be allowed to make a rational, informed,
voluntary decision as to which diseases and vaccines parents will subject their
children to in our country's battle against disease.
Public health authorities have yet to concede to this demand. Transcending
this refusal, is the \catch 22" which lies at this controversy's core. Public health
ocials staunchly stand behind this weapon against disease, maintaining that
it is one of the most innocuous and eective vaccines ever devised. Despite
confrontations with regard to its safety, public health authorities nd refuge
in the popular rhetoric that \no conrmed reactions" have been found. How-
ever, no reactions could have been conrmed because no studies to detect them
have been conducted. The abyss of scientic knowledge and research, insulating
this vaccine from attack, has consequently enabled public health ocials to dis-
miss the signicance of reactions reported following the vaccine's administration
as being just coincidentally, rather than causally, related. Following with this
perspective, the NIH has rejected Dr. Dunbar's research proposals, requesting
government funding and support, because epidemiological studies have not yet
\proved" that a causal relationship exists between the vaccine and the adverse
11events reported.7 This lack of proof is very much the reason why Dr. Dunbar
wants and needs to study this vaccine. Without government backing, she has
been left to fund her research goals privately.
Clearly, individuals need to acknowledge the potential danger that this vac-
cine may pose before money will be spent or valid research conducted to assess
its alleged side eects. Until molecular biologists and neuroimmunologists are
given the chance and encouraged to precisely dene the biological mechanism
for response to vaccination and to develop pathological proles to distinguish
vaccine adverse events from other events, we will not be able to address causal
relationships between vaccines and temporary or permanent health problems.
Moreover, we will not be able to identify those who may be at risk for respond-
ing adversely. Because no follow-up studies have been completed which are
long enough in duration to detect the specic types of responses this vaccine is
purportedly causing and which can identify those individuals who may be genet-
ically susceptible to responding adversely, scientic knowledge currently lacks
an adequate understanding of the mechanisms by which our immune system
responds to the hepatitis B surface antigen, a component of the vaccine and the
virus itself. This lack of adequate study has become especially dangerous and
worrisome given the vaccine's recent imposition on all newborns. The vaccine
was never tested in newborns, no vaccines have ever been mandated at birth
before and newborns have under developed immune systems which can be easily
overwhelmed, shocked and perturbed so as not to be able to function properly
7Personal communication with Dr. Dunbar.
12later in life.
This chasm of knowledge in the scientic compass guiding vaccine develop-
ers, medical providers, and policymakers and the refusal of public health ocials
to acknowledge what science does and does not know about the vaccine and its
risks fuel a concern that the public is being misguided as to the vaccine's safety.
Moreover, this controversy has suggested that adequate systems are not in place
in America's mass vaccination infrastructure to properly evaluate and monitor
reactogenicity to the hepatitis B vaccine. Clearly, it is as much a part of the
duciary relationship of public health ocials to prevent adverse events as it is
to prevent the spread of diseases. Until such ocials do respond appropriately,
the sentiment that children are being involuntarily subjected to a national ex-
periment will continue to permeate the public conscience, however only more
profusely and intensely.
In saturating the vacuum of knowledge and understanding that cushions this
vaccine from censure with the free exchange of information, consumer activist
groups have become pivotal for stimulating public awareness and nourishing
constructive change in our public health landscape. As long as vaccine injury
remains a politically incorrect subject for open discussion and honest scientic
investigation, an understanding of vaccine injury and deaths will continue to
lie in the caskets of those it may have helped to bury and the public's con-
dence in our public health landscape will continue to ferment. Progress in
adverse event reporting, scientic research and data collection can only be re-
alized when eorts in these areas are made an ocial public health policy and
13the information consequently accumulated are believed and truthfully dissemi-
nated among the public. Since vaccine coverage and ecacy depends on public
condence that routine immunizations are safe, there can only be losers in this
politically charged debate if \opposing sides" do not learn to intelligently, truth-
fully and rationally coexist. In light of this reliance, the need to create allies
between consumer advocacy groups and public health ocials cannot be fur-
ther emphasized. Clearly, the U.S. will never be able to win the battle against
disease, when there is discord within its own army.
Neither Dr. Dunbar nor Barbara Loe Fisher advocate halting the hepatitis B
immunization program, especially in certain dened genetic populations. What
they do advocate, however, is that the least toxic and most technologically ad-
vanced vaccines be made available to Americans as a preventative health care
choice, that vaccine risks be fully dened and communicated to the public and
that individuals high with an increased risk for responding adversely be identi-
ed.8 Currently available scientic evidence and reports of adverse events have
undeniably demonstrated the importance of and need for studying hepB vac-
cine side eects in more detail, especially in the Caucasian population groups
in which the vaccine is routinely, if not obligatorily, administered. Scientists,
consumer activist groups, parents and the public, more broadly, are asking or
rather pleading that the government stop, take a step back and study the long
term eects of the hepB vaccine before they are told that it is their patriotic
duty to sacrice the lives of their children in the nation's war against disease.
8Opening Statement by Barbara Loe Fisher at the Institute of Medicine Vaccine Safety
Forum, Workshop on Risk Communication and Vaccination, May 13, 1996 [hereinafter Risk
Communication Workshop].
14Parents who know and love their children most are asking that America listen
to them as voices of children who cannot yet speak. Parents are responsible for
their children's welfare and they, not the government or the vaccine manufac-
turers, will have to bear the burden if their children come home wounded or live
with excruciating grief if they die.
The purpose of this paper is to provide an overview of the issues briey intro-
duced. Based on an evaluation of publicly available information and written
from a consumer's perspective, this paper will present some of the known prob-
lems and most contested issues surrounding the safety of the hepB vaccine,
as it aects U.S. citizens, as well as explore how they are playing out on this
controversy's battleeld. As you read this paper and discover the possible ram-
ications of administering the hepatitis B vaccine, especially among infants and
young children, it is important that you, the reader of this paper and archaeolo-
gist of facts, take a step back and review the artifacts with an open and objective
mind. It is only within this purview that you will be able to appropriately ask
yourself: should I be required to submit myself or my loved ones to this vaccine?
15HEPATITIS B
THE VIRUS
Certain diseases are caused by pathogens, otherwise known as viruses, from
the Latin word for \poison." Viruses cannot reproduce unless present within a
host cell. Outside of a living cell, the virus exists as a macromolecular package,
or virion. The virion contains a small amount of genetic material. The ge-
netic material of the virion is surrounded by a protein capsule, or capsid. Many
viruses, such as the hepatitis B virus (HBV), have a membranous envelope sur-
rounding the capsid, which contains some virus specic proteins. The hepatitis
B surface antigen (HBsAg) is one. This surface antigen is used in the vaccine
and is thought to be related to the adverse side eects which this vaccine has
been alleged to cause.
HBV is an infectious DNA virus of the hepadnavirus family in the Orthohepad-
navirus genus.9 The mature HBV virion is a 42 nm, spherical, double-layered
dane particle containing a partially double stranded circular DNA molecule
having 3200 nucleotides; only a small subpopulation of these heterogeneous
dane particles constitute the infectious form of the virus (which does take other
forms), and is present in the blood of some who have the disease.10
9Geo F. Brooks, Janet S. Butel, L.Nicholas Ornston, JAWETZ, MELNICK & ADEL-
BERG'S MEDICAL MICROBIOLOGY(1995).
10Response sheet to the Hepatitis B virus and Hepatitis B Vaccine \Fact Sheets" distributed
by the Public Health Alert System, prepared by Bonnie Dunbar, Ph.D., Professor, Department
of Cell Biology, Baylor College of Medicine and Sheri M. Skinner, Ph.D., Department of Cell
Biology and member of BCM Safety and Security Committee, Baylor College of Medicine.
Response sheet obtained from Dr. Dunbar and can be requested from the National Vaccine
Information Center [hereinafter Response Sheet]. Authors relied on several authorities in
making their assertions; citations to these references are omitted here. Please refer to response
16TREATMENT FOR HBV
There is no known cure for HBV. Thus, prevention of chronic infection is im-
portant because once a person is infected, there are few treatment options, all
of which are very expensive. The FDA has only approved of two medications
for the treatment of HBV infection, namely interferon-alpha and lamivudine.
Interpheron alpha is administered through injections which have been reported
to produce severe side eects. It is only used on patients with abnormal liver
enzymes. In December of 1998, the FDA approved Lamivudine for treating
chronic HBV in adults. This DNA polymerase inhibitor was originally used for
treating HIV, and unlike interferon alpha, it is available in oral form and has
fewer reported side eects. However, lamivudine poses a signicant risk of viral
mutations that could lead to drug resistance. 11 Additionally, its apparent ef-
fectiveness is diminishing. It is eective in only approximately 40% of patients
with chronic HBV liver disease and not all HBV infected persons are candidates
for treatment. While liver transplantation is an option for those infected pa-
tients suering from advanced liver disease, the availability of organs is limited
and an organ recipient must remain on immunity suppressing drugs for the rest
of his life.12
sheets for further inquiry.
11The Safety of the Hepatitis B Vaccine, American Medical Association, fact sheet available
at < http://wwww.ama-assn.org/med-sci/98jan03.htm> [hereinafter AMA Fact Sheet].
12Harold S. Margolis, testimony before the U.S. Representatives Committee on Government
Reform Subcommittee on Criminal Justice, Drug Policy, and Human Resources (May 18,
1999), available at <http:www.cdc.gov./ncidod/diseases/hepatitis/margolis.htm> [hereinafter
Margolis' Testimony].
17CLINICAL FEATURES
Once exposed to HBV and the virus is transmitted, clinical features of HBV
range from none (50% of cases)  mild (30%)  fulminant death (0.2%). Phys-
ical symptoms may include profound fatigue ( 20% of cases), anorexia/gastric
disturbance (50% of cases), jaundice ( less than 20% of cases), myalgia ( 50%
of cases) and rash (less than 20% of cases).13 Other infected individuals may
experience low grade fever, pain and swelling in the joints, headaches and a
cough that may occur one or two weeks preceding an onset of jaundice and an
enlargement and tenderness of the liver.
As outlined by Stevens and Lowe,14 infection is estimated to be subclinical in
65% of patients, but HBV may cause clinical patterns of infection, which physi-
cians diagnose and classify as acute or chronic hepatitis.
Acute hepatitis B is common among patients who recover from an hepB illness
with jaundice, malaise, and anorexia. Many of such individuals develop lifelong
immunity to the virus.15 The clinical manifestations of acute hepatitis range
from being subclinical in form to culminating into fulminant hepatitic failure
(causing massive necrosis [death] of liver cells) in approximately 2% of cases.16
According to Harrison's Principles of Internal Medicine, in cases of acute hep-
atitis B, \most patients do not require hospital care" and \95% of patients have a
favorable course and recover completely" with the fatality ratio being \very low
13Response Sheet, supra note 10.
14Dunbar's Proposal, supra note 6.
15Id.
16Id.
18( approximately 0.1%)" after experiencing three to four weeks of nausea, fatigue,
headache, arthritis, jaundice and tender liver.17 Those who recover completely
from HBV acquire life-long immunity.18 Dr. Worman, of Columbia University,
estimates that while 90-95% of acutely infected adults recover without sequelae,
about 5-10% of acutely infected adults become chronically infected.19 In clari-
cation of this statistic, Dr. Dunbar asserts that chronicity occurs in less than
5% of acute cases20 and cautions against overstating the signicance of those
acute cases which are later re-diagnosed as constituting the \chronic" form.
she explains that a chronic hepatitis diagnosis should not be perceived as an
all or nothing diagnosis for a manifestation of HBV which is very dangerous.
\Chronicity" is dened as a case in which the virus has not yet been cleared
from the blood six months following exposure.21 Thus, a diagnosis of \chronic"
hepatitis does not necessarily entail the dangerous form usually associated with
this manifestation of the disease.
According to Dr. Worman of Columbia University, the chances of becoming
chronically infected is inversely related to age. He estimates that approximately
90% of infected neonates and 50% of infected young children will become chron-
ically infected, in contrast to the 5% to 10% of immunocompetent adults he
17Barbara Loe Fisher, When It Happens To You or Your child, the Risks Are
100%, THE VACCINE REACTION (newsletter excerpts from Hepatitis B Vac-
cine: The Untold Story, National Vaccine Information Center). Available at <
http://www.909shot.com/newsletterexcerpts.htm > [hereinafter Happens To You].
18Id.
19Howard Worman, M.D., Hepatitis B, available at <
http://cpmcnet.columbia.edu/dept/gi/hepB.html> [hereinafter Worman].
20Response Sheet, supra note 10.
21Response Sheet, supra note 10.
19suspects will be similarly infected with HBV.22
The natural history of chronic HBV infection will vary dramatically between
individuals. Some individuals with chronic hepatitis will develop a condition
commonly referred to as a chronic carrier state, whereby patients are still poten-
tially infectious, but have no symptoms or abnormalities on laboratory testing.
As with other statistics asserted with respect to this disease, authorities vary
in their approximation of what proportion of HBV infected individuals become
carriers of HBV. Moreover, it is important to note that of those who do become
carriers of HBV, not all develop the chronic form. Some authorities estimate
that only 1-5% of adults23 exposed to the virus become \healthy carriers" while
other authorities, such as the Public Health Alert System (PHAS), maintains
that 6% to 10% of those who acquire HBV as adults will become carriers.24
Although PHAS states that 15,000 to 20,000 new carriers develop annually in
the U.S., it is important to understand that if this gure is accurate, it refers
to \healthy carriers."25 These people will have no symptoms and declining,
but continuous infectiousness.26 Moreover, most of these individuals will reach
the end of their lives with little or no damage to their livers, despite the virus
living there.27 Only one-quarter of those carriers who do not recover completely
22Worman, supra note 19.
23Response Sheet, supra note 10.
24Hepatitis B Vaccine Fact Sheet, Public Health Alert System (PHAS), Harris County
Health Department [hereinafter PHAS]. Fact sheet available upon request from the National
Vaccine Information Center.
25Response sheet, supra note 10.
26Report by Dr. Sheri Skinner to the Baylor College of Medicine Safety Committee [here-
inafter Skinner Report], available at <http://webpages.netlink.co.nz/ias/dunbar.html>. Ci-
tations to references relied upon by Dr. Skinner are omitted. Please see the report for more
information about these references.
27Id.
20( fewer that 5% infected with the hepB virus) are in danger of developing life
threatening liver disease later in life (hepatocellular carcinoma).28 To support
the prevalence of the carrier state, PHAS states that over 200 million HBV
carriers are estimated worldwide.29 While this generalized statistic appears
weighty, only.037% of the above gure would be attributable to U.S. residents
and such carriers would constitute only.029% of the U.S. population of over 260
million.30 Thus, while several federal health authorities point to carrier state
gures to support the need for the mass vaccination against the HBV, perhaps,
as Bader points out, percentage gures indicating the approximate number of
patients advancing to carrier state \should not be taught at all; instead, a no-
tation of the fact should be made that chronicity varies widely depending upon
a number of dened and undened factors."31
In addition to possibly becoming a carrier of the HBV, individuals with chronic
hepatitis B may develop clinically insignicant or minimal liver disease and never
develop complications, while others may develop clinically apparent chronic hep-
atitis. Some chronic manifestations, though rare, may even progress into cir-
rhosis, which increases a persons risk of developing hepatocellular carcinoma (
primary liver cancer) later in life. This type of cancer is relatively rare in the
United States, but it is the leading cause of cancer death in the world where
28Skinner Report, supra note 26.
29PHAS, supra note 24.
30Response Sheet, supra note 10. The Authors relied on gures given by Hollinger, F.B.
et. Al., Controlling hepatitis B virus transmission in North America, Proceedings of the
International Conference on Prospects for Eradication of Hepatitis B Virus, VACCINE, 8 (
Suppl.), S-122-S-128 (1990). Hollinger's statement that \Over 75,000 carriers reside in the
U.S." when applied to the statement that \over 200 million carriers are estimated worldwide"
means that 75,000/200,000,000 or.037% of the world's carriers may be attributed to individuals
comprising the U.S. population.
31Skinner Report, supra note 26.
21HBV infection is endemic.32 Generally, this rare type of cancer or other forms of
life threatening liver complications occur in approximately one quarter of those
with the chronic form of HBV.33 While the fact sheet distributed by PHAS
attributes 80% of hepatocellular carcinoma cases to individuals infected with
HBV chronic infection,34 this seemingly large percentage only amounts to ap-
proximately 0.2% of 1% of HBV cases occurring in the U.S. 35
In sum, how do adults, specically, respond to hepatitis B infection?36

50% have low viral growth and an early system response and therefore, de-
velop no symptoms. They resolve or defeat the virus and have lifelong immunity.
37

30% or more experience what they think is the u, also go undiagnosed,
resolve the virus and develop life long immunity.38

Approximately 20% have higher viral growth and a later immune response
so that they get sick enough to be diagnosed as having hepatitis B. However,
32Worman, supra note 19.
33Skinner Report, supra note 26.
34PHAS, supra note 24.
35Response Sheet, supra note 10.
36Skinner Report, supra note 26.
37Id.
38Id.
22the vast majority of these individuals resolve the virus and obtain lifelong im-
munity.39 Rarely do they become chronic carriers (less than 5%) of the virus.40

About 2/10ths of 1% get sick, do not defeat the virus and die of liver com-
plications.41

Approximately 1-5% of adults42 become so-called \healthy carriers." They
have no symptoms but are still able to spread the virus.43
In sum, of the adults who are infected with the virus, almost 95% of them
will recover, most with no symptoms at all and with lifelong immunity to the
virus. Less than 5% will live essentially symptom free, but with declining and
continuous infectiousness. About 1/4th of this 5% will face life threatening liver
complications decades later in life. About 1/5th of 1% of all infected adults will
die soon after becoming infected with the virus.44
MORTALITY
39Id.
40Id.
41Id.
42Id.
43Id.
44Id.
23The Centers for Disease Control, the American Medical Association (AMA),
PHAS, and the Advisory Committee for Immunization Practices (ACIP) assert
that approximately 4,000 to 5,000 people in the U.S. die each year from hepatitis
B related chronic liver disease or liver cancer.45 In clarifying this statement and
depreciating its import, Dr. Dunbar and Dr. Skinner state that these statistics
are representative of HBV related deaths in individuals whose immune systems
were overwhelmed by the virus, were unable to ght the acute infection, and who
died soon after infection (only 1/5th of 1% of all infections) or of approximately
one-quarter of chronically infected individuals who were also immunologically
unable to rid themselves of the virus within six months of exposure and conse-
quently died of cirrhosis or hepatoma some decade after being infected.46 PHAS
also states that 250,000 HBV related deaths are reported annually worldwide.47
Dr. Dunbar and Dr. Skinner explain that even if accurate, the great majority
of these deaths would have occurred among the chronically HBV infected pop-
ulation of the world. Based on the gures given by Hollinger et al. for carriers
residing in the U.S., only.037% of the above gure could be attributed to U.S.
Residents.48
Surely, generalized statistics may be useful for providing a quantitative assess-
45PHAS, supra note 24; CDC, Healthtouch, Hepatitis B Vaccine & Hepatitis B Immune
Globulin, , available at < http://www.healthtouch.com/level/leaets/cdc/cdc176.html>
[hereinafter Healthtouch]; Hepatitis B Virus: A Comprehensive Strategy for Elim-
inating Transmission in the United States Through Universal Childhood Vaccina-
tion: Recommendations of the Immunization Practices Advisory Committee (ACIP),
Morbidity & Mortality Weekly Report ( MMWR) 40(RR-13):1-19 (1991),available at
<http://www.cdc/gov/ncidod/diseases/hepatitis/v40rr13.html> [hereinafter ACIP], citations
omitted. See Source for references relied upon; AMA, supra note 11.
46Response Sheet, supra note 10.
47PHAS, supra note 24.
48Response Sheet, supra note 10.
24ment of the risks which an individual exposed to the HBV faces. However,
a more accurate understanding of this risk for U.S. citizens requires a more
detailed and comprehensive assessment of qualitative factors, at least among
dierent population groups within the U.S., by age of infection, gender, general
health, behavioral proclivities, geographic location, and the general function-
ing of the group's immune system. Of course, a more particularized evaluation
based on individual factors, including the specic functioning of an individual's
immune system, would provide an even better estimate of the health risk posed
to individuals confronted with the virus.
TRANSMISSION
Hepatitis B is not common in childhood and is not highly contagious. Un-
like smallpox or the whooping cough and much like AIDS, hepatitis B is spread
through the blood or bodily uids like semen. Since inoculation of the virus is
thought to occur through breaks in the skin or mucous membranes, many have
characterized HBV as primarily an adult disease, aecting adults engaged in
high-risk behaviors. According to CDC Prevention Guidelines: A Guide to Ac-
tion (1997), a book written by federal public health ocials at the U.S. Centers
for Disease Control (CDC), \the sources of [hepatitis B] infection for most cases
include intravenous drug use ( 28%), heterosexual contact with infected persons
or multiple partners (22%) and homosexual activity (9%)."49 Other populations
49Happens to You, note 17.
25at risk, while to a lesser extent, include health care workers exposed to blood,
patients requiring multiple blood transfusions, sta of custodial institutions and
newborns born to infected mothers.50
In support of the disease's infectivity, the CDC and the PHAS have asserted
that HBV is 100 times more infectious than HIV.51 When asked to support this
assertion, the CDC referred to a 1991 Morbidity and Mortality Weekly Report
(MMWR), stating that the risk of HIV transmission was.3% while the risk of
HBV transmission was 30%.52 However, Dr. Dunbar and Dr. Skinner maintain
that the CDC has failed to provide adequate documentation to substantiate
these gures. Furthermore, this MMWR report, used by the CDC to validate
its gures, relies largely upon anecdotal reports of HBV and HIV transmission
instances ( 24 of the total 44 references were abstracts, letters, editorials or pa-
pers considered to be \anecdotal reports").53 It is interesting to note that the
CDC and other public health organizations have denigrated this type of evidence
when oered to support a possible causal relationship between the hepatitis B
vaccine and the adverse events reported to follow its administration { events
that would trigger a more forthcoming response. Moreover, while this disease is
infectious, as is HIV, and many public health fact sheets list bloodborne, sex-
ual or perinatal routes as means for transmitting HBV, it is important not to
overstate the ease by which HBV can be transmitted through these paths. Ex-
50Id.
51PHAS, supra note 24; CDC, Hepatitis B and the Vaccine that Protects You, available
at <www.cdc.gov/nip/news/vacsafe/htm> [hereinafter CDC Fact Sheet] [ Citations omitted;
please see fact sheet for further inquiry into references relied upon].
52Response Sheet, supra note 10.
53Id.
26posure to HBV through these routes does not necessarily result in transmission
of the virus or result in its infection. Transmission may take place by these
means only if the infectivity of the contaminated material is sucient, which it
frequently is not, and the recipient is suciently immunolgically compromised
so as to be unable to neutralize infection. 54 Only 20% of the U.S. adult popu-
lation encountering HBV are unable to mount a sucient immune response.55
In further support of the disease's infectivity, the CDC has asserted that 5%
or more of U.S. individuals can be expected to be HBV infected.56 Though
grounded in scientic evidence, as opposed to anecdotal reports, some have
nevertheless questioned the validity of this statement. This assertion was based
on a study done by the National Center for Health Statistics, entitled the Na-
tional Health and Nutrition Examination Survey (NHANES II). The values in
these reports were estimates extrapolated from data of 14,488 persons who were
chosen to be representative of the U.S. population. This small sample size
(.000054% of the U.S. population) has led some to question the accuracy of
what it has been purported to represent.57 Even the CDC has alluded to the
limits of relying upon such data. The American Journal of Public Health, which
was written by physicians from the CDC, warned in reference to this statistic
that \While these conclusions may be valid, they fail to provide a context that
takes into account the sample size limitations of NHANES...".58 Therefore,
54Response Sheet, supra note 10.
55Id.
56Dr. Waisbren, Sr., M.D., F.A.C.P.,F.I.D.S.A., Universal Hepatitis B Vac-
cination: A Moratorium Should Be Placed on This Experiment, available at
<http://access1.net/via/VACCINE/hepbmoratorium.html>[hereinafter Moratorium].
57Id.
58Id.
27as explained previously, generalized assertions and statistics, even if technically
true and publicized by public health ocials, should not necessarily be taken at
face value without a more thorough understanding of the context from which
they were derived and are to be applied.
HBV INFECTION IN INFANTS AND YOUNG CHILDREN
Hepatitis B is primarily an adult disease, is not highly contagious, is not
deadly for most who contract it, and is not in an epidemic form in the U.S.
( except among high risk groups). Nevertheless, as of 1991, the Immuniza-
tion Practices Advisory Committee (ACIP) of the CDC recommended that all
infants be injected with the rst dose of the HBV vaccine at birth.59 A simi-
lar recommendation was made by the Committee on Infectious Diseases of the
American Academy of Pediatrics (AAP).60 Such recommendations were made
despite the lack of knowledge about the health or completeness of a baby's im-
mune and neurological systems at birth.61
In justifying the administration of the hepB vaccine among young infants and
children, the ACIP's recommendations warn that in the \United States children
become infected with HBV through a variety of means."62 However, in a 1997
public hearing, Eric Mast, M.D., chief of the surveillance section of the hepatitis
branch of the CDC, admitted that HBV is \not transmitted commonly by casual
59ACIP, supra note 45.
60Happens to You, supra note 17.
61Id.
62ACIP, supra note 45.
28contact."63 The ACIP also asserts that \horizontal transmission of HBV during
the rst ve years of life occurs frequently in populations in which HBV infection
is endemic."64 However, HBV is not endemic in this country. Thus, perinatal
transmission seems to be the only other viable means by which the HBV dis-
ease can be transmitted to babies born in the U.S. According to Harrison's
Principles of Internal Medicine (1994), perinatal transmission of HBV occurs
primarily in infants born to mothers carrying the HBsAg antigen and mothers
with acute hepatitis B during the third trimester of pregnancy or during the
early postpartum period. Although the precise mode of perinatal transmission
is not known, epidemiological evidence suggests that most infections occur at
the time of delivery and are not related to breast feeding.65 Moreover, not all
babies born to HBV infected mothers are consequently infected. According to
the ACIP, the risk of perinatal HBV infection among infants born to HBV-
infected mothers ranges from 10% to 85%, depending on the mother's hepatitis
B antigen status.66
Despite the generalized statistics provided by federal health authorities which
allude to the importance of vaccinating U.S. newborns against a life threaten-
ing risk of contracting HBV, Harrison's Principles of Internal Medicine (1994)
states that perinatal transmission of hepatitis B is \uncommon in North Amer-
ican and western Europe."67 Meheus' study of the prevalence of HBV markers
63Happens to You, supra note 17.
64ACIP, supra note 45.
65ISSELBACHER, BRAUNWALD, WILSON MARTIN, FAUCI, & KASPER, HARRI-
SON'S PRINCIPLES OF INTERNAL MEDICINE 1466 (13th ed. 1994) [hereinafter Princi-
ples of Internal Medicine].
66ACIP, supra note 45.
67Principles of Internal Medicine, supra note 65.
29by race, sex, and age in the U.S. from 1976-1980 supports this contention.68
Thus, \perinatal or childhood transmission of HBV is a minor contributor
to the prevalence of HBV in this part of the world except in specic at-risk
groups."69 While federal health authorities mandate that all babies be vacci-
nated with the hepB vaccine, only some babies born to HBV infected mothers
are at any real risk for contracting HBV.
To suggest that perinatal transmission of HBV in the U.S. is more signicant
than commonly believed, the ACIP states that approximately 150,000 infants
are born to women who have immigrated to the U.S. from areas of the world
where HBV infection is highly endemic.70 However, the CDC fails to qualify
this assertion by indicating what percent of these women transmit the virus to
their infants or what percentage of infants born in the U.S. are born to such
women so as to warrant the hepB vaccination of all U.S. infants. Moreover,
infants born to HBsAg-positive immigrant mothers, like those born to infected
American mothers, can be identied through prenatal screening programs for
selective immunization. While the CDC does refer to an additional potential
threats posed to children born to HBsAg-negative immigrant mothers, namely
from \other HBV carriers in their families or communities,"71 the CDC fails
to point to evidence to substantiate this assertion or explicitly specify how the
virus can be contracted from such individuals. Common scientic opinion main-
tains that one cannot contract or transmit the virus casually.
68Response Sheet, supra note 10.
69Id.
70ACIP, supra note 45.
71ACIP, supra note 45.
30In further support of the mass vaccination of infants, especially newborns, PHAS
states that as many as 90% of infants with perinatal HBV become carriers,72
and 30% to 50% of children infected between the ages of one and ve years
become carriers.73 Although these statistics seem to be potentially worrisome,
the estimated gures of infants born to HBV infected mothers who consequently
become carriers of the virus is low. In the 1988, a few years before the federal
promulgation that newborns be hepB vaccinated, the estimated numbers of
HBV carrier infants resulting from birth to HBV infected mothers by dierent
ethnic/racial origins was, White:0.15%; Black 0.6%; Hispanic 0.5% and Asian:
2.0%.74 Moreover, according to Hollinger et al. (1989), the prevalence of HBV
markers for the HBV antigen in children under twelve years old was only 4.8%,
despite the fact that 3.2% of infants were born to infected Caucasian mothers
and 13.7% of infants were born to infected African-American mothers.75 Fur-
thermore, as the ACIP concedes, more than 90% of perinatal infections and
their contribution to HBV carrier states in the U.S. can be prevented if HBsAg
positive mothers are identied in advance and their infants are given the hepati-
tis B vaccine at birth.76 In light of these studies and the single route by which
HBV is likely to be transmitted to young U.S. children or infants, perinatal
or childhood transmission of HBV was and is still a minor contributor to the
prevalence of hepatitis B in the United States.
72PHAS, supra note 24.
73Id.
74Response Sheet, supra note 10.
75Id.
76ACIP, supra note 45.
31INCIDENCE
As with other statistics pertaining to the HBV disease burden, the broad
range of estimated cases of HBV in this country presents a problem in assessing
the risks of contracting hepatitis B in the U.S so that the potential threat posed
by the disease can be weighed against the benets and risks of administering
the vaccine in the United States. Despite disparate views, several public health
ocials maintain that acute and chronic consequences of hepatitis B infection
are major health problems in the U.S. so as to warrant the mass administration
of the hepB vaccine. The ACIP asserts that the reported incidence of acute
hepatitis B increased by 37% from 1979 to 1989 and further alleges that an
estimated 200,000-300,000 new hepatitis B infections occurred annually during
the period between 1980 and 1991.77 The CDC does not specify whether these
assertions refer to infections which occurred in the United States. Other public
health ocials estimate that at a minimum, there are approximately 140,000 to
200,000 new infections of HBV annually in the United States.78 In similar sup-
port of the prevalence of HBV in this Country, U.S. Hepatitis B vaccine maker
SmithKline- Beecham (SKB) stated in its 1990 hepatitis B vaccine product in-
sert that \the CDC estimates that there are approximately 0.5 to 1.0 million
chronic carriers of the hepatitis B virus in the U.S. and that this pool of carriers
grows by 2% to 3% (12,000 to 20,000 individuals) annually."79 The CDC and
77ACIP, supra note 45.
78PHAS, supra note 24; CDC Fact Sheet, supra note 51; AMA Fact Sheet, supra note 11.
79Happens to You, supra note 17.
32the AMA seem to be in agreement.80
Other scientic authorities, however, deem these statistics to be unsubstanti-
ated and specious. In clarication, Dr. Dunbar and Dr. Skinner suggest that
the estimated numbers of new HBV cases arising the U.S. annually are mislead-
ing, if not wholly inaccurate. Even if these numbers are true, it is important to
note that they refer to all adults, with or without symptoms of the disease, who
encountered the virus and responded in some way to it.81 This is signicant be-
cause almost 95% of the individuals counted in the statistics above will recover,
most without experiencing any symptoms and all developing lifelong immunity
to the virus.82
In addition to being misleading, such statistics are quite inconsistent with other
data representing the incidence of infection in the U.S. during the same time pe-
riod and indicating that HBV infection is not a major concern in this part of the
world except among high risk groups. Historically, the U.S. has had one of the
lowest rates of hepatitis B in the world even before a vaccine was in use (0.1%
to 0.5% of the general population as compared to countries in the Far East and
Africa where the disease aects 5-20% or more of the population).83 Moreover,
the rate of hepatitis B infection in the U.S. has only shown an increasing and
consistent decline. In 1990, a year before the CDC recommended that all chil-
dren be vaccinated with the hepatitis B vaccine, there were only 21,102 total
cases, not cases arising just that year, of hepatitis B reported in the U.S.84 In
80CDC Fact Sheet, supra note 51, AMA Fact Sheet, supra note 11.
81Response Sheet, supra note 10.
82Id.
83Happens to You, supra note 17.
84Id.
331991, the year in which the CDC promulgated the mass vaccination of children,
there were only 18,0003 total cases of hepatitis B reported in the U.S. out of a
total U.S. population of 248 million.85 Moreover, the Morbidity and Mortality
Weekly Report avers that there were less than 14,000 cases of HBV infection in
1992 nationwide.86 In 1996, there were only 10,637 U.S. cases of hepatitis B
reported, with a total of 279 cases reported in U.S. children under the age of
14.87 As demonstrated by these statistics and further supported by the Guide
to Clinical Preventive Services, in the United States \the greatest reported in-
cidence [of hepatitis B] occurs in adults aged 20-39" and \the number of cases
peaked in 1985 and has shown a continuous gradual decline since that time."88
Despite the CDCs contrary insinuations in the statistics which it has oered
to justify the vaccines administration, the CDC has admitted to this apparent
decline. In its October 31, 1997 Morbidity and Mortality Weekly Report, the
CDC stated that \Hepatitis B continues to decline in most states, primarily
because of a decrease in the number of cases among injecting drug users and, to
a lesser extent, among both homosexuals and heterosexuals of both sexes."89
This broad and inconsistent range of estimated HBV cases in the U.S. presents
a problem for determining the risk posed to an U.S. individual exposed to HBV.
This problem is compounded by three apparent additional problems: ( a) the
majority of HBV cases appear to be occur among I-V drug users, sexually
promiscuous persons, and medical contacts who may not necessarily want to
85Id.
86Dunbar's Proposal to the NIH, supra note 6.
87Happens to You, supra note 17.
88Id.
89Id.
34admit the source of their infection and therefore, fail to report their infection;
(b) the genetic predisposition of most who are exposed to the hepatitis B virus
who are able to fend it o without serious illness. Consequently, the numbers of
reported cases may overstate the signicance of the virus's potential for harm in
those exposed to the virus; and (c) contraction of the disease by non-responders
to the vaccine after vaccination. HepB vaccinated individuals may be contribut-
ing to the HBV disease burden by engaging in risky behavior thinking that they
are immune from contracting the disease when they are not.90
Despite the variation in estimated cases of hepatitis B in the United States and
these additional complexities, Dr. Dunbar has composed two tables evaluating
the risk U.S. individuals face when exposed to the HBV virus. Table 1 pro-
vides a summary of the hepB infection status in the U.S. and table 2 estimates
the risks of contracting HBV in the United States. Both tables use the higher
gures of estimated cases cited by federal health authorities. As the following
tables demonstrate, the incidence of the hepatitis B virus in the United States
is low.
TABLE 1: SUMMARY OF HEPATITIS B STATUS IN THE
UNITED STATES91
Values used:
U.S. population of 261,000,000;
HBV incidence: 170,000. This gure represents an average of the 140,000 to
90Dunbar's Proposal to the NIH, supra note 6.
91Response Sheet, supra note 10.
35200,000 infected U.S. individuals as given in the Hepatitis B \Fact sheet," dis-
tributed by the Public Health Alert System92 and posted online by the CDC93
and AMA.94
TOTAL HIGH-RISK
GROUPS95
GENERAL
POPULATION
Total individuals
infected per year:
percentage of
U.S. infected U.S.
population
170,000
(0.065%)
(Percentage of
total U.S. popula-
tion)
100,300
(.038%)
69,700
(.027%)
1. ACUTE96
Subclinical (50%)
(No Symptoms)
85,000
(.033%)
50,150
(0.019%)
34,850
(.013%)
Mild (30%)
(Flu like Symp-
toms)
51,000
(.02%)
30,090
(.012%)
20,910
(.008%)
Severe (20%)
(Hospitalized)
34,000
(0.013%)
20,060
(.008%)
13,940
(.005%)
Death from fulmi-
nant form (.2%)
68
(0.00003%)
40
(0.00002%)
28
(0.00001%)
2. CHRONIC97
Healthy Carriers
(1-5%)
1700-8500
(0.00065% -
0.003%)
1003-5015
(0.00038%-
0.0019%)
697-3495
(.00027%-
0.0013%)
Cirrhosis or Hep-
atoma deaths (
may occur up
to decades af-
ter infection)
(.0025-.0125%)
425-2125
(0.00016%-
0.0008%)
251-1254
(0.0001%-
0.00048%)
175-871
(0.00007%-
0.00033%)
92PHAS, supra note 24.
93CDC Fact Sheet, supra note 51.
94AMA Fact Sheet, supra note 11.
95High risk groups ( sources of infection) include IV drug users (28%), heterosexual contact
with infected persons or multiple partners ( 22%) and homosexual activity (9%). Response
Sheet, supra note 10, citing data obtained from the CDC.
96Id. Blood chemistry of recovered patients returns to normal within six months.
97Id. Virus has not yet been cleared from the blood six months following exposure.
36References for percentages, see footnote.98
98See references cited in Response Sheet, supra note 10.
37TABLE 2: ESTIMATION OF THE RELATIVE RISK OF CONTRACTING
HEPATITIS B IN THE UNITED STATES AND SUFFERING FROM
SEVERE DISEASE OR DEATH AS A CONSEQUENCE
In table 2, Dunbar99 has estimated the relative risk of severe death or disease
from Hepatitis B in the U.S., given the worst and best incidence rates proered
by federal health authorities ( namely 14,000 vs. 300,000 cases). Moreover, she
has assumed that every individual has the same risk (that there is no dierence
in risk between the normal population and individuals comprising high risk cat-
egories, such as drug users). Clearly, the risk would be greatly reduced if the
distinction between the normal population and high risk categories were estab-
lished. Furthermore, the numbers might vary if it was possible to assess how
many non-responders to the vaccine contract the virus and subsequently suer
from serious symptoms or die. Based on these considerations, Dr. Dunbar's
best assessment of HBV risk is outlined in the table below:
Estimated Relative Risk of Severe Disease or Death from Hepatitis
B in the United States
Worst Case Best Case % Infected
CASES PER
YEAR
300,000 (1% of to-
tal population)
14,000 (.005% of
total population)
CASES
RECOVERED
250,000+ 11, 520+ 83% +
HEALTHY
CARRIERS
15,000-30,000+ 750-1400+ 10%+
Fulminant hep-
atitis, cirrhosis
and carcinoma or
Death
2500 116 .83%
99Dunbar's Proposal, supra note 6.
38Estimated Risk
of serious illness
or death ( U.S.
population of
265,000,000)
.0009% .000044%
In table 3, Dr. Skinner has compared the worst case scenario of living with
hepatitis B as compared to suering from an autoimmune disorder, possibly
induced by the hepatitis B vaccine:
Table 3: SYMPTOMS, DURATION AND INFECTIOUSNESS
OF LIVING WITH THE WORST CASE OF A HEPATITIS B IN-
FECTION AS COMPARED TO AN AUTOIMMUNE DISEASE:
THE ILLNESS SYMPTOMS & DU-
RATION
INFECTIOUSNESS
HEPATITIS B {
acute form
Worst Acute form:
nausea, vomiting, low
grade fever, constant
fatigue, may develop
jaundice which fades
along with symptoms
over approximately four
weeks. Must stay home
to recover for a few
months. Fatigue can
last up to a year. Blood
chemistry returns to nor-
mal within six months.
Mothers pass to ba-
bies if they become
infected during third
trimester.
Blood is infectious as
long as viral antigen
is in the bloodstream,
generally for 3 months.
Major danger is to sexual
partner (20% to 70% of
non-immune spouses will
catch it from their in-
fected mate). Less than
1% of other family
members are found
to become infected.
Fetal infection prob-
ably occurs during the
birth canal, or possibly
through the placenta.
Breast milk is an unlikely
source.
39HEPATITIS B |
chronic form
Most do not have symp-
toms, but virus has not
been cleared from the
blood six months fol-
lowing exposure. Ten
to thirty or more years
later, about a quarter of
these people will develop
life threatening cirrhosis
or even more rarely, liver
cancer.
Blood ultimately be-
comes \relatively non-
infectious," but the
individual must still be
careful.
Autoimmune disor-
ders
Depends on sys-
tems aected
 Inammation
of blood vessels
(vasculitis), joints
(arthritis), can
cause disabling pain.
 Attack on the
tissue of the nerves
can cause blind-
ness (optic neuritis).
 Motor function
impairment (multiple
sclerosis, GBS and
other neuropathies).
 Problems
with thinking
and memory.
 Temperature
control problems
 Disabling fatigue
 Eventual fail-
ure of attacked
organs ( diabetes)
 All disorders
are frequently per-
manent, although
some may experience
periods of remission.
Not infectious
40THE HEPATITIS B VACCINE & ITS PROMULGATION
BASIC IMMUNOLOGY
Our immune system saves us from death by infection by initiating responses
to destroy or eliminate invading organisms and toxic molecules produced by
them. Because these immune reactions are destructive, it is essential that they
be made only in response to molecules that are foreign to the host. Occa-
sionally, the immune system will fail to distinguish foreign molecules from self
molecules. This failure will cause it to react destructively against the host's
own molecules, causing an autoimmune disease which can be fatal. Almost any
macromolecule, as long as it is foreign to the recipient, can induce an immune
response. Any substance capable of eliciting an immune response is referred to
as antigen (antibody generator).100
There are two broad classes of immune responses: (1) antibody responses, and
(2) cell-mediated immune responses. Antibody responses involve the induction
of antibodies, small molecules of protein that attack the invading organism.
These antibodies circulate in the bloodstream and permeate other bodily uids.
They bind specically to a foreign substance, or an antigen, that induced them.
By binding to antigens, antibodies inactivate viruses and bacterial toxins by
100MICHAEL ALBERTS, D. BRAY, J. LEWIS, K. ROBERTS, J.WATSON, MOLECULAR
BIOLOGY OF THE CELL (3rd ed. 1989).
41blocking their ability to bind to receptors on host cells. Antibodies can also
destroy invading microorganisms.101 Some antibodies can even react with self
molecules within the organism that produced the antibody so as to cause severe
autoimmune diseases.102
Cell-mediated immune responses involve the production of specialized cells that
react with foreign antigens on the surface of host cells. The cells responsible
for immune specicity belong to a class of white blood cells, known as lympho-
cytes. Cell mediated immune responses involve a class of lymphocytes called
T cells. T cells mediate immune responses against genetically foreign versions
of cell-surface proteins called histocompatibility molecules. The major histo-
compatibility complex (MHC) is a complex of molecules which bind peptide
antigens and present them to T cells for destruction or inactivation. In humans,
the MHC is a cluster of genes. The most important cluster of such genes are
called human leukocyte antigens (HLA) and they encode for proteins in this
complex.103
THE VACCINE
A vaccine is a preparation of weakened or killed viruses or bacteria or highly
puried components of such microorganisms, which may be administered to an
individual to induce immunity against disease. Vaccination rests on the the-
101Id.
102Id.
103Id.
42ory that periodically challenging and articially stimulating the human immune
system with small amounts of inactivated (killed) viruses and bacteria or atten-
uated (partially inactivated) live viruses will force it to produce antibodies that
will confer immunity in the same way that a bout with the natural disease will.
However, vaccines do not work in the body in the same way as a natural disease
does. When bacteria or viruses enter the body and the disease progresses in a
normal fashion, the immune system is stimulated to produce a type of natural
immunity, which is often permanent. Vaccines, on the other hand, which are
often directly injected into the blood or swallowed by mouth, provide, at best,
articial, temporary immunity. Some vaccines fail to provide any immunity at
all.104
The hepatitis B vaccine (generally referred to as \the vaccine" in this paper)
protects against infection with HBV by producing immunity or antibodies to the
surface protein or outer coat of the hepB virus. This outer coat is called hepati-
tis B surface antigen, referred to as HBsAg. The rst vaccine was produced by
purifying this surface protein from the plasma of chronically infected persons.
This plasma-derived hepatitis B vaccine was licensed by the U.S. in 1981 and
was administered to high risk populations in the 1980's, until a genetically en-
gineered, recombinant hepatitis B vaccine was developed. The plasma derived
type is no longer produced in the United States and currently available vaccines
are produced by recombinant DNA technology. These licensed vaccines are de-
104BARBARA LOE FISHER, THE CONSUMER'S GUIDE TO CHILDHOOD VACCINES
(1997).
43rived from hepatitis B surface antigens produced in yeast cells. A portion of the
hepatitis B virus gene is cloned in yeast and the vaccine is produced from cul-
tures of this recombinant yeast strain. Recombivax-HB, manufactured by Merck
Sharp and Dohme (MSD), was licensed in 1986 and Engerix-B, manufactured
by Smith-Kline Biologicals (SKB), was licensed in 1989. Another recombinant
vaccine, Gen Hevac B, manufactured by the Pasteur Institute (PI), is licensed in
France. Because the genetically engineered vaccine was developed only recently,
there is still little known about it.105
The PHAS,106 the AMA,107 and the CDC108 state that the recombinant
vaccine does not contain live components of HBV and thus, protects against
infection from the Hepatitis B virus (HBV). In support of the vaccine's safety
and reliance upon such authorities, several public health authorities have in-
ferred that the vaccine is innocuous because it cannot cause the HBV disease.
True, the recombinant vaccine cannot cause the disease known as hepatitis B,
as the live virus can. However, the recombinant vaccine does contain a protein
that is found on the surface of the virus which initiates immune reactions to
that surface.109 Worthy of attention is the fact that the severe autoimmune
eects allegedly induced by the HepB vaccine are the same as or similar to
those reported as a consequence of (a) infection with HBV, (b) the plasma de-
rived vaccine, and the (c) recombinant vaccine derived from a cloned HBV gene
105Grotto Y. Mandel, M Ephros, I. Ashkenazi and J. Shemer, Major Adverse Reactions to
Yeast-derived Hepatitis B Vaccines|a review, VACCINE, Vol.16, no.4. pp.329-334 (1998).
106PHAS, supra note 24.
107AMA Fact Sheet, supra note 11.
108CDC Fact Sheet, supra note 51.
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44in yeast.110 All three sources contain the HBsAg surface protein. As will be
further discussed, the fact that the yeast derived vaccine has a dierent form
of glycosylation than the native viral protein has suggested to some scientists
that the autoimmune side eects allegedly caused by this vaccine are initiated
by the peptide structure of the HBsAg protein.111 Thus, while the hepatitis B
vaccine cannot produce HBV as we know it, the protein which it contains can
stimulate the immune system in a variety of ways, perhaps even to cause life-
threatening autoimmune conditions, which are in some ways similar and even
more detrimental than those caused by the disease itself.112
VACCINE RECOMMENDATIONS
CDC vaccine recommendations are made through a deliberative process in-
volving advice and guidance from the Advisory Committee on Immunization
Practices (ACIP). This federally chartered, scientic advisory committee pro-
vides the CDC and the Department of Health and Human Services ( DHHS)
with recommendations on how to decrease the incidence of disease through the
use of vaccines and other biological products as well as how to improve the safety
of these products' use.113 Upon being nalized by the ACIP, a vaccination rec-
110Dunbar's Proposal to the NIH, supra note 6.
111Id.
112Response Sheet, supra note 10.
113Dr. Margolis' Testimony, supra note 12. The ACIP currently includes 12 voting members
selected based on their infectious disease expertise, evaluation of vaccine performance and
safety experience and immunization program knowledge. While members of the ACIP come
from a diversity of backgrounds, ACIP meetings are attended by ex ocio members who rep-
45ommendation is submitted to the CDC for consideration. If the agency accepts
the recommendations, the document is edited and published in the Morbidity
and Mortality Weekly Report ( MMWR) as an ACIP recommendation.114
The ACIP rst published recommendations for the HBV vaccine in 1982.
Epidemiological data at this time pointed to adult infections as contributing to
almost all of the HBV disease burden in the U.S.115 As a consequence, the ACIP
recommended that high risk groups be vaccinated, such as health care workers
and hospital sta, clients and sta of institutions for the developmentally dis-
abled, hemodialysis patients, hemophiliacs, homosexuals, household and sexual
contacts of HBV carriers, intravenous drug users, inmates of long-term correc-
tional facilities, Alaskan Eskimos and infants born to women with chronic HBV
infection. Vaccine use became more prevalent as federal health authorities pro-
mulgated its general safety and eectiveness and vaccine manufacturers found
it to be inexpensive to produce. 116
Beginning in 1990, the CDC, FDA, other governmental agencies, non-governmental
investigators, and vaccine manufacturers provided new information pertaining
resent federal agencies, liaison members of professional societies, groups implementing vacci-
nation programs, and the general public. All ACIP meetings are open to the public, providing
time for public comment as well presentations of data from vaccine manufacturer representa-
tives. Vaccine manufacturers are represented at ACIP meetings by the liaison representative
from the Pharmaceutical Research and Manufacturers of America. Vaccine recommendations
initially are drafted by a working group that includes ACIP members, ex ocio and liaison
representatives, vaccine manufacturers and CDC experts. Draft recommendations are sent to
all ACIP members for comment, discussed during public meetings, nalized and adopted by
vote of ACIP members.
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46to the prevalence of the hepB virus and strategies for its eradication. Speci-
cally, the ACIP was presented with data suggesting that the incidence of HBV
had increased during the early 1980's, despite the availability of the vaccine.
According to Dr. Margolis, perinatal and early childhood infections also con-
tributed to a substantial proportion of the chronic hepatitis B disease burden in
the United States at this time.117 However, the ACIP attributed the apparent
increase in the U.S. HBV disease burden to ineectual eorts to vaccinate per-
sons in the major risk groups for contracting the disease. For example, programs
targeting drug users failed to suciently impel them to receive three doses of
the vaccine.118 Additionally, because health care workers were not often aware
or informed of population groups at signicant risk for contracting HBV, they
did not successfully identify candidates for vaccination during routine health
care visits.119 Moreover, many sexual contacts of HBsAg carriers, identied in
screening programs for blood donors, were not vaccinated.120 Despite the regu-
lations implemented to promote hepB vaccination and the ensuing decrease in
the rate of health care worker HBV infection, the overall rate of HBV in the
U.S. seemed to remain unaected.121 Consequently, government health author-
ities believed that regulations had to be developed to ensure implementation of
vaccination programs among those occupationally and behaviorally at risk.122
The ACIP did not believe that educational programs would suciently reduce
117Id.
118ACIP, supra note 45.
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47parenteral drug use and unprotected sexual activity, or fully eliminate other
high{risk behaviors responsible for HBV transmission so as to aect the overall
rate of HBV infection in the U.S.123 Thus, in light of these considerations, the
ACIP advanced in its June 1990, Protection Against Viral Hepatitis recommen-
dations that \for the vaccine to have an impact on the incidence of hepatitis B,
a comprehensive strategy must be developed that will provide hepatitis B vac-
cine to persons before they engage in behaviors or occupations that place them at
risk of infection" (emphasis mine).124 Similarly, in its 1991 recommendations,
the ACIP stated that \since most HBV infections occur among adults, disease
control could be accelerated by vaccinating emerging at-risk populations" and
that \universal infant vaccination would eliminate the need for vaccinating ado-
lescents and high-risk adults."125 Since governmental eorts to vaccinate those
contributing to the HBV burden in the U.S. had essentially failed, the ACIP
decided to immunize young infants as \an alternative to high-risk group vacci-
nation... and as a possible strategy to control transmission of the disease."126
Thus, the CDC endorsed a strategy to eliminate HBV transmission among high-
risk adults by immunizing all infants.
The comprehensive strategy recommended by the ACIP was developed and -
nally published in November 1991. According to Dr. Margolis, this strategy
was subsequently endorsed by the American Medical Association (AMA), the
American College of Obstetricians and Gynecologists, the American Academy
123Id.
124Margolis' Testimony, supra note 12.
125ACIP, supra note 45.
126Margolis' Testimony, supra note 12.
48of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP).
The objective of the strategy was and is currently set \to eliminate transmis-
sion of HBV infection."127 The components of this strategy consisted of 1) the
prevention of perinatal HBV infection by screening all pregnant women and
providing post-exposure immunization to at risk infants of chronically infected
mothers; 2) routine hepatitis B vaccination of infants as part of the childhood
immunization schedule; 3) routine vaccination of adolescents; and 4) vaccina-
tion of adolescents and adults in groups of increased risks for HBV infection.128
Individuals in the last category include:

Sexually active heterosexual adults with more than one sex partner in the
past six months, or that have a history of sexually transmitted disease;

Homosexual and bisexual men;

Illicit injection drug users;

Persons at occupational risk of infection;
127Id.
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49
Hemodialysis patients;

Sexual contacts of persons with chronic HBV infection;

Client and sta of institutions for the developmentally disabled. 129
The ACIP currently recommends that everyone younger than 18 years of age
receive the hepatitis B vaccine. In contrast, the ACIP only specically endorses
the vaccine for adults over 18 who are at risk for contracting HBV.130
Although the following authorities are often cited as supporting the ACIP's
recommendations, Dr. Skinner contacted the following individuals by phone
and asked whether their organizations \recommended" any vaccines. They all
replied in the negative. They recommend vaccination procedures, dependant
upon the populations at risk and the best possible way to cover those popu-
lations. Furthermore, they neither test nor assert the safety or ecacy of any
specic vaccine. When asked as to which authorities they depended upon to
determine vaccine safety, they responded as indicated below:131
129CDC Fact Sheet, supra note 51.
130Id.
131Skinner Report, supra note 26.
50Organization and Spokesperson Their Authority on Safety
American College of
Preventative Medicine
(ACPM) : H.K. Keimowitz,
Exec. Director
(202) 466-2044
CDC, National Coalition for Adult
Immunization
American Medical As-
sociation (AMA)
Mr. Liznicki for Dr. J. Allen, M.D.
(312) 464-4520
CDC, FDA
American Academy of Fam-
ily Physicians (AAFP)
Robert Graham, M.D. Exec. V.P.
(816) 333-9700
Substance is on the market, therefore
must have passed FDA inspection
American College of
Physicians (ACP)
G. Thomason, Scientic Policy Oce
(215) 351-2400 ext. 2847
Substance is on the market
The Federal Drug Administration's (FDA) stamp of approval should not be
taken as the last word on the vaccine's safety. The FDA based its decision to
approve the vaccine upon clinical trials and post-marketing surveillance studies
in which patients and their doctors were asked to report possible adverse eects
experienced in response to the vaccine within four to ve days after each in-
jection [four days for the Smith-Kline and ve days for the Merck vaccine].132
As this paper will later explain, the adverse events reported as being caused
by hepB vaccination appear to be autoimmune in origin. Since such problems
take weeks, if not months, to produce noticeable symptoms, these types of prob-
lems could not have been detected in these clinical and surveillance studies. Dr.
Waisbren has also been especially critical of the FDA's current stance, or rather,
132Id.
51course of inaction. In his testimony before the U.S. House of Representatives
on May 18,1999, Dr. Waisbren inquired why the FDA has not been reacting to
the numerous theories in the medical literature, proposing the means by which
the vaccine may cause neurological complications.133 Concerned that new vac-
cines being developed and marketed may cause similar adverse eects, he also
questions why the FDA has not asked whether vaccines can exhibit molecular
mimicry with human tissue, or whether a vaccine exhibits complimentarity with
common viruses already lying within vaccinated patients. As will be explained,
answers to these questions would address the hypothesized means by which the
vaccine is believed to cause the adverse reactions reported.134 Additionally, he
wonders why the FDA has not demanded that HLA patterns of patients who
have experienced adverse side eects be determined or that synthetic vaccines
containing only immunogenic antigens be produced.135 Concessions to these
requests would be important and extremely benecial in protecting individuals
who may be at a heightened risk for responding adversely to the vaccine. As will
be further discussed in this paper, many scientists believe that only a geneti-
cally susceptible subset of vaccinated individuals will develop adverse responses
to the vaccine and that the protein derived from the hepatitis virus and used in
the vaccine is implicated in this causal relationship.
While similarly cited in support of the vaccine's endorsement, the fact that the
133Burton A. Waisbren, Sr.., M.D., F.A.C.P., F.I.D.S.A., Testimony before the
U.S. House of Representatives Subcommittee on Criminal Justice, Drug Policy and
Human Resources (May 18, 1999) [hereinafter Waisbren Testimony], available at
<http://www.house.gov.reform/cj/hearings/5.18.99/Waisbren.html>.
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52vaccine \is on the market"136 may not be a legitimate source upon which to
rely as evidence of the vaccine's safety. Placing a vaccine out on the market
does allow for the testing of the vaccine's safety in population groups and un-
der circumstances not studied in pre-licensure trials. However, this potentially
useful and important resource of information cannot be relied upon as a valid
source of the vaccine's safety if many of the adverse events reported by \mar-
ket" participants are largely ignored or dismissed by the FDA and other federal
health authorities. For instance, the Institute of Medicine (IOM), of the Na-
tional Academy of Sciences (NAS), only began to examine reports of adverse
eects associated with the hepB vaccines in 1992 after Congress directed them
to, through DHHS.137 DHHS nally responded when unheeded reports turned
into public outcries. Parents could no longer contain their concern about their
children's deteriorating health following their hepB immunization or their frus-
tration with health authorities' failure to acknowledge the signicance of their
reports.
Conicts of interest for these cited authorities may be another important issue
for further research in attempting to adequately understand the vaccine's en-
dorsement. It is well documented that committee members advising the CDC
and members of organizations (such as the AAP and World Health Organi-
zation [WHO] ) obtain substantial funding from pharmaceutical companies.138
Additionally, the lobbyists who consult for the pharmaceutical companies are
136Skinner Report, supra note 26.
137Id.
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53also many times the same lobbyists for medical health care providers.139 More-
over, investigators who have carried out clinical trials on the vaccine's safety
have beneted personally. Some have obtained laboratory funding for acting
as consultants in promoting the vaccine and expert witnesses in legal conicts.
It appears that lack of government funding for independent research has forced
many scientists into these ethical constraints. 140
JUSTIFICATIONS FOR THE STRATEGY TO ELIMINATE HBV
AMONG ADULTS AND HIGH RISK POPULATIONS BY
IMMUNIZING ALL INFANTS AND CHILDREN
Even though hepatitis B is generally an adult disease, is not highly con-
tagious, is not deadly for most who contract it, and is not in epidemic form
in the United States (except for those in high risk groups, such as IV drug
users), federal health authorities, such as the ACIP and the AAP, nevertheless
recommended in 1991 that all infants be injected with the rst dose of the
hepatitis B vaccine at birth before being discharged from the hospital newborn
nursery. This recommendation was given even though the only newborns at
risk for contracting hepatitis B are those born to hepatitis B infected moth-
ers and only a small percentage of babies born in the U.S. will grow up to be
susceptible to contracting HBV. This recommendation is even more surprising
since almost nothing is known about the health and integrity of a baby's im-
mune and neurological systems at birth. One can assume that less is known
about their responses to vaccines. Despite these facts, the ACIP, AMA and
139Id.
140Id.
54CDC generally assert two main reasons why all infants should be vaccinated, as
opposed to only those infants born to mothers who are infected with HBV.141
The following justications are still used today to promote the mass hepatitis
B vaccination campaign for infants and young children. First, some authorities
contend that children bear a large proportion of the U.S. HBV disease burden.
Second, health authorities reason that vaccinating individuals at a young age
could protect them if exposed to HBV infection later in life, since HBV infected
or susceptible individuals failed to voluntarily participate in and comply with
vaccination eorts that targeted them.
Disease burden attributable to young infants and children
In justifying the routine vaccination of all children and adolescents, some
health authorities contend that children comprise a major portion of the HBV
disease burden. The CDC asserts that before the routine infant hepatitis B
immunization policy was instituted, approximately 30,000 infants and children
were infected each year.142 Moreover, they assert that one third of U.S. chronic
HBV infections stem from infected infants and young children.143 The CDC,144
Dr. Margolis,145 and the AMA146 rely on such statistics to suggest that peri-
141see CDC Fact Sheet, supra note 51; ACIP, supra note 45; AMA Fact Sheet, supra note
11.
142CDC, supra note 51.
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55natal and infancy infections contributed to a substantial proportion of the hep-
atitis B disease burden in the U.S., and would do so until this day, if not for
the mass hepB vaccination policy. However, no scientic references are given
to substantiate such assertions.147 Moreover, this statistic is inconsistent when
compared to other studies done and statistics presented, including those made
by the CDC, before the federal policy to vaccinate all newborns and young in-
fants was promulgated (for ease of reference, some of the studies and statistics
previously mentioned in this paper will be repeated here). These alternative
statistics indicate that newborns, infants and young children did not bear, nor
were at risk of bearing, a great hepatitis disease burden in the U.S.
For example, Esteban assessed the risk of acquiring HBV in infancy and child-
hood. He found that for U.S. born mothers (for whom there is a low incidence
of HBV infection), the published rates of perinatal transmission in 1988 by in-
fected mothers was quite low.148
Origin HBsAg
positive
(%)
Number of
Cases Studied
White 0.15 901
Hispanic 0.5 513
Black, U.S. born 0.6 799
Asian, U.S. born 2 118
Other 0.5 78
147In support of the paragraph in which these statistics are contained, the CDC's web-page
cites a paper authored in part by Dr. Margolis (1991) as a reference; however, it is not clear
whether this source is cited as a reference for these assertions specically, as opposed to only
the sentence preceding its notation.
148Response Sheet, supra note 10.
56Similarly, Hollinger et al. 149 found that the prevalence of HBV markers in
children under 12 years of age was low { only 4.8% ( including 3.2% of births
to infected Caucasian mothers and 13.7% born to infected African American
mothers). Mehaues' graph illustrating the prevalence of HBV markers by race,
sex and age in the U.S. from 1976-1980 further supports the conclusions reached
by Hollinger et al. and Esteban, that perinatal or childhood transmission of
HBV was a minor contributor to HBV prevalence in this part of the world,
except in specic high risk groups, in the period preceding the call for the mass
vaccination of all infants and newborns.150
It is unlikely that the estimated 30,000 cases of HBV infected children are
representative of cases that would otherwise arise in the U.S. if not for the mass
vaccination policy, given other statistics oered to represent the same time pe-
riod for which this gure was given. In 1990, a year before the CDC ordered
that all children be vaccinated, there were a total of 21,102 cases of hepatitis B
reported in the U.S. out of a total population of 248 million. In 1991, the year
calling for the vaccination of all infants, there were only 18,003 total cases of
HBV reported in the U.S. of a similar total U.S. population of 248 million.151
According to October 31, 1997 MMWR published data by the CDC, there were
10,637 cases of hepatitis B reported in the U.S. in 1996, with 279 (.02%) cases
reported in children under the age of 14.152 Such statistics suggest that chil-
dren bore an insignicant HBV disease burden. Consistent with the apparent
149Id.
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57decline in the incidence of HBV ( as illustrated by these statistics), the Guide
to Clinical Preventive Services, states that the \greatest reported incidence [of
hepatitis B in the United States] occurs in adults aged 20-39" and the number
of cases peaked in 1985 and has shown a continuous gradual decline since that
time."153 Even if one assumes that there were approximately 30,000 newborns
or young infants infected in 1985, when the number of hepatitis B infections
peaked so as to result in a signicant HBV disease burden, one would still ex-
pect more than 279 reported cases of HBV in children under fourteen years
of age in 1996154, since children born in 1985 would only be eleven years old.
While the inconsistencies could be attributed to a gross under-reporting of cases
among infected children, if the estimated 30,000 cases of hepatitis B occurring
in infants represent those actually reported, there is no reason to believe that
reporting eorts would subsequently ebb to such a drastic extent, if at all.
Related to the signicant disease burden justication oered by several federal
health authorities and in further support of the federal endorsement of HBV
vaccination in infants and newborns is the expressed concern that young chil-
dren are at a heightened risk of suering from chronic infections, complications,
and death if they are exposed to and do contract the hepatitis B virus.155 The
Guide to Clinical Preventive Services (1996), written under the supervision of
the U.S. Department of Health and Human Services (DHHS), states that the
risk of developing a chronic hepatitis B infection is higher in infected infants
153Id.
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58than in infected older adults and children.156 While infections during infancy
represent only 1-3% of HBV cases, DHHS asserts that \infections during infancy
account for 20-30% of chronic infections."157 In addition to heightening the con-
cern with respect to the disease burden attributed to HBV infected infants and
children, some have used these statistics to suggest that a large proportion of
adults with chronic HBV became infected as young infants or as children, rather
than by engaging in high risk behavior as teenagers or adults.158 In support,
the CDC and AMA allege that approximately 30% of people infected with HBV
have no idea how they became infected.159 Perhaps it is because they would
prefer not to specify the means. Even if infants do account for 20-30% of all
chronic infections, such statistics should be viewed in the context of the fact
that chronicity occurs in less than 5% of all acute cases and results in a very
small proportion of chronically infected individuals in the U.S. when compared
to the U.S. population as a whole.160 Thus, the fact that infants comprise 20%
of a small percent of cases may not amount to a signicant number of HBV
infected infants so as to justify the mandatory vaccination of all infants. This
is especially important in light of the fact that the only real way a child can
be chronically infected is through mother-to-child transmission, a route highly
\uncommon in North American and Western Europe."161 Moreover, improved
screening methods and a selective, rather than universal, immunization program
156Happens to You, supra note 17.
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59can help prevent and reduce perinatal infection.
Although the ACIP states that each year, approximately 150,000 infants are
being born to women who have immigrated to the United States from areas
of the world where HBV infection is highly endemic,162 the HBV risk posed
to such infants cannot be adequately assessed nor relied upon as evidence of
the need for immunizing all infants. As indicated in the preceding section, the
ACIP fails to substantiate this assertion by indicating how many infants are
subsequently infected or what percent of the total U.S. infant population these
infants comprise, if in fact they are consequently infected. Moreover, even if
this risk is substantial, foreign mothers, like those from the U.S., can be identi-
ed before the risk realizes and alternative strategies can also be formulated to
identify and selectively immunize their infants.
In nal support of the HBV disease burden borne by young infants, the AMA163
and the CDC164 aver that many cases of chronic infections suered by infants
and young children arise among children whose mothers were not infected with
HBV and thus, cannot be protected by perinatal hepatitis B prevention pro-
grams. However, neither authority provides any scientic reference to substanti-
ate such assertions or explains how such children may have otherwise contracted
the HBV disease. The ACIP has claimed that horizontal transmission of HBV
during the rst ve years of life occurs frequently in populations in which HBV
is endemic.165 HBV is currently not endemic in the United States and public
162ACIP, supra note 45.
163AMA Fact Sheet, supra note 11.
164CDC Fact Sheet, supra note 51.
165ACIP, supra note 45.
60health authorities have not provided any examples or instances by which HBV
infection can be transmitted horizontally in the United States through casual
contact. Moreover, Barbara Fisher's research on HBV using medical textbooks,
vaccine maker product inserts, published and unpublished CDC data and tran-
scripts from government meetings have persuaded her that contrary to what
some federal and state health ocials are telling public and state legislators,
HBV is not a disease that can be transmitted through casual contact.166 Al-
though the CDC currently operates a website that states that a person can
get infected \by sharing personal items, such as a razor or toothbrush,"167 in
1998 the CDC admitted to the fact that there is not even one documented case
of HBV transmission from sharing toothbrushes or razors and ear piercing.168
In the absence of such evidence, the likelihood that children born to HBsAg
negative mothers, whether American or foreign, will acquire HBV and become
infected is close to, if not, nil.
The vaccine's ability to provide immunity against the HBV when
infants may engage in high risk behavior and become susceptible to
infection
Since hepB vaccination of persons in high risk groups has generally not been
a successful public health strategy,169 the CDC and other health authorities
contend that vaccinating babies and young children can oer them immunity to
the HBV virus at a time when they may become susceptible to acquiring the
166Happens to You, supra note 17.
167Healthtouch, supra note 45.
168Happens to You, supra note 17.
169CDC Fact Sheet, supra note 51.
61disease.170 In support of this justication, the ACIP and other health authori-
ties refer to clinical trials nding that U.S. licensed hepatitis B vaccines are 80%
to 95% eective in preventing HBV infection and clinical hepatitis among sus-
ceptible children and adults.171 In support of the vaccine's ecacy, the CDC
also asserts that more than 95% of children and adolescents and more than
90% of young, healthy adults develop adequate antibody to three doses of the
vaccine.172 Furthermore, of those vaccine recipients who develop a protective
antibody response, some authorities advance that such individuals become vir-
tually 100% protected against clinical illness.173 While these assertions seem
encouraging, these public sources of information do not specify whether these
conclusions were drawn from studies conducted among U.S. population groups,
a factor that will be discussed to be highly relevant in adequately evaluating
the safety and ecacy of the hepB vaccine.
Like other generalized statistics oered by such health authorities, the percent-
ages cited above should not be taken at face value. First, these statistics may
not be legitimate sources upon which to draw conclusions about the vaccine's
eectiveness as it relates to specic population groups in the United States for
whom the vaccine is mandated. For example, if 100 people are vaccinated and
ve contract the disease, the vaccine is declared to be 95% eective. However,
if only ten of the 100 were actually exposed to the disease, then the vaccine
was only 50% eective. This example demonstrates the importance of ana-
170See CDC Fact Sheet, supra note 51; AMA Fact Sheet, supra note 11; ACIP, supra note
45.
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62lyzing the risk of exposure for the population group for which these statistics
are given. While the ecacy statistics cited by health ocials are useful in
identifying the vaccine's ability to protect hepB susceptible children against
infection, these statistics are being advanced to support the vaccination of all
newborns and young children, not just those at risk of contracting the hepB dis-
ease. Therefore, the signicance of such statistics cannot be fully appreciated
or undermined without considering the generally low rate of HBV exposure for
U.S. newborns and young children and the undiscriminating recommendation,
if not requirement, that all U.S. children and infants be hepB vaccinated and
perhaps, consequently subjected to risk for responding adversely.
In addition, the general eectiveness of a vaccine does not necessarily justify
its mass administration among infants and young children, when the duration
of its acclaimed eectiveness has not been determined and will likely vary de-
pending on the vaccine recipient.174 In failing to recognize the importance of
evaluating the population groups from which ecacy statistics were derived,
health authorities are assuming that all vaccine recipients, regardless of race,
culture, diet or any other circumstances respond to the vaccine the same. Since
the length of protection oered by the vaccine is likely to vary in dierent re-
cipients of the vaccine, an accurate assessment of the vaccine's ecacy for U.S.
citizens will require an investigation into the length and nature of protection
oered by the vaccine as it relates to dierent U.S. population and age groups,
if not individuals, receiving the vaccine.175
174Response Sheet, supra note 10.
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63In support of the vaccine's eectiveness in protecting children from HBV in-
fection, Dr. Margolis and other governmental authorities, such as the ACIP,
point to the success of ongoing hepatitis B immunization programs in other
countries, countries in which the disease is endemic.176 Specically, Dr. Mar-
golis has referred to the vaccine's ecacy in immunizing Alaska Native infants,
who have relatively higher rates of HBV infection than found in much of the
U.S. Previous studies showed that 8% to 13% of Alaska Native children were
chronically infected with HBV and Alaska Natives had the highest rate of liver
cancer in the United States.177 Since 1983, all Alaska Native infants, beginning
at birth, have been routinely vaccinated with the available U.S. licensed hep-
atitis B vaccines. A study conducted in 1993 found that among such children
younger than eleven years of age, none had chronic HBV infection.178 Other
studies conducted among American Samoan children, children in Gambia and
children in China have shown that routine hepatitis B immunizations in these
population groups have lowered their HBV infection rates by more than 90%.
There has also been a signicant decrease in liver cancer in Taiwan since the
vaccine's introduction.179 According to Dr. Margolis, such studies \provide ev-
idence that hepatitis B immunization will prevent liver cancer and chronic liver
disease."180
The vaccine's ability to prevent liver cancer has not been denied. However, it
is its ability to do so in particular U.S. populations, without signicant risk
176See Margolis' Testimony, supra note 12; ACIP, supra note 45.
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64of adverse side-eects and for a specic period of time, which have been ques-
tioned. The evidence oered by Dr. Margolis and the CDC as to the vaccine's
success in other countries is interesting in view of the fact that these studies
were done in population groups that are genetically distinct from those in the
U.S. This is an important fact not only for evaluating the vaccine's eectiveness,
but also for assessing the vaccine's safety, as will be further discussed, and for
which these statistics are oered in support. To date, Dr. Dunbar nds it to be
an \amazing coincidence" that all of the studies touted for the vaccine's long-
term safety and many of the studies cited in support of the vaccine's ecacy
have been in genetic populations where one would not expect vaccine recipients'
immune responses to the vaccine or the virus to be similar. It has long been
established that the genetic response to the virus and the vaccine in Alaskan
populations is distinct from those of other populations. 181 Therefore, the
studies cited by Dr. Margolis, while persuasive, should be evaluated in the con-
text of the genetic populations in which they were conducted. Since Caucasian
populations are experiencing the most severe adverse reactions to the vaccine,
separate epidemiology studies, whether for the vaccine's ecacy or safety, need
to be carried out for Caucasian populations before one can truly assess the ben-
ets or risks of administering the vaccine to them. Dr. Dunbar anticipates that
a genetic inquiry into the large number of carriers and non-responders found
181Dr. Dunbar letter to Dr. Kane, author of articles published in the Proceedings of the
International Congress: Action towards Control of Hepatitis B as a community Health Risk,"
heavily relied upon by federal health authorities. This symposium was made possible by an
educational grant from SmithKline Beecham Biologicals, Rixernsart, Belgium. Dr. Kane is
also the director of the hepatitis vaccine program at the World Health Organization (WHO).
Letter obtained from Dr. Dunbar [hereinafter Kane Letter].
65in foreign population studies would demonstrate that an epidemiological study
in such distinct genetic populations would not be representative of responses
by the Caucasian populations of England, France, Canada and the U.S. | the
populations reporting the most severe adverse reactions to the vaccine and for
which these foreign ecacy statistics are cited in refutation.182
The importance of particularizing generalized statistics of the vaccine's ecacy
according to specic population groups being vaccinated is further amplied by
the fact that immunological reactions against the hepatitis B virus as well as
to the antigen used in the vaccine have been shown to have great genetic vari-
ability. Approximately 10% to 30% of vaccine recipients will not respond to the
vaccine.183 This response, or rather lack thereof, has been shown to be related
to the genetics of the immune system184 and numerous studies have showed a
genetic predisposition by vaccine non-responders.185 Moreover, some scientists
have discovered signicant histocompatibility genetic linkages among patients
who are experiencing severe reactions following their receipt of the hepB vaccine
as opposed to those who do not respond to this vaccine at all.186 Just as the
vaccine's ecacy varies according to dierent recipients of the vaccine, those
reporting adverse events as a consequence of vaccination vary with respect to
when they believe such adverse events were triggered { some occurring after
the rst, second or not until after the third injection.187 Furthermore, for some
182Id.
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66non-responders to the vaccine who underwent further boosters, these adverse
reactions became even more severe.188
In light of such considerations, the vaccine's ecacy for U.S. citizens would be
more accurately evaluated if particularized according to discrete U.S. popula-
tion groups vaccinated. Even if the percentage of those who do not respond to
the vaccine is relatively small when compared to the vaccinated population at
large, the signicance of these individuals must not be easily dismissed or glossed
over in assessing the vaccine's ecacy. This is especially important when these
statistics are advanced to support the vaccine's safety for particular groups of
individuals for whom its risks may far outweigh its benets. Moreover, without
considering the particularities of the discrete genetic population groups in which
the vaccine is being administered, health authorities may be overlooking signif-
icant evidence hiding in the genes of those who do not respond to the vaccine,
which may help to explain why some individuals are responding adversely to it.
Clearly, our ability to fully understand the vaccine's eects, both positive and
negative, and the spectrum of responses to the vaccine, including those report-
ing life threatening adverse responses, will require further investigation into the
genetic make-up of those vaccinated. Given the genetic basis of the immune
response to HBsAg and the genetic relation of those reporting adverse events
attributable to hepB immunization, genetic typing may also prove valuable for
predicting the failure of the vaccine in some individuals who contribute to the
U.S. HBV disease burden, by engaging in risky behavior thinking that they are
188Id.
67protected from HBV infection when they are not, as well as for screening out
individuals who may be at a heightened risk for responding adversely to the
vaccine.
Even if the vaccine is shown to be eective in protecting specic population
groups within the U.S. from HBV infection, a more accurate appraisal of the
vaccine's ecacy must also take into account the length of time for which such
protection is oered, especially since it relates to the justication given in sup-
port of the mass vaccination of all newborns and young infants. While the
vaccine has been shown to generally protect against HBV infection, it does so
\for an as yet undetermined length of time."189 The 1998 Physician's Desk
Reference190 description of the Merck Recombivax HB vaccine states that the
\the duration of the protective eect of Recombivax HB in health vaccinees
is unknown at present and the need for booster doses is not yet dened."191
The same can be said for Smith Kline Beecham's Engerix-B vaccine since it is
essentially identical to Merck's vaccine. In contrast to those individuals who
may respond to the vaccine and may become virtually protected against clini-
cal illness for an undetermined length of time, those individuals whose immune
systems' meet and neutralize the virus develop life long immunity to it ( ap-
proximately 95% of all adults who are exposed to the virus). 192
Of signicance to the justication advanced for the vaccination of newborns and
young infants is the assertion made in the CDC Prevention Guidelines: A Guide
189Response sheet, supra note 10.
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68to Action (1997), that
The duration of protection [of hepatitis B vaccine] and need for booster
doses are not yet fully dened. Between 30% and 50% of persons who develop
adequate antibody after three doses of vaccine will lose detectable antibody
within seven years but protection against viremic infection and clinical disease
appears to persist.193
In his recent statement before the U.S. House of Representatives Committee
on Government Reform on May 18,1999, Dr. Margolis asserted that a \num-
ber of follow-up studies have shown that the initial 3-dose immunization series
provides protection from HBV infection for years. These studies have followed
more than 2,000 persons, vaccinated either as infants, children, or adults and the
periods of follow-up have ranged from ve to fteen years."194 While he avows
that \all studies indicate that immunity is long-term, and may be lifelong,"195
he fails to specify the population groups from which such statistics were derived
and the duration of the vaccine's ecacy when administered to dierent pop-
ulation groups, accounting for factors such as race and age. In support of the
vaccine's duration ecacy, Dr. Margolis theorizes that even though immunized
people may lose antibody circulating in their blood, such individuals still can
be protected from chronic HBV infection as immune cells of vaccinated indi-
viduals remember that they were vaccinated and consequently, rapidly produce
antibodies when exposed to HBV.196 Dr. Margolis, however, never claims that
such immunologic memory lasts forever or at least as long as needed to confer
protection for a vaccinated infant when the infant, if ever, becomes susceptible
193Happens to You, supra note 17.
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69to infection many years later. Thus, if immunity only lasts seven years or even
as long as fteen years,197 and if teenage transmission of HBV is a concern,
newborns vaccinated at birth or early infancy will require additional boosters,
if not the entire vaccination protocol, at an age when they might be susceptible
to acquiring HBV. In light of these considerations, it seems that the CDC has
endorsed an ineective, if not unwarranted, strategy to eliminate HBV trans-
mission among adults at risk of contracting HBV by immunizing all infants who
are currently not at a signicant risk for contracting the disease, may never be
at risk and may not be adequately protected by the vaccine administered during
their early infancy if they ever are.
In sum, it is highly improbable that a U.S. newborn has any signicant risk of
contracting hepatitis B as a child, other than being born to an infected mother,
because the disease is caused by a blood-borne virus. It is hard to believe that
30% of people who claim they have no idea how they acquired HBV were infected
as infants and are not able to point to some time or situation in their sexual
or drug history when they may have been exposed to the virus. Obviously,
newborns are not likely to engage in intravenous drug use or promiscuous sex.
Nor are they likely to suer an accidental needle stick, as might a health care
worker. Nevertheless, all newborns, not just those at risk of contracting HBV,
have been commanded to receive the HBV vaccine before leaving the hospital.
This obligation is justied, in part, on the assumption that all babies may grow
up to be drug addicts or engage in promiscuous sexual behavior and that vacci-
197CDC Fact Sheet, supra note 51.
70nating them now will protect them when they do engage in such risky behavior.
However, the only way that U.S. born infants are likely to be exposed to the dis-
ease is by being born to an already infected mother. Given that serious doubts
and perhaps dangerous concerns persist with respect to the vaccine's long term
ecacy and its safety, public health eorts should be focused on reducing the
HBV disease burden among those really at risk for contracting and transmit-
ting the disease, rather than targeting those who are not given the choice to
voluntarily participate or have the ability to resist the mass vaccination eorts
that assault them. Innocent babies should not have to bear the burden of those
who engaged in risky behavior and are irresponsible in protecting themselves or
others from infection.
If the disease burden among children and young infants is as signicant as
some health authorities have asserted, then it may be better to focus our public
health eorts and resources on improving universal screening procedures for all
pregnant women to determine whether their babies should be vaccinated, on
the basis of being HBsAg positive, engaging in high risk behavior, or emanating
from a country in which the virus is endemic. The Merck Manual (1992), a ma-
jor medical reference used by physicians, asserts that \postexposure vaccination
is recommended for new born infants of hepatitis B positive mothers."198 Per-
haps as this reference suggests, all newborn infants should not be vaccinated,
rather only those at risk of contracting HBV. Although selectively screening
pregnant women for HBsAg has failed to identify a proportion of HBV infected
198Happens to You, supra note 17.
71mothers,199 the ACIP underscores that universal prenatal testing measures has
the potential to identify an estimated 22,000 HBsAg-positive women and could
consequently prevent at least 6,000 chronic HBV infections annually.200 Given
the failure of governmental authorities to substantiate claims as to how infants
acquire the disease, other than by perinatal transmission, or bear a large HBV
disease burden as a result, routine screening of all pregnant women for hepatitis
B infection is one of the most important public health measures that can be
taken to reduce the incidence of chronic hepatitis B cases in the U.S., especially
if it is attributable to infections acquired in early infancy as some public health
ocials have contended.
REINFORCING SCREENING PROCEDURES AS AN
ALTERNATIVE TO COMPELLING HEPB VACINNATION
Studies conducted in California, Connecticut, Kansas and the United States
for the year of 1992-1993 found that although maternal HBsAg screening is
well integrated into routine prenatal care, screening of pregnant women and
reporting of results to health care providers is not complete in many geographic
areas in the U.S. and there remains much room for improvement.201 Inadequate
immunoprophylaxis of infants born to HBsAg positive women is related to the
failure of health practitioners to adequately document maternal screening re-
sults in the delivery room.202 Additionally, the U.S. health care system's failure
199ACIP, supra note 45.
200Id.
201Maternal Hepatitis B Screening Practices, available at
<http://ch.nus.sg/MEDNEWS/may94/7163 7.html> (citations omitted) [hereinafter Mater-
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202Id.
72to adequately screen and treat infants exposed to HBV can be attributed to the
selective practices of pediatricians. In focusing on ACIP's screening recommen-
dations for certain racial and ethnic groups, many pediatricians may have been
missing a substantial proportion of mothers who are HBsAg positive.203 De-
ciencies in screening programs are especially important, since the prevalence of
chronic HBV infection among infants is higher among those born to women who
have not been screened or who have not received prenatal care.204 It is interest-
ing that unlike the majority of states requiring that children be vaccinated, only
a few states have enacted maternal HBsAg screening laws. Such state inaction
is especially troublesome when national surveys have suggested that state laws
improve HBsAg screening practices.205 It makes one wonder why states are con-
centrating their eorts and resources on enacting laws which mandate that all
young children be vaccinated against a disease which they are not generally at
risk of contracting, rather than on improving universal screening measures which
could identify those that are. If our goal is to prevent the spread of HBV, and
preventing perinatal HBV transmission is necessary to accomplishing this goal,
then we may better serve our aim by sustaining eorts to eectively screen HBV
infected pregnant women, rather than by dispersing eorts and resources among
dierent health policies. This is especially true when some of these policies may
not only be unwarranted, but also potentially dangerous for a specic group of
patients for whom the benets of receiving the vaccine do not outweigh the risks
of contracting HBV or responding adversely to the vaccine. Specically, public
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73health resources and eorts should be focused on better educating health care
providers of the importance of screening all women for HBsAg and perhaps, en-
forcing such behavior through law. In addition, hospitals should develop policies
to ensure that all women are screened for HBsAg before delivering their baby,
prenatal screening is performed for women without previous HBsAg screening
results, and that infants born to HBsAg positive women receive appropriate
medical treatment and are reported to local health departments.206 Hospital
policies should also ensure that maternal screening results are documented in
infants' medical records and conveyed to subsequent child care providers. Fi-
nally, legislators should be provided with information and support that could be
used in drafting laws requiring that all pregnant women be screened, as opposed
to mandating that all infants be vaccinated.207
RECOMMENDATIONS NOW MANDATED: CURRENT
STATE AND LOCAL IMMUNIZATION LAWS
In an eort to reduce vaccine preventable diseases in the United States, state and
local counties have passed immunization laws, following the questionably justi-
ed ACIP and AAP infant and childhood vaccination recommendations. State
laws requiring immunization date from the early 1800s, when Massachusetts
enacted a smallpox vaccination requirement for its residents. The 1960's and
206Id.
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741970's marked the modern era for school and licensed day care immunization
laws, as states tried to eliminate measles in the United States.208 Critics of the
federal policy argue that before vaccines were introduced in the early 1900's,
deaths and injuries from childhood diseases in technologically advanced coun-
tries, such as the U.S., were already declining because of better sanitation,
nutrition and health care. Although vaccination measures have been credited
for eradicating smallpox and eliminating polio from the Western Hemisphere,
success deserving great applaud, there is a scientic question as to whether
the success of some vaccines against certain diseases should be employed as a
seal of approval so as to justify the administration of all vaccines against all
diseases among all age groups {categories encompassing varying characteristics
and proclivities. Moreover, human vaccination may not eectively eradicate
some viruses and bacteria that also live in animals, such as HBV. More threat-
ening is the fact that some viruses and bacteria are adaptable and can change
their character in order to resist our eorts to eradicate them. One example
is the way some bacteria have changed their character and become resistant to
penicillin and other antibiotics. This may have been the case in the late 1980's
when, after two decades of measles vaccination in the U.S., a more virulent type
of measles was seen in an outbreak among children and adults.209 HBV has
threatened to do the same, as seen by lamivudine's decreasing eectiveness in
208David Satcher, M.D., Ph.D., Assistant Secretary for Health and Surgeon General, U.S.
Public Health Service, Department of Health and Human Services, Statement before the
U.S. House of Representatives Committee on Government Reform (Aug.3, 1999), available
at <http://www.house/gov/reform/hearings/healthcare/99.08.03/satcher.html> [hereinafter
Satcher].
209Alan Phillips, Dispelling Vaccination Myths: a documented report, available at
<http://www.livelinks.com/sumeria/health/myth2.html> [hereinafter Dispelling Vaccination
Myths].
75treating HBV infection.210
All school and licensed day care immunization laws are state based. In the U.S.,
there are no federal laws mandating immunizations for school entry and day care
attendance. The U.S. Supreme Court has armed the right of states to pass and
enforce compulsory immunization statutes, and has upheld the constitutionality
of state vaccination laws. While all fty states have school immunization laws
in eect, the specic vaccines, number of doses and vaccine schedules required
vary by state.211 Exemptions to immunization laws also vary by state. All
states allow exemptions for medical reasons, forty-eight states will accept re-
ligious exemptions and approximately fteen states will consider philosophical
exemptions in some instances.212
So far at least forty-two states and the District of Columbia have laws requir-
ing childhood inoculation in some form against HBV infection.213 Although
hepatitis B is not highly contagious in the general population, except in adults
engaging in high risk behavior, and is not in epidemic form in the United States,
many state health departments are treating hepatitis B like smallpox or polio.
In fact, several state health departments and schools are requiring that children
receive appropriate doses of the hepB vaccine before being admitted into school
and others are threatening unvaccinated students with expulsion if they do not
comply.
210AMA Fact Sheet, supra note 11.
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76The low incidence of hepatitis B in some states preceding the spreading con-
tagion of state mandates has led some parents to question why their state is
following in this mass vaccination haul. For example, in Autumn of 1999, each
kindergarten child in Ohio was obliged to receive the hepatitis B vaccine and
the mandate is expected to eventually cover all students. Ohio already had
a very low incidence of hepatitis B before the vaccine was mandated. Nearly
two-thirds of Ohio's counties reported no new HBV cases in 1996 or 1997. Of
the 120 new Ohioan hepatitis B cases reported in 1996, zero cases occurred in
children under age ten. In 1997, only two of Ohio's ninety-four reported HBV
cases occurred in children under age ten (one case in an infant, whose infection
was presumably acquired from an infected mother). Moreover, more than 99%
of Ohioans do not even carry the virus.214 Similarly, in 1997, the Illinois De-
partment of Health issued an order requiring that all 5th and 6th graders report
on the rst day of school with either proof that they have received three doses
of the hepatitis B vaccine or else face expulsion. In 1996, 335 cases of HBV
were reported in Illinois with only ten cases reported in children under fourteen
years of age and only ve like cases were reported in 1997.215 These statistics
have left many parents in Illinois to question why their state is commanding
that more than two and a half million Illinois children receive three doses of the
hepatitis B vaccine, at a cost of $40 per shot, to prevent ve to ten cases of
hepatitis B in children under the age of fourteen when hepatitis B is not highly
contagious or in an epidemic form among the general population, and especially
214Kristine M. Severyn , Hepatitis B vaccine for Ohio's Kindergartners Unnecessary, Waste-
ful, CINCINNATI ENQUIRER, Friday, Jan. 15, 1999 [hereinafter Severyn].
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77not in this young age group.216
The validity of state mandated requirements has also been questioned in states
with higher incidences of hepatitis B. For example, a Californian law became
eective in July of 1999, which required that students entering the seventh grade
obtain the three shot series. Without proof of immunization, students would
not be allowed to attend school. Hepatitis B shots are also required for children
attending childcare or entering kindergarten in California. In San Francisco,
where there were approximately 3,000 intravenous drug users under the age of
thirty, there were only twenty-three reported cases of hepatitis B in 1996 for this
age group. The youngest victim was seventeen. While the number of hepatitis
B cases may be higher, unreported cases would probably aect the incidence of
HBV infection among drugs users and promiscuous individuals who would not
want to admit the source of their infection, rather than represent the disease
burden borne by young children under the auspices of parental and physician
care.217
In furtherance of this mass vaccination eort, some states are enacting hep-
atitis B vaccine legislation to shield such bills from the public eye.218 Other
states are even using false and misleading information to ensure and encour-
age parental compliance. For example, in December of 1998, Tennessee was
working on plans that would require children to be immunized against HBV
before entering kindergarten. To fuel future compliance with this requirement,
216Id.
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78Tennessee promulgated and publicized unsubstantiated and inaccurate justi-
cations for vaccinating young infants and children. Specically, it frightened
parents with the assertion that HBV can be easily transmitted, simply by \shar-
ing ...household utensils like razors, toothbrushes, or silverware."219 Moreover,
the state reassured parents that the \vaccine is meant to be eective for at least
thirteen years, so Tennesseans inoculated as kindergartners could still be pro-
tected when they reach their teens and are more likely to be sexually active."220
As explained before, such justications are unfounded and specious. The dis-
ease has not been shown to be casually transmitted through these means. Even
if the vaccine is meant to provide long lasting immunity, its durational ecacy
has not yet been determined.
In sum, many state health boards are treating hepatitis B like smallpox or polio
and are thus, promulgating rules requiring its vaccine's use. Most states have
even gone so far as to enact quarantines which exclude children from attend-
ing school in order to control the transmission of an infectious disease among
a group not otherwise signicantly infected. In targeting millions of innocent
newborns and children for mandatory vaccination procedures, instead of specif-
ically focusing on those suspected of carrying the disease, many parents believe
and are declaring that their human rights and those of their children are being
unnecessarily compromised, if not violated.221 In fact, some parents who have
refused to vaccinate their children have been charged with child neglect and
219Pediatrics ( HBV immunization) Tennessee T0 go Ahead with Mandatory Hepatitis B
Vaccine, HEPATITIS WEEKLY, Monday Dec. 7, 1998.
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79threatened that their children will be taken away if they do not comply with
the state mandated vaccine. Without proof that their children have been vac-
cinated, some parents have been denied food stamps, welfare benets and even
health insurance. Traumatically, other parents have been coerced into vacci-
nating their children with the same vaccine they believe has possibly injured or
killed another one of their children. Parents are not the only ones feeling state
duress. Doctors have called the NVIC, wanting to give medical exemptions to
children they thought were at a signicant risk of reacting adversely to the vac-
cine; in fear of being harassed by state health ocials, many failed to do so.222
Moreover, despite their formal recognition, many school board ocials have not
accepted religious exemptions in practice. Traumatized and in constant fear
that public health ocials will take away their partially vaccinated children,
parents no longer believe that they have a choice in the governance of their chil-
dren's or in their own lives. While our human rights are defended by religious
canons and our U.S. constitution, state mandated vaccination laws and eorts to
enforce them have psychologically transported many American parents to some
third world dictatorship, rather than making them feel grounded in \America,
where respect for individual human life and freedom and the right to obey our
conscience says everything about who are as a people and as a nation."223
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80ALLEGED SIDE EFFECTS OF AND ADVERSE REACTIONS TO THE HEPB VACCINE
THE STANCE OF PUBLIC HEALTH AUTHORITIES
The growing number of states mandating the hepatitis B vaccine for new-
borns and young children intensies the importance of assuring that the vaccine
is safe. Otherwise, in mandating vaccination protocols without substantially
testing and adequately addressing vaccine safety concerns, states may be, in
eect, subjecting children and infants involuntarily to a national experiment.
Despite this concern, many federal authorities and health practitioners share in
Dr. Margolis' belief that the hepatitis B vaccines are \among the safest vaccines
we have."224 In support, the CDC and other health authorities advocate that
the vaccine has been shown to be very safe with minimal side eects. Most
health authorities cite pain at the injection site ( 3% to 29%) and/or mild fever
(1% to 6%) as being the most common side eects of the vaccine.225 However,
they attribute even these mild side eects to the injection event and not to the
hepatitis B vaccine, itself.
In support of the vaccine's safety, federal authorities point to results of pre-
licensure studies, which did not detect severe adverse events and report local
reactions to be greater in persons receiving the vaccine than in those receiving a
placebo or another vaccine. 226 Additionally, mild side eects were not observed
to occur more frequently among children receiving both the hepatitis B vaccine
and the DTP vaccine, than among children only receiving the DTP vaccine. 227
224Margolis' Testimony, supra note 12.
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81Dr. Margolis nds further support for the vaccine's safety in post-licensure stud-
ies which have similarly \not shown a scientic association between hepatitis B
vaccination and severe neurological adverse events."228
Beyond clinical trials, the CDC,229AMA230 and ACIP,231 nd support for
the vaccine's safety in the fact that more than 20 million persons have received
the hepB vaccine in the United States and more than 500 million persons have
received it worldwide. In contrast to the prevalence of the vaccine's administra-
tion, the CDC considers serious side eects reported after receiving the hepatitis
B vaccine to be \very uncommon."232 Even though a low rate of anaphylaxis
(hives, diculty breathing, shock) has been observed in vaccine recipients based
on reports to the Vaccine Adverse Event Reporting System (VAERS), the CDC
estimates that the incidence of such reactions is low { namely one in 600,000
vaccine doses distributed.233 In support, the CDC contends that only one case
has been reported in 100,764 vaccinated children (ten to eleven years of age)
with the recombinant hepB vaccine in British Columbia and no cases were ob-
served in 166,757 children hepB vaccinated in New Zealand.234 Though oering
such statistics in similar support of the vaccine's safety, the ACIP concedes to
the limitations of relying entirely on the data of these foreign studies. The
large scale vaccination programs conducted for infants in Taiwan, Alaska and
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82New Zealand often used the plasma-derived hepatitis B vaccine, rather than the
recombinant form, and more importantly, systematic surveillance for adverse
reactions has been limited in these foreign populations.235 Notwithstanding the
purported low incidence of anaphylactic reactions as a consequence of the hepB
vaccine, the CDC still warns of their life threatening nature and urges that fur-
ther vaccination with the HepB vaccine be contraindicated in persons with a
history of such reactions after receiving a previous dose of the vaccine.236 Over-
all, however, federal health authorities nd refuge from these safety concerns
in the signicant number of HBV doses administered worldwide as compared
to the signicantly fewer numbers of serious adverse reactions reported thereto.
Such statistics, federal health authorities contend, suggest that the vaccine is co-
incidentally, if at all, related to reports of adverse reactions purportedly caused
by this vaccine.
VIEWS OF VACCINE CRITICS
Health authorities are overlooking a biologically plausible
underpinning for adverse reactions to the hepB vaccine and are
disregarding positive rechallenges of such events in vaccine recipients
Contrary to the conclusions reached by many federal health authorities, sci-
entists and patients have not found that \ the hepatitis B vaccines have been
shown to be very safe when given to infants, children or adults."237 Both the
235ACIP, supra note 45.
236CDC Fact Sheet, supra note 51.
237Id.
83published studies of reactions to viral infections, such as HBV, and the temporal
relationship of the vaccine's administration with the onset of adverse events re-
ported thereto strongly suggest to critics of the federal policy that these adverse
events are related to the nature of the viral protein contained in the recombi-
nant surface antigen, the principal component, of the vaccine.238 Supporters
of the mass vaccination of newborns and infants, like Dr. Susan Ellenberg, of
the FDA, would more readily attribute causality to an adverse event following
the administration of a vaccine if the event conforms to a specic clinical syn-
drome whose association with vaccination has strong biological plausibility and
the event recurs on re-administration of the vaccine (positive rechallenge)239 {
the existence of both are subjects of disparate views and a polemic debate.
Many scientists believe that public health authorities are disregarding a bi-
ologically plausible mechanism by which the vaccine can induce the adverse
events reported as following its administration. It is apparent that the hepati-
tis B virus (and the vaccine developed from the hepatitis B surface antigen) is
unique from many other viruses and vaccines. In the late 1960's, patients with
high titers of infectious HBV were found to have a specic antigen, associated
with three types of particles. The antigen present on the outer part of one of
the particles is referred to as the hepatitis B surface antigen (HBsAg) and its
antibody is referred to as anti-HBsAg. Both the plasma and the recombinant
238Kane Letter, supra note 181.
239Susan S. Ellenberg, Director, Biostatistics & Epidemiology Division, Center for Biologics
Evaluation and Research Food and Drug Administration, Department of Health and Human
Services, Statement before the Subcommittee on Criminal Justice, Drug Policy and Human
Resources, Committee on Government Reform, U.S. House of Representatives, May 18, 1999
[hereinafter Ellenberg].
84vaccine contain this antigen. While the recombinant vaccine cannot cause the
disease of Hepatitis B as we know it, the vaccine does contain this protein found
on the virus' surface, which initiates immune system reactions to that surface
when an individual is exposed to the virus. Thus, while the recombinant vaccine
cannot cause the HBV disease, the protein which it contains can stimulate the
immune system so as to cause life threatening autoimmune conditions, similar
to those manifesting in people suering from HBV.240
It has long been established that viral infections, like that which causes the
Hepatitis B virus, can be associated with autoimmune diseases. Experiments
performed within the past sixty years on animals demonstrate that polypeptide
chains of the types found in viruses that are homologous or nearly homolo-
gous with myelin can cause demyelination and that the viruses themselves can
cause demyelination.241 Some studies have showed that there are some HB-
sAg peptides (as used in the HBV vaccine and found in the HBV virus) that
have strikingly similar regions to myelin proteins.242 Moreover, the hepatitis
B infection itself has been shown to cause autoimmunity, demyelination and
other polyneuropathies, resembling the adverse reactions reported as a conse-
quence of the vaccine.243 Additionally, immune complexes containing HBsAg
have been found in patients with acute and chronic hepatitis B and immune
240Response sheet, supra note 10.
241For a discussion of such research see <http://www.waisbrenclinic.com>, Dr. Waisbren
, How safe is universal hepatitis B vaccination [hereinafter Waisbrenclinic], citing numerous
scientic studies and reports [citations omitted].
242Dunbar's Proposal to the NIH, supra note 6.
243See Waisbrenclinic, supra note 241.
85complex diseases leading to exrtrahepatic manifestations, which are similar to
those reported by hepatitis B infected subjects. Reports of extrahepatic adverse
reactions to the hepatitis B virus infection include the following reactions,244
Adverse reaction/Diagnosis Reference
Systematic \Lupoid hepatitis," Sys-
temic lupus erythamotsus
Borisova and Krel, 1992; Chng et al.,
1993
Arthritis ( polyarthritis, rheumatoid
arthritis)
McCarty and Ormiste, 1973; Gocke,
D., 1975; Duy et al., 1976; Onion et
al., 1971; Wands et al.,1975; Chistau
and Helin, 1987; Morris and Stevens,
1978; Pease and Keat, 1985; Tsukada
et al., 1987; Ytterberg, 1993.
Vascular Disorders (Vasculitis, pol-
yarteritis, Erythema nodosum)
Gocke, D. 1975; Sarent et al., 1976;
Duy et al., 1976; Trepo et al.,
1974; Michalak, 1977; Maggiore et al.,
1983; Di Giusto and Bernhard, 1986;
Tsukada et al., 1987; Rogerson and
Nye, 1990.
Guillain Barre Syndrome Neirmeijer and Gips, 1975; Penner et
al., 1982; Tsukada et al., 1987; Tabor
et al., 1987
Demyelinating disorders (optic neuri-
tis, demyelinating neuropathy etc.)
Galli et al., 1986; Tsukada et al.,
1987; Inoue et al., 1994; Achiron,
1994
Chronic Fatigue Berelowitz et al., 1995
Glomerulonephritis Venkataseshan et al., 1990
In the past thirty years many medical authorities have discussed and warned
about possible neurological complications associated with hepatitis B vaccines,
partly in recognition of the extrahepatic manifestations of the HBV disease
and their possible relation to the HBV surface antigen used in the vaccine.245
244Dunbar's Proposal to the NIH, supra note 6.
245See Waisbrenclinic, supra note 241.
86As early as 1974, in an article entitled \Hepatitis Vaccine: A note of cau-
tion," Zuckerman warned that autoimmunity could follow the administration
of the hepatitis B vaccine because the disease [HBV] involved autoimmunity.246
Moreover, he urged a \careful assessment of all vaccine eects on the immune
system."247 As late as 1988, just before the federal policy to vaccinate all new-
borns was promulgated, Hilleman, sometimes called the \father" of the hepatitis
B vaccine,248 cautioned:
[T]he message from the hypothetical hepatitis B example is the administra-
tion of antigens or monoclonal bodies that directly or indirectly raise antibodies
that attach to cell receptors may carry large liabilities even though they
might provide a convenient means for preventing viral access to host cells..
antibodies attached to cell receptors may invite the same kind of ad-
verse response that are believed to be responsible for a variety of
autoimmune disorders (emphasis added).249
More recently in 1996, Burton A. Waisbren, M.D., a cell biologist and in-
fectious disease specialist who is a founding member of the Infectious Disease
Society of America and was the past President of the Infectious Disease Society
of Milwaukee, pointed out in the Wisconsin Medical Journal that
there is an increasing number of reports in the referred medical literature
about demyelinizing diseases occurring after an individual has received the hep-
atitis B vaccination...since the hepatitis B virus itself has been reported to
cause autoimmune problems, should we not be wary of giving antigens that
seem to have triggered these problems?250
The following includes a representation of published reports of autoimmune
type adverse events associated with the administration of the hepB vaccine:
lupus: Tudela & Bonal (1992); Mamoux & Dunont (1994); Guiserix (1996);
246Id.
247Id.
248Id.
249Id.
250Happens to You, supra note 17.
87arthritis, including polyarthritis and rheumatoid arthritis: Christan &
Helin (1987); Hachulla et al. (1990); Rogerson & Nye (1990); Biasi et al. (1993),
(1994); Vautier & Carty (1994); Hassan & Oldham (1994); Rheumatic Review
(1994); Gross et al. (1995); Pope et al (1995); Cathebras et al. (1996); Soubrier
et al. (1997); Guillain Barre Syndrome ( GBS): Shaw et al. (1998),
Tuohy (1989); Vascular Disorders (vasculitis, polyarteritis, erythema
nodosum, cryoglobulinemia uveitis): DiGuisto and Bernhard (1986); Fried
et al., 1987; Goolsby, 1989; Cockwell et al. (1990); Rogerson and Nye, (1990);
Poullin & Gabriel (1994); Mathieu et al. (1996); Carmeli and De-Medina, 1993;
Mathieu and Krivitsky (1996); Graniel et. al (1997); demyelinating disorders
such as optic neuritis, Bell's Palsy, demyelinating neuropathy, trans-
verse myelitis and multiple sclerosis: Ribera and Dukta (1983); Shaw et
al. (1988); WHO (1990); Reutens et al. (1990); Herroelen et al. (1991); Nadler
(1993); Brezin et al. (1993); Mahassin et al. (1993); Kaplanski et al. (1995);
Baglivo et al. (1996); Marsaudon & Barrault (1996); Berkman et al. (1996);
Devin et al. (1996); Dunbar et al. (unpublished observations); Senejoux et al.,
(1996), Bonls et al. (1996); Manna et al. (1996); Waisbren (1997); diabetes
mellitus: Poutasi (1996); Classen (1996); Chronic fatigue: Salit (1993);
Delage et al. (1993) and other diseases/symptoms: Biron et al. (1988); Tre-
visani et al. (1993); Germanaud et al. (1995); Tartaglino et al. (1995); Macario
et al. (1995) Senejoux et al. (1996); Noble et al. (1997).251 Though not an all-
inclusive illustration of what scientists conjectured prior and subsequent to the
251Id. See also Waisbrenclinic, supra note 241 for many other related references.
88mass vaccination policy, such research and the cautionary statements elicited
from them, at the very least, warranted a scrupulous follow up investigation of
what was regarded by several to be highly suspect and potentially dangerous.
The majority, if not all, of the side eects reported to the recombinant
hepatitis B vaccine are the same or similar to those reported as extrahepatic
manifestations of the virus itself. Moreover, as Hauser et al. (1987) indicate in
the text titled \Adverse Events of Childhood Vaccines," (1993), \the antibodies
after infection with hepatitis B virus or after administration of plasma derived
vaccine or recombinant vaccine are all alike in terms of their ability to elicit
protective determinants that are active against all subtypes of the virus... "
and that \the results of the trials of recombinant vaccine are much the same
as those of trials of the plasma-derived vaccine." 252 Although these authors
acknowledged that studies were not designed to assess serious adverse events, the
authors expressed that \overall the number of examples of adverse neurological
outcomes following receipt of hepatitis B vaccine are of concern, particularly
those resulting in demyelinating neurologic disease."253 The similarity between
the adverse manifestations to HBV and both vaccines, despite the fact that the
recombinant hepB vaccine involves a dierent form of glycosylation than the
native viral protein, has suggested to some scientists that these reactions share
a genetically inuenced immune complex mediated pathogenesis.254
252Dunbar's Proposal to the NIH, supra note 6.
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89This hypothesis is further supported by substantial evidence of strong associations between autoimmune disorders, such as rheumatoid arthritis, and MHC genes (a cluster of genes located in close proximity that determine histocompatibility antigens involved in immune responses).255
Moreover, experiments have shown that the HLA patterns of animals have been shown to inuence their susceptibility to developing demyelinating diseases.256
This is signicant in light of the strong genetic association with the immune response to the hepatitis B surface antigen, contained in the vaccine and the virus. Specically, the human antibody response to the hepatitis B surface antigen has been linked to the MHC complex.257
A recent report presented at the National Rheumatology entitled, \An epidemic of rheumatoid arthritis caused by the Hepatitis B vaccine," demonstrated that the severe adverse eects reported in response to the vaccine are correlated to MHC genes.258
Moreover, in 1996, Montinari et al. published a study in Italy evaluating thirty children and adults, the majority aged three to nine months, who suered central nervous system disorders, such as autism and seizures, after receiving their hepatitis B vaccination. This study sought to investigate whether the administration of the recombinant hepB vaccine could trigger a demyelination process in the brain that was immunogenetically based and autoimmune in type. The authors concluded that \autoimmune diseases are more frequent in nations where vaccines are widely used, the so called `clear communities,"' and they identied several potential genetic markers that \may visualize risk patients for autoimmune diseases following hepatitis B vaccination."259
Montinari's work to identify genetic predispositions for reacting adversely to the hepatitis B vaccine is important in light of the study conducted in 1989 by Alper et al. to identify genetic factors for those who do not respond to the hepB vaccine, and are consequently not protected from HBV infection. The failure of some patients to respond to the vaccine, whether plasma or recombinantly derived, is linked to the workings of the MHC complex.260
Specically, the results obtained by Alper et al. supported the authors' \hypothesis that the production of anti-HBsAg [vaccine-induced antibodies] is a dominant trait and that the inability to produce high titers of anti-HBsAg after adequate immunization is a recessive trait...".261
Moreover, the authors concluded that the genetic markers they identied were most prevalent in Caucasians of European descent and were \associated with a wide variety of diseases with autoimmune features in this population, including Type 1 diabetes mellitus."262
Other studies have shown that amounts of antibody produced in response to HBsAg are genetically inuenced even in patients demonstrating adequate antibody response.263
Particularly interesting is the fact that there are genetic linkages among patients reporting severe reactions allegedly caused by the vaccine, as opposed to those who do not respond to the vaccine at all.264
Therefore, these and other studies make evident that individuals are likely to have a genetic predisposition to responding to the vaccine, whether not at all or perhaps adversely. Since the vast majority of patients reporting adverse reactions to the vaccine are Caucasian in origin,265
consistent with the ndings of Alper et. al., epidemiological study of the vaccine's safety in other genetic populations should not be proered as evidence of the vaccine's safety for Caucasian populations being mandated to receive the vaccine and are possibly suering from adverse reactions as a result. As emphasized earlier, investigating the immune mediated pathogenesis of responses to this vaccine and performing HLA genetic typing of vaccine recipients are essential for adequately addressing the safety concerns haunting this vaccine's promulgation. Such scrutiny may not only be valuable, but perhaps also necessary, for predicting the failure or success of this vaccine, including non-response or possible autoimmune side eects caused thereby.
The vast majority of individuals reporting adverse eects from the vaccine
are describing similar symptoms, including rash, joint pain, chronic fatigue, neu-
rological demyelinating disorders, neuritis and rheumatoid arthritis as well as
lupus or multiple sclerosis type syndromes.266 These severe side eects are asso-
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90ciated with genetically driven autoimmune responses, much like those of which
HBV infected individuals complain. New information has suggested means by
which the peptide structure of the protein, used in the vaccine and derived from
HBV, may initiate the primary autoimmune responses to the HBV virus and
its vaccines.267
To explain the apparent adverse reactions to the vaccine, Dr. Dunbar and many
scientists postulate that by a process called \molecular mimicry" the hepatitis
B surface protein, used as an antigen in the recombinant vaccine (HBsAg), can
provoke an autoimmune attack on a similar protein found in the nerves or other
tissues of a genetically susceptible group of vaccine recipients.268 The molecular
mimicry theory suggests that pathogens, like viruses and bacteria, can trigger
autoimmune diseases when a person's immune system makes a grave mistake.
Confusing foreign proteins with the body's own proteins, the immune system's
agents attack the body along with the pathogens they are intended to pro-
tect it against.269 In a 1996 presentation at the Institute of Medicine Vaccine
Safety Forum, Dr. Waisbren warned of \molecular mimicry" and the possible
dangers associated with using genetically engineered hepatitis B vaccines con-
taining polypeptide sequences that are present in human neurologic tissues, such
as myelin. He hypothesized that through molecular mimicry, polypeptides can
act as autoantigens and induce autoimmune demyelinating diseases of the brain,
and scientists all over the world.
267Dunbar's Proposal to the NIH, supra note 6.
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269For a more detailed explanation of how molecular mimicry works, see Virus's Similarity
to Body's Proteins May Explain Autoimmune Disease, Science Times, New York Times Dec.
31, 1996 [hereinafter Times].
91such as multiple sclerosis.270 The theory that molecular mimicry between viral
and self antigens could, in some instances, initiate autoimmunity has gained
increasing acceptance in the past few years.271 Although for a long time, some
individuals did not believe that molecular mimicry was possible, recent research
has shown otherwise.272 Moreover, some scientists are even reporting that vari-
ous other diseases, such as Lyme disease, the Herpesvirus or the Coxsackie virus,
are inducing arthritis, Multiple Sclerosis like symptoms, and diabetes through
such mimicry { much like the diseases and symptoms reported by those infected
with the HBV virus or injected with the vaccine.273
Despite the skepticism of vaccine endorsers as to the biological plausibility of
the molecular mimicry hypothesis, Dr. Dunbar and others nd further support
for questioning the vaccine's safety in the \positive rechallenges" of adverse re-
actions in vaccine recipients, conrmed upon re-administration of the vaccine.
In addition to the dozens of publications tying the virus, as well as the vaccine,
to autoimmune and other connective disease disorders, patient reports made
to the Vaccine Adverse Event Reporting System (VAERS) provide further evi-
dence that this viral antigen may be related to the autoimmune diseases it has
been notoriously assigned to cause. Between October 1990 and September 1991,
700 hundred reports of adverse reactions to the hepatitis B vaccine were sent to
270Happens to You, supra note 17.
271See Waisbrenclinic, supra note 241 and numerous references cited; Dr. Dunbar's proposal
to the NIH, supra note 6.
272Id.
273A Shadow Falls on Hepatitis B Vaccination Eort, SCIENCE, July 31, 1998, vol. 281,
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92VAERS.274 Sixteen percent of these reports were of damage presumed to be to
the myelin of the nervous system. There were twenty-one cases of facial paraly-
sis and six cases of Multiple Sclerosis (MS).275 Eighty-two of the complications
occurred in patients who received the plasma derived vaccine and eighteen oc-
curred in those who received the recombinant vaccine. This dierence can be
explained by the fact that the recombinant vaccine had just been introduced
into general use.276
More generally, for the twenty month period between November 1, 1990 and
July 31, 1992, there were 4,227 reports of side eects from the hepatitis B vaccine
made to the Vaccine Adverse Events Reporting System. Of this number, 383
were characterized as serious, fty-seven as life threatening, 241 cases resulted
in hospitalization, 108 individuals were disabled and 17 had died.277 The FDA
estimates that only ten percent of doctors report vaccine injuries and deaths.278
Given that these reports were obtained during a time when the hepB vaccine
was only recommended, as opposed to mandated, the numbers of actual injuries
and deaths occurring today as a consequence of hepB vaccination are expected
to soar in comparison.
Specically, the numbers of adverse events reported in children responding to
the vaccine has intensied the concern with respect to the vaccine's safety, es-
pecially in light of recent state mandates. While many adults in fear of adverse
274Waisbrenclinic, supra note 241, receiving data from VAERS through the Freedom of
Information Act.
275Id.
276Id.
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278Dunbar's Testimony, supra note 4.
93reactions have a choice to protect themselves from hepatitis B, or rather the
vaccine, the state mandated and government endorsed hepatitis B vaccination
schedule for infants and young children may be subjecting innocent children
and infants to what some have called a \dangerous and scientically unsub-
stantiated policy."279 Independent analysis of raw computer data generated by
the government operated Vaccine Adverse Event Reporting System (VAERS)
conrms that in 1996, there were 872 serious adverse events reported to VAERS
in children under fourteen years of age who had been injected with the hepati-
tis B vaccine. The children were either taken to the hospital or an emergency
room, had life threatening health problems, were hospitalized or were left dis-
abled following vaccination. Of these cases, 214 of the children had received the
hepatitis B vaccine alone and the rest had received the hepatitis B vaccine in
combination with other vaccines. In 1996, forty-eight children were reported to
have died after they were injected with the hepatitis B vaccine, thirteen of whom
had only received the hepatitis B vaccine before their deaths.280 In infants who
died under one month of age, most of the deaths were classied as SIDS.281
Prior to this mass vaccination call, the syndrome of SIDS never struck infants
this young and SIDS is ocially dened as death occurring in infants older than
one month of age.282 More than 6000 children dying of SIDS every year.283
Many wonder how many of these infants could have died as a result of hepB
279Happens to You, supra note 17.
280NVIC, Hepatitis B Vaccine Reaction Reports Outnumber Reported Disease Cases in
Children According to Vaccine Safety Group, Press Release, Jan.27, 1999, available at
<http://www/909shot.com/prhepb.html> [hereinafter NVIC Press Release].
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94vaccination. In contrast to reports of adverse side eects occurring in children
following their hepB immunization, only 279 cases of hepatitis B disease were
reported in children under age 14 in 1996 (see graph 1 appended at the end of
this section, page 94a).284 Of these, fty-four occurred in the newborn to one
year old age group in a population of 3.9 million babies born in the U.S. that
year.285
Hepatitis B disease statistics obtained from eight states provide additional evidence for questioning whether the benet of vaccination can possibly outweigh the risks from the vaccine, especially in young children under ve years old. A study performed in New Hampshire found that serious reactions to the vaccine were sixteen times greater than incidents of the disease.286
Moreover, in 1997, New Hampshire reported one case of hepatitis B in children under ve years of age; Washington state reported two cases; Michigan reported nine cases; and Texas reported thirteen cases. Pennsylvania, Massachusetts, New Jersey and Illinois reported no cases of hepatitis B in children under ve years of age (see graph 2 appended to the end of this section, at page 94a).287
In that same year, however, there were a total of 106 VAERS reports of hepatitis B vaccine-related serious adverse events. In these eight states, ten deaths were reported in children younger than ve years of age; moreover, thirteen of the reported serious adverse events and two of the deaths occurred in children only receiving the hepatitis B vaccine (see graph 3 appended to the end of this section, at page 94a).288
More generally, between July 1, 1990 and October 31, 1998 there were 24,775 hepatitis B vaccine related adverse events reported to VAERS in all age groups, including 9,673 serious adverse events and 439 deaths. Out of this total, 17,497 reports were in individuals who received the hepatitis B vaccine without any other vaccine. Of these reports, 5,983 were for serious events and 146 represented deaths. The NVIC asserts that these statistics indicate that 35% of reports in all age groups after receipt of the hepatitis B vaccine are solely for serious adverse events ( see graph 4 appended to the end of this section, at page 94a). Furthermore, 2,424 of these adverse events, with 1,209 being serious and 73 resulting in death, were reported in children younger than the age of fourteen who received the hepatitis B vaccine alone without any other vaccine. Thus, 52%, or approximately one out of two reports for children under the age fourteen, who had only received the hepatitis B vaccine, were for serious events.289
As indicated previously, Dr. Dunbar has investigated the nature of the
more than 20,000 reports of adverse reactions to the hepB vaccine made by
patients to the VAERS. She has found that the vast majority of patients re-
porting vaccine associated complications are complaining of similar, if not iden-
tical symptoms (namely joint pain, rash, chronic fatigue, neurological disorders,
neuritis, rheumatoid arthritis, lupus like syndrome and multiple sclerosis like
symptoms).290 Dr. Dunbar has divided the adverse events reported by pa-
tients and documented in medical journals as following this vaccine into three
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95major classes of diagnoses: optic neuritis/multiple sclerosis; severe joint pain,
frequently diagnosed as rheumatoid arthritis; severe fatigue, commonly diag-
nosed as chronic fatigue syndrome, post-viral fatigue syndrome, or myalgic en-
cephalomyelitis.291 Despite the diculty physicians and scientists experience in
precisely diagnosing the adverse events reported by vaccinated individuals, due
to overlapping symptoms between such diseases and their syndromes, the re-
actions reported are nevertheless similar and predominantly range within these
category types.292 Over the past few years, Dr. Dunbar has also been in con-
tact with numerous physicians and research scientists from several countries
who have independently described thousands of identical severe reactions oc-
curring in Caucasian recipients of the vaccine. It is apparent from these adverse
reaction reports that the same types of adverse reactions are being reported
for the plasma and recombinant forms of the vaccine. This is not surprising,
however, as explained before, since the same recombinant DNA methods are
used to produce both of these vaccines.293
Evidence in rebuttal to the AMA's, CDC's, and other health authorities'
blanket assertion that \scientic data does not support an association between
the hepatitis B vaccine and other neurological diseases" is not limited to the
hundreds of thousands of adverse events reported to VAERS as following the
administration of the hepatitis B vaccine or even the hundreds of similar doc-
umentations made in medical records and scientic journals. The Physician's
291Dunbar's Proposal to the NIH, supra note 6.
292Id.
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96Desk Reference and yers that now accompany the vaccine warn of inamma-
tory, demyelinating and other disorders that may be caused or induced by the
vaccine.
For example, in the 1998 Physician's Desk Reference, SmithKline Beecham
included the following statement:
WARNING: Multiple Sclerosis: In persons with multiple sclerosis, stimula-
tion of the immune system may induce an exacerbation of the disease. Conse-
quently, in persons with multiple sclerosis who have not been previously infected
with hepatitis B as demonstrated by serological absence of immunity the ben-
et of immunization must be weighed against the risk of exacerbation of the
disease.294
This reference further states that \[a]dditional adverse experiences have been
reported with the commercial use of the Engerix-B vaccine. Those listed below
are to serve as alerting information for physicians."295 The list includes ana-
phylaxis, arthritis, GBS, transverse myelitis, optic neuritis, multiple sclerosis,
visual disturbances, and the like.296 Furthermore, because the FDA did not
require drug companies to provide scientic evidence that the hepatitis B vac-
cine did not compromise the immune and neurological systems of children and
adults over weeks, months or years post-vaccination, the length of time required
for the type of adverse events being reported to manifest, Merck & Co. warned
in their 1996 product insert that \as with any vaccine, there is the possibil-
ity that broad use of the vaccine could reveal adverse reactions not observed
in clinical trials."297 Similarly, Smith Kline Beecham warned in 1993 that \it
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97is possible that expanded commercial use of the vaccine could reveal rare ad-
verse reactions."298 In 1996, Merck further alluded to the possible threat the
vaccine could pose to newborns in stating that \ it is also not known whether
the vaccine can cause fetal harm when administered to a pregnant women or
can aect reproduction capacity" and because \it is not known whether the
vaccine is excreted in human milk...caution should be exercised when the vac-
cine is administered to a nursing woman."299 Furthermore, although doctors
sometime administer the hepatitis B vaccine to children along with many other
vaccines, Merck stated in its 1996 product insert that \specic data are not yet
available for the simultaneous administration of RECOMBIVAX HB with other
vaccines."300
The expanded, broad use of the hepB vaccines have provided data, meeting the
expectations of these warnings. The vaccine manufacturers have warned of dis-
orders, which are similar, if not identical, to those observed in vaccine recipients
and post-marketing reports. If these post-marketing reports are not related to
the hepatitis vaccine received by these individuals, then the population report-
ing such reactions is indeed a strange one when one considers the generally low
attack rates of these diseases in the general population. Notwithstanding these
reports and despite their own warnings, these same pharmaceutical companies
continue to ignore or refute post-marketing data in line with the eects alluded
to in their precautionary statements. Consequently, the public has been left
to believe that such warnings were fueled by the motivations of vaccine manu-
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98facturers to protect themselves from liability, rather than the individuals who
would receive their vaccine. Moreover, in light of these warnings, or rather
premonitions, and the refusal of vaccine manufacturers to acknowledge their re-
alization in vaccine recipients, the public is also questioning the reliability and
validity of studies being conducted, purportedly to assess the vaccine's safety.
Due to inadequate governmental funding, most of these studies are being funded
by these same manufacturers. With such considerations in mind, one is left to
wonder whether the motivations that instigated the warnings of such entities
have similarly sown the seeds of and continue to inspire and stimulate these
projects and studies.
99Public health authorities rely on inadequate studies
To devitalize the causal import of numerous reports and published data of
adverse reactions following the hepatitis B vaccine's administration, the CDC
and other health authorities point to studies which have allegedly not shown
a scientic association between hepatitis B vaccination and severe neurological
adverse events reported thereto.301 In response and rebuttal to this assertion,
many scientists argue that this statement cannot be said. The studies upon
which federal authorities rely are outdated and several have been shown to be
inadequate with respect to detecting the type of reactions allegedly caused by
this vaccine and within the specic population groups thought to be adversely
aected. For example, health ocials have often cited studies for the proposition
\that these [hepB vaccine related] side eects are reported no more frequently
among those vaccinated than among persons not receiving the vaccine."302 Of
interest is the fact that the two references upon which this assertion often relies
are Szmuneness (1980) and Francis (1982). Both of these references are dated
more than ten years before the vaccine was generally administered to children
and before the recombinant derived vaccine was in use. Similarly, the assertion
that adverse events have not been observed more frequently among children
receiving the hepB vaccine in conjunction with the DPT vaccine than among
children only receiving the DTP vaccine does not do much to alleviate fears with
301See Margolis' Testimony, supra note 12; CDC Fact Sheet, supra note 51; AMA Fact
Sheet, supra note 11.
302See CDC Fact Sheet, supra note 51.
100respect to the vaccine's safety. The DTP vaccine has been said to adversely af-
fect vaccinated children, such as by inducing brain inammation, permanent
brain dysfunction and SIDS.303
Moreover, clinical studies quoted in the Pediatric Desk Reference for both the
Recombivax HB and Engerix B vaccines were based on studies conducted with
observation periods during which one would not likely be able to detect the
type of adverse events being reported as following hepB vaccination. In 1986,
the FDA gave Merck & Co., and later SmithKline Beecham pharmaceuticals,
licenses to market their genetically engineered hepatitis B vaccines in the United
States. The FDA allowed both drug companies to use \safety" studies which
only included a few thousand children, monitored for four or ve days after vac-
cination.304 As \proof" of their vaccine's safety, Merck & Co. stated in their
1993 product insert that \in a group of studies, 1636 doses of RECOMBIVAX
HB were administered to 653 healthy infants and children ( up to 10 years of age)
who were monitored for ve days after each dose."305 The length of the short
observation period in these studies is signicant in light of the considerable body
of scientic literature and reports establishing that the adverse eects allegedly
triggered by the vaccine, such as polyarthritis, systemic vasculitis, lupus as well
as symptoms of multiple sclerosis, are autoimmune in nature. An autoimmune
response to an antigen does not normally manifest itself in such a short period
of time, such as four to ve days, and its detection usually takes longer than
303BARBARA LOE FISHER, THE CONSUMER'S GUIDE TO CHILDHOOD VACCINES
(1997).
304Happens to You, supra note 17.
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101thirty days. Therefore, it would be highly improbable for such clinical stud-
ies to have detected the type of autoimmune side eects allegedly caused by
the vaccine. 306 Despite the short observation periods of such clinical studies,
seventeen percent of all vaccinated individuals with the Merck vaccines still re-
ported systematic complaints, including fatigue and weakness, fever, headache
and arthralgia (joint pain)307 { perhaps marking the genesis and initial devel-
opmental stages of what would later ourish into severe autoimmune disorders
or diseases of the central nervous system.
Federal reliance upon pre and post-marketing studies for the conclusion that
there is no causal association between the hepB vaccine and the adverse events
reported as following its administration has been further questioned in light of
the historic ndings by the Institute of Medicine (IOM) in 1994. At the IOM,
physicians and scientists reviewed the medical literature for evidence that vac-
cines, including the hepatitis B vaccine, can cause a variety of immune and
neurological health problems. An independent committee of physician experts
concluded that there were no case controlled observational studies or controlled
clinical trials conducted on the hepatitis B vaccine either before or after li-
censure to scientically evaluate persistent reports of adverse eects that the
hepatitis B vaccine can cause, such as SIDS; Guillain Barre Syndrome (GBS);
and other central demyelinating diseases, including transverse myelitis, optic
neuritis, multiple sclerosis, and immune system dysfunctions, such as chronic
arthritis. These are the very diseases being reported as a consequence of HepB
306NVIC Press Release, supra, note 280; personal communication from Dr. Dunbar.
307Happens to You, supra note 17.
102vaccination.308 In this report, titled \Adverse Events Associated with Child-
hood Vaccines," the IOM clearly states the following in the chapter on vaccines:
Conclusion on Biological events following immunization:1. Guil-
lain Barre Syndrome: the evidence is inadequate to accept or reject a
causal relationship between hepatitis B vaccine and GBS."
2. Other demyelinating Diseases: the evidence is inadequate to ac-
cept or reject a relation between hepatitis B vaccine and optic neuritis, ms,
or transverse myelitis.
3. Arthritis: the evidence is inadequate to accept or reject a causal
relation between the HepB vaccine and either acute or chronic arthropathy.
4. Anaphylaxis: none of the clinical trials reviewed by the committee
contained information regarding hepatitis B vaccine and anaphylaxis.
5. SIDS: the evidence is inadequate to accept or reject a causal re-
lation between hepatitis vaccine and SIDS.
6. Death: the evidence is inadequate to accept or reject a causal re-
lation between hepatitis B vaccine and death from any cause other than those
listed above.309
The Institute of Medicine further explicitly underscored the limited and in-
adequate nature of the pre- and post- licensure clinical studies; it stated that
\ it is important to note that individual trials usually involved a few hundred
subjects for study...[and]....when larger vaccination programs were monitored,
observations of adverse events were necessarily less detailed and less accurately
reported."310 Moreover, they acknowledged that the studies that have been
conducted \were not designed to assess serious, rare adverse events; the total
number of recipients is too small and the follow up generally too short to detect
rare or delayed serious adverse reactions."311 Surprisingly, public health o-
cials, have relied on these inadequate studies to refute reports of such adverse
reactions.
308Id.
309Response Sheet, supra note 10.
310Happens to You, supra note 17.
311Id.
103More generally, a signicant conclusion of the IOM report was that almost no
basic scientic research has been undertaken to dene, at the cellular or molec-
ular level, the biological mechanism of vaccine induced injury or death. The
IOM closed its report by declaring that
the lack of adequate data regarding many of the adverse events under study
was of major concern to the committee...the committee encountered many gaps
and limitations in knowledge bearing directly or indirectly on the safety of vac-
cines. These include inadequate understanding of the biologic mechanisms un-
derlying adverse events following natural infection or immunization, insucient
or inconsistent information from case reports and case series, inadequate size or
length of follow up of many population-based epidemiological studies... 312
Despite IOM's conclusion, the CDC and several other public health authori-
ties still maintain, that while reported, there is no conrmed scientic evidence
that the hepatitis B vaccine causes chronic illness, including multiple sclerosis
( MS), chronic fatigue syndrome (CFS), rheumatoid arthritis, and autoimmune
disorders.313 Not only have public health authorities relied upon surveillance
studies which have been proven to be inadequate with respect to being able to
detect the type of reactions possibly caused by the vaccine, but several health
authorities have also relied upon many studies which were and continue to be
conducted in population groups where one would not expect to nd the severe
side eects being reported by U.S. citizens as a consequence of the hepB vac-
cine. For example, in support of the vaccine's safety, the CDC refers to evidence
of large scale hepatitis B immunization programs in Taiwan, Alaska and New
Zealand which did not observe a \clear" association between hepB vaccination
and the onset of adverse events.314 It is astonishing that most, if not all, of the
312Happens to You, supra note 17.
313See CDC Fact Sheet, supra note 51; AMA Fact Sheet, supra note 11.
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104studies that have been touted by federal agencies for long term safety have been
in genetic populations where one could predict not to see the autoimmune side
eects reported. Specically, Dr. Dunbar is most interested in the hepB vaccine
epidemiological studies performed in Alaska and New Zealand, both of which
contain genetically unique populations groups.315 This is particularly interest-
ing in view of the long established scientic belief that the genetic responses to
the hepatitis B virus and vaccine in these population groups are distinct from
those of individuals comprising other ethnic and racial populations. Dr. Dun-
bar and others have been unable to obtain the specic data or experimental
design of such studies from those directly involved in these experimentations.
Consequently, Dr. Dunbar has persistently asked that federal health authorities
supply her with the actual epidemiological data drawn from these studies on
which they rely so heavily. Her requests have been ignored or denied. She an-
ticipates that the large number of carriers and non-responders in this population
would demonstrate that an epidemiological study in these genetic populations
should not be extrapolated for use as being representative of responses by the
Caucasian populations of England, France, Canada, and the U.S., who are re-
porting adverse reactions to the vaccine. Dr. Dunbar's colleagues have also
informed her that that the majority of clinical trials conducted for this vaccine
were carried out in Asia and Africa. Conrmation of such reports would be crit-
ical since scientic literature indicate that these populations also have immune
responses that are genetically distinct from those of Caucasians. Since patients
315Personal communication from Dr. Dunbar.
105reporting adverse events to the vaccine in the U.S. and abroad are primarily
Caucasian in origin, one would not expect these population groups to respond
similarly to the vaccine.316 Thus, if epidemiology studies are relied upon and
oered as evidence of the vaccine's safety, they must be specically conducted
for the populations for which they are asserted.
Reactions receiving heightened concern
Multiple Sclerosis
Notwithstanding the inadequacies of studies conducted to detect adverse
events as a consequence of the hepB vaccine, vaccine manufacturers and federal
authorities still continue to deny a causal relationship between the hepB vaccine
and the onset of autoimmune and neurological disorders allegedly triggered by
its administration. A disorder receiving heightened concern, initially in France
and now in the U.S., is that the hepatitis B vaccine may cause Multiple Sclero-
sis (MS) or at least exacerbate it. Multiple Sclerosis is a disease of the central
nervous system characterized by the destruction of the myelin sheath surround-
ing neurons so as to result in the formation of \plaques." MS is a progressive
disease, usually uctuating between exacerbating and remitting episodes. Most
patients either die or experience permanent disability when remissions do not
316Dunbar's letter to Dr. Kane, supra note 181.
106reach baseline levels. The cause of MS is unknown and the most widely held
hypothesis is that it occurs, like diabetes, in patients with a genetic suscepti-
bility. Some environmental factors may trigger \exacerbations." MS is three
times more common in women than men and its diagnosis is usually made in
young adults. 317
As with other diseases allegedly caused or induced by this vaccine, the CDC
and other federal authorities believe that unsubstantiated case reports and me-
dia attention fuel unwarranted concern with respect to this vaccine, rather than
valid scientic studies. Despite the signicance of IOM's conclusions, the CDC,
AMA and ACIP still continue to maintain that the scientic evidence to date
does not support the suspicion that HBV may cause MS or other similar de-
myelinating diseases aecting the nervous system. 318 In his statement before
Congress in August of 1998, Dr. Margolis professed the conclusion reached by
the National Multiple Sclerosis Society after analyzing French studies; he stated
that according to the \view of the medical advisory board of the National Mul-
tiple Sclerosis Society, there is no current evidence of a link between hepatitis
B vaccine and MS."319 Apparently, the European Viral Hepatitis Prevention
Board and the World Health Organization reached similar conclusions.320
The CDC and other federal public health authorities have relied upon some of
the following reasons in dismissing a possible causal relationship between hepB
317CDC Fact Sheet, supra note 51.
318See AMA Fact Sheet, supra note 11; CDC Fact Sheet, supra note 51; ACIP, supra note
45; PHAS, supra note 24; Margolis' Testimony, supra note 12.
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107vaccination and cases of MS which follow.
First, extensive pre-licensure clinical trials did not document such an eect.321
Second, the CDC considers the hundreds of millions of immunized MS free per-
sons as providing negative evidence for any possible causal link to the vaccine.
Furthermore, the CDC has suggested that causation issues should be viewed
within the framework of generalized vaccination eorts and success, rather than
in the context of individual cases. In this purview, if vaccination causes MS,
the CDC believes that it does so only rarely.322
Third, some studies in MS patients have shown that exacerbations of MS ap-
peared to be more frequent after nonspecic viral illnesses, presumably caused
by the generalized stimulation of the immune system that occurs with such in-
fections, rather than being induced by the vaccine.323 While there have been
reports of exacerbations of MS following the immunization of persons who al-
ready had MS, the CDC and AMA contend that there is no evidence establishing
that the vaccine has increased the rate of MS in otherwise healthy persons.324
Furthermore, these authorities relegate U.S. and French ndings of temporal
associations between MS and the administration of the hepatitis B vaccine as
being mere instances of expected coincidence, given the large number of vaccina-
tions administered worldwide.325 As with all case reports, the CDC denigrates
such evidence as only constituting possible signals of a causal association, re-
quiring conrmation by further controlled studies.
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108Fourth, the CDC concedes that determining whether the hepatitis B vaccine
actually causes an overall excess of MS in the vaccinated population as opposed
to being just one of multiple possible triggers for MS in genetically susceptible
individuals can only be evaluated in a population-based study, which has not
yet been conducted.
Fifth, MS cases occurred before there was a hepatitis B vaccine.326
Sixth, the prevalence of MS is highest in Europe and North America where the
prevalence of HBV infection is at its lowest.327
Seventh, natural HBV infection is not a risk factor for the development of MS.328
Finally, the CDC believes that the autoimmune nature of MS diminishes the
plausibility of the \molecular mimicry" hypothesis, the leading theory explain-
ing the possible biological mechanism by which the vaccine can drive the ad-
verse reactions reported thereto. MS is autoimmune in origin, meaning that
it involves a disease in which the person's antibodies attack the body's own
myelin (a sheath that covers the nerves). The CDC contends that the molecu-
lar mimicry hypothesis requires that the hepatitis B vaccine be somehow similar
to the three dimensional structure of the myelin in vaccinated individuals in or-
der to provoke the formation of anti-myelin antibodies. According to the CDC,
recent research using genetic sequencing ( not yet published), has not shown
such similarity between the hepatitis B vaccine and the myelin basic protein so
as to be able to induce a MS response.329
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109In light of all this evidence, the CDC concludes that \while a potential as-
sociation cannot currently be ruled out, such an association seems uncommon
and the risk low. Given the risk and severity of hepatitis B disease, the benet
to risk ratio is heavily in favor of hepatitis B vaccination."330
Despite federal health ocials' rejection of a causal relationship between the vac-
cine's administration and either the induction or exacerbation of MS, a number
of published reports have linked the hepatitis B vaccine with ensuing episodes
of MS, MS-like, or demyelinating polyneuropathies.331 Moreover, in the 1998
Physician's Desk Reference, SmithKline Beecham included the following state-
ment:
WARNING: Multiple Sclerosis: In persons with multiple sclerosis, stimula-
tion of the immune system may induce an exacerbation of the disease. Conse-
quently, in persons with multiple sclerosis who have not been previously infected
with hepatitis B as demonstrated by serological absence of immunity the ben-
et of immunization must be weighed against the risk of exacerbation of the
disease.332
Furthermore, in 1997 individuals from the WHO, CDC, NIH, Walter Reed
Army Institute of Research, various academic institutions, Pasteur Merieux
Connaught (PMC), Pasteur Merieux MSD Joint Venture, Smith Kline Beecham,
and Merck & Company, INC., met to discuss the safety of the hepatitis B vac-
cines, especially as they relate to MS. Dr. McFarland of the NIH armed that
molecular mimicry is a possible etiologic factor of MS. In contrast to what the
CDC contend, he explicitly emphasized that the theory of molecular mimicry
does not require that the vaccine exactly match of the amino acid sequence
330Id.
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110structure or have a similar spatial conguration to the myelin of vaccinated
individuals.333
As with other studies oered by federal health authorities to deny a causal
relationship between the vaccine and the adverse events reported, Dr. Dunbar
has desperately attempted to get the data for the studies performed in France,
relied upon by so many U.S. health authorities, such as the CDC and WHO,
as establishing that there is no correlation between the vaccine and MS. Of no
surprise, her eorts have proved futile. CDC members have admitted to Dr.
Dunbar that they have never seen the data on which they so rely. In response
to Dr. Dunbar's simple requests for such documentation, some federal health
authorities told this vaccine developer that her views \belong in church and
in anti-vaccine meetings."334 Moreover, a French colleague of Dr. Dunbar has
informed her that many French scientists believe the study to be a \joke," and
that French scientists are under \gag orders" not to talk about it.335 It is sur-
prising that these studies continue to be cited and publicized, even though they
are quite inconsistent with the ndings of other respected French scientists and
physicians. For instance, physician Philippe Jacubowicz, who heads an organi-
zation in Paris called REVHAB, has collected data on more than 600 cases of
333Study Group on Hepatitis B Vaccines Minutes, obtained from Dr. Dunbar. A meeting
was held on March 21, 1997 in Georgia to discuss the available information on the possible
association between the hepatitis B vaccine and multiple sclerosis and to consider plans for
future epidemiological studies. Participants included individuals from the World Health Or-
ganization (WHO), Centers for Disease Control (CDC), National Institutes of Health (NIH),
Walter Reed Army Institute of Research, various academic institutions, Pasteur Merieux Con-
naught (PMC), Pasteur Merieux MSD Joint Venture, Smith Kline Beecham, and Merck &
Company [hereinafter Study Group].
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111illnesses, many with MS like symptoms, in people who have received the hep-
atitis B vaccine.336
Similarly in the U.S., FDA ocials have identied more than 111 MS cases in
VAERS reports.337 Consistent with the conclusions reached by other federal
health authorities with respect to the vaccine's safety, the FDA maintains that
a review of the medical records from these cases do not prove that they were ac-
tually caused by the hepB vaccine. This view is espoused despite the suggestion
by other evidence that the actual number of possible MS like cases caused by the
vaccine is signicantly higher than what is reported to the FDA or documented
in clinical trials and studies. Interestingly, it appears that the CDC, WHO,
FDA and drug companies are dismissing many reported adverse reactions as
\not being MS."338 As with other blanket statements made by such ocials,
such assertions cannot be made. The term \multiple sclerosis" is in most cases
not accurately diagnosed and many doctors do not even agree on the denition
of this disease.339 In the 1997 study group on hepatitis B vaccines, Dr. McFar-
land of the NIH spoke of the inherent diculty associated with diagnosing MS.
Since the \MS" disease includes many polyneuropathies, cases of MS can be
dismissed or mis-diagnosed as being a specic polyneuropathy which it in fact
encompasses. Dr. McFarland even suggested that scientists and physicians use
\optic neuritis" as the initial demyelinating diagnostic event of MS in further
studies.340 While this condition may have heretofore been dismissed as not be-
336Shadow Falls, supra note 273.
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112ing MS, Dr. McFarland recommended that this event be used \because it was
relatively easy to diagnose and because a high proportion of these individuals
would go on to develop MS."341
Accurately diagnosing or detecting a case of MS is further complicated by the
fact that the course of MS is variable and often unpredictable and \MS" is es-
sentially a diagnosis requiring two neurological episodes separated by time and
space involving the central nervous system. Additionally, since there are no
specic diagnostic tests for MS and many people have the active disease before
any clinical symptoms become apparent, Dr. McFarland believes that clinical
manifestations or reports of the disease represent only the \tip of the iceberg" of
MS cases actually occurring or being documented in clinical studies, if any have
in fact been appropriately done.342 Therefore, while it may be more correct to
speak of the adverse events possibly causally related to the vaccine collectively
as polyneuropathies, since many of the reports are autoimmune reactions, in-
cluding arthritic and demyelinating disorders, it is important to note that many
of the cases dismissed as not being MS or not detected as MS in clinical studies
may be indeed cases of MS attributable to hepB vaccination. Consequently,
this consideration saps the force of many, if not all, of the reasons proered by
health authorities to deny a causal relationship between MS and the vaccine;
the majority, if not all these reasons, depend on the accurate detection and di-
agnosis of MS by physicians and scientists, an ability demonstrated to be laden
with complexities, inaccuracies and diculties.
341Id.
342Id.
113Federal health authorities' have attempted to evade the established com-
plexity associated with accurately diagnosing cases of MS by nding refuge in
clinical trials which have not documented a causal association between the hep-
atitis B vaccine and MS. Even if one puts this retreat, demonstrated to be
laden with pitfalls, aside, this conclusion still cannot be relied upon in sup-
port of the vaccine's safety. As with other adverse events alleged to have been
caused or triggered by the vaccine, no appropriate studies have been conducted
or published to evaluate such a causal relationship.343 IOM's landmark report
acknowledged, that the \evidence is inadequate to accept or reject a causal re-
lation" between the vaccine and demyelinating diseases, such as MS. However,
the report did acknowledge that the \number of reports questioning the relation
between one or the other of these [demyelinating] disorders of similar character
suggests the need for systematic research."344 Such research is especially needed
since the IOM found that there were no case controlled observational studies
or clinical trials conducted before or after the vaccine's licensure to scienti-
cally evaluate persistent reports that the hepatitis B vaccine can cause multiple
sclerosis.345 The 1997 study group on hepatitis B vaccines reached a similar
conclusion after discussing the available information on the possible association
between the hepatitis B vaccine and MS and considering plans for future epi-
demiological studies. Specically, they attributed the complications associated
with planning a study to evaluate whether MS is caused or exacerbated by the
hepatitis B vaccine to the clinical and epidemiological characteristics of MS,
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114its rare occurrence, and diculties physicians confront in trying to dene it or
diagnose, as discussed earlier in this section. In light of these obstacles, they
acknowledged that it would have been and continues to be very dicult to de-
sign a study with sucient power to detect a dierence in MS cases arising in
hepB vaccinated populations as compared to controlled populations. However,
participants did agree that future attempts to study MS as it relates to the
vaccine's administration, should at least include the following parameters:
(a)
the observation time limit for such a study should be extended to 60 days
from vaccination (as opposed to the four to ve day limit previously used in
many pre- and post- marketing surveillance studies);
(b)
optic neuritis would be useful as targeting the initial manifestation of MS
related demyelination, since it is easily diagnosed and frequently heralds the
development of MS (implicating many cases which may have been dismissed as
not being MS); and
(c)
the control group should be matched for ethnic origins (and possibly geo-
graphical dierences) because of the strong ethnic and genetic dierences associ-
115ated with the incidence of MS346 (this recommendation is especially signicant
since many of the studies touted for the vaccine's long term safety and e-
cacy have been conducted primarily in population groups which are genetically
distinct from the U.S. population groups reporting adverse reactions to the vac-
cine).
In addition to the questionable diagnoses and evaluations made by physi-
cians and the inadequate or non-existent clinical trials relied upon by federal
authorities, Dr. Dunbar diminishes a remaining reason advanced by several
health authorities to dismiss a causal relationship between the vaccine and MS.
Specically, she regards PHAS' and the CDC's assertion that the prevalence
of MS is highest in Europe and North America where the prevalence of HBV
infection is lowest to be nothing more than a \red herring," if not misleading,
unfounded and of no force.347 In addition to the inherent diculties associated
with diagnosing MS, the apparent reduced incidence of MS and other demyeli-
nating polyneuropathies outside the U.S. is likely to be due to lack of adequate
medical facilities for accurate diagnoses. As the CDC has also conceded, system-
atic surveillance for adverse reactions has been limited in these populations.348
Moreover, Dr. Dunbar and Skinner explain that while the initiation of polyneu-
ropathic episodes (such as MS) among genetically predisposed populations (
e.g., Caucasians of Northern European origin) could be expected to follow oc-
casions of Hepatitis B vaccination in these same populations, they would not
346Study Group, supra note 333.
347Response Sheet, supra note 10.
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116expect the generalized prevalence of ocially diagnosed cases of MS to follow the
generalized prevalence of HBV infection.349 The capability of each individual
to neutralize a viral infection, such as HBV, is a function of age, race, gender,
general and immunological health, and genetic predisposition | all of which
vary by geographic location and which may be dierent from those factors im-
plicated in triggering or causing MS.350 Superimposed upon all these variations
in the way individuals exposed to the virus respond to it is the varying nature
of the viral antigen implicated in the infection of each case.351 Because viral
constituents present in blood samples dictate the virus' level of infectivity, levels
of infectivity among infected individuals vary widely as well. In light of these
variations, the inconsistent and accidental contamination with blood samples
(by which HBV can be transmitted) would not necessarily follow and should
be distinguished from the purposeful and direct presentation of a consistently
immunogenic bolus of a viral antigen to the immune system of a vaccine re-
cipient (as presented by the hepatitis B vaccine, which may cause MS). In the
rst instance, contamination with blood samples varying widely in infectivity
may not be sucient to induce any transmission of infection or the induction
of an autoimmune response in genetically predisposed patients. In the second,
the immunization must induce some kind of reaction from any immune system
genetically capable of reacting, whether the result is helpful or harmful.352 In
light of such circumstances, one would not expect cases of MS to necessarily
349Response sheet, supra note 10.
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117follow the incidence of HBV in a population.
Sudden Infant Death Syndrome
Like MS, the possibility that the vaccine may be contributing to the preva-
lence of SIDS is receiving increasing attention, especially because of recent state
mandates requiring that all newborns and young infants be routinely vaccinated
against HBV. In addition to relying on studies conducted in genetically distinct
population groups or those which have not yet been conducted to disconrm the
vaccine's potential harm, most of the studies relied upon to determine whether
the benets of administering the vaccine to infants outweigh its risks have con-
centrated on the adult population, not the population obliged to receive the
vaccine. The CDC and other health authorities continue to deny any causal
association between the hepatitis B vaccine and SIDS, despite IOM's ndings
that there is insucient evidence to deny or conrm such an association.353 In
support of their refutation, the CDC refers to the National Center for Health
Statistics, the primary federal organization responsible for the collection, analy-
sis, and report of health statistics, which has shown a consistent decline in new
born deaths since 1935 ( in infants of one day to thirty days of age). The CDC
and Dr. Margolis attribute this decline to great improvements in sanitation,
health care and infectious disease control. While infants have been receiving
the hepatitis B vaccine routinely since 1991, an examination of newborn death
353Response Sheet, supra note 10.
118statistics reported during this time do not seem to show a rise, but have rather
continued to slowly decline.354 For example, in 1992, the rst full year after
the hepatitis B vaccine was rst universally recommended for infants and when
hepatitis B vaccination coverage was 8%, there were 4,800 SIDS deaths. In con-
trast, when coverage rose to 82% in 1996, the number of SIDS deaths actually
decreased to 3,000 deaths. Dr. Margolis attributes this decline to changes made
in sleeping positions for infants.355 Dr. Margolis explained that if the hepati-
tis B vaccine were a major cause of SIDS, he would have expected an increase
in SIDS, not a decrease. Furthermore, both Dr. Margolis and the CDC cast
remaining doubts with respect to the vaccine's safety, as it aects newborns,
to the forces of chance and coincidence. They avow that statistically, newborn
death can occur within twenty-four hours of vaccination by coincidence alone
since almost all infants are vaccinated during their rst year of life and any
infant with a medical illness or who dies is likely to have been vaccinated earlier
in life.356
Although the statistics to which federal authorities point show a general decline
in newborns deaths, classied as SIDS, such statistics do not exclude the possi-
bility that the vaccine's administration among newborns may have decelerated
the rate of this \slow" decline or is actually increasing SIDS deaths in infants
of certain age groups. One study found the peak incidence of SIDS to occur
at the ages of two and four months in the U.S., precisely when the rst two
354CDC Fact Sheet, supra note 51; Dr. Margolis' Testimony, supra note 12.
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119routine immunizations are given.357 Other studies have invalidated or at least
questioned the reliability of studies claiming that there is no SIDS-vaccine rela-
tionship when they found that confounding eects skewed results in favor of the
vaccine.358 Moreover, without the vaccine's administration, the decline in SIDS
deaths could have been much steeper, if not for the vaccine's side eects, so as
to result in a fewer number of newborn SIDS deaths reported today. Further-
more, most of the studies evaluating the risks of the vaccine for newborn infants
have been conducted among adult populations. While not much is known with
respect to the adult response to the vaccine, as the IOM and many others have
concluded, even less is known about the immunological reactions in infants, es-
pecially since they cannot communicate about the ailments from which they
suer. Additionally, in the event of deaths following vaccination, there is gen-
erally inadequate information collected by pathologists to adequately evaluate
reactions in newborns.359 Furthermore, VAERS data indicates that in infants
who died under one month of age following their hepB vaccination, most of
the deaths were classied as SIDS. Before the introduction of the vaccine, the
syndrome had never struck infants so young and SIDS is ocially dened as
occurring in infants who are older than a month of age. In the mid 70's, Japan
raised their vaccination age from two months to two years; their incidence of
SIDS dropped dramatically.360 With 6,000 children dying from \SIDS" each
year, we must wonder how many of these deaths may have been caused by the
357Dispelling Vaccination Myths, supra note 209.
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120hepatitis B vaccine.361
In the absence of adequate studies and an understanding of the human response
to the hepB vaccine, especially in newborns, we have no idea whether the po-
tential threat posed by the vaccine to newborns is limited to causing short term
severe consequences, such as SIDS, or rather whether it embraces long term
debilitations, as well. Dr. Dunbar \would challenge any colleague, clinician
or research scientist to claim that we have a basic understanding of the hu-
man newborn immune system."362 In view of inadequate scientic and medical
information on neonatal immunology, many, like Dr. Dunbar, nd it to be re-
markable that \newborn infants, especially those not at risk for the hepatitis
B disease are being administered multiple injections of this vaccine and that
there have been few, if any clinical trials to adequately evaluate the potential
long term eects of neonatal immunization, especially as it relates to genetic
diversity."363 Such trials would be critical, especially in view of animal studies
well establishing that the newborn system is very distinct from that of the ado-
lescent or adult. In fact, newborn immune systems in animal models have been
shown to be easily \perturbed to ensure that [they] cannot respond properly
later in life."364
Long-term debilitations
361Incao, supra note 281.
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121Evidence of the vaccine's possible harm towards and consequent need for
further study in newborns should not be limited to an evaluation of its short-
term eects, namely SIDS deaths. Perhaps, as newborn animal model studies
have suggested, the vaccine may be in fact perturbing the ability of vaccinated
newborns to respond properly later in life. Evidence of the vaccine's possible
long-term harm should be viewed in the context of the overall health of U.S.
children since eorts to vaccinate them have begun. Despite advancements in
science and increases in adult longevity, the general health of U.S. children has
declined signicantly since the 1960's, when vaccines began to be widely used.
In 1950 (before mass immunizations began), the U.S. had the third lowest infant
mortality rate in the world. By 1986 and then in 1995, the U.S. had dropped to
the 17th and 23rd place, respectively. Although now rst in vaccine compliance
through government mandates, as of 1999, the U.S. has dropped to the 24th
position in a rating of the overall health of children in dierent countries.365
According to the National Health Interview Survey, conducted annually since
1957 by the National Center for Health Statistics, a shocking 31% of U.S. chil-
dren have chronic health problems, 18% require special health care or related
services, and 6.7% have a signicant disability due to chronic or mental con-
ditions.366 Moreover, the rate of disability arising from chronic conditions in
children has increased almost four times since 1960. The fact that respiratory
allergies, asthma, and learning disabilities comprise the majority of such disabil-
365Letter testimony submitted to US Congress by a District Health Services Coordinator
( Registered Professional Nurse), supported by the Missouri Central District School Nurse
Association [hereinafter Nurse letter].
366Id.
122ities367 is signicant in light of the fact that three controlled studies conducted
in England and New Zealand comparing hepB immunized children to those who
were not have shown that vaccinated children have signicantly more asthma,
ear infections, hospitalizations and inammatory bowel disease.368 Since vacci-
nations shift the balance of the immune system towards its chronically reacting
side, vaccines may be contributing to the large scale and unprecedented increase
in chronic conditions among children, becoming more widespread every day as
we add more inoculations to an already crowded list. Such chronic conditions
include allergies, asthma, diabetes and neurological dysfunctions, such as learn-
ing disabilities.
Barthelow Classen, M.D., CEO of Classen Immunotherapies Inc., has published
an epidemiological study in the New Zealand Medical Journal, reporting a 60%
increase in Type 1 diabetes ( juvenile diabetes), from 1988 to 1991, following a
massive campaign in New Zealand to vaccinate babies six weeks of age or older
with the hepatitis B vaccine. His analysis of 100,000 New Zealand Children,
prospectively followed since 1982, showed that the incidence of diabetes before
the hepatitis B vaccination program began in 1988 was 11.2 cases per 100,000
children per year, while the incidence of diabetes following the hepatitis B vac-
cination campaign was 18.2 cases per 100,000 children per year.369
This report carries special import in light of the intensifying concern of U.S.
diabetes experts who are currently seeing an alarming increase of type 1 dia-
betes among U.S. children and infants. The Children's Hospital Diabetes Clinic,
367Incao, supra note 281.
368Id.
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123for instance, perceived 1997 as being especially \alarming." More than 50% of
newly diagnosed patients were under the age of three. Just recently, the clinic
started treating its youngest patient, a six week old baby. As with SIDS, the
disease never struck infants this young before. The medical profession rst took
note of the signicant shift in the population of Type 1 Diabetes around 1993,
right after the government rst promulgated its policy that all newborns be
vaccinated with the hepatitis B vaccine. While the medical profession rst dis-
missed the rise as a uke that would not persist, the numbers keep on growing.
At this hospital alone, the diabetic population served has grown from 350 pa-
tients in 1990 to more than 800 in 1998. Where the clinic used to see a few
newly diagnosed patients a year, they now see more than 100 cases.370 Type
1 diabetes is genetic and millions of children can carry its genes without ever
manifesting the disease. Something is needed to trigger the disease to onset its
perils. Internationally and nationally, researchers are pointing to immunization
schedules as the culprit and the hepB vaccine as an accomplice.371
Recently, a central district school nurse association has written to Congress,
asking that the government consider its grave concerns about the hepatitis B
vaccine. For the past few years, the nurses comprising this association have
noted a signicant increase in the number of children entering school with de-
velopmental disorders, learning disabilities, Attention Decit Disorder and/or
other serious chronic illnesses such as diabetes, asthma, and seizure disorders.
370Janice Kayser, Children and Diabetes, FREEMAN, Sept.26,1998 (Media clipping obtained
from the NVIC).
371Id.
124They see one common thread. According to these nurses, \they are the children
who received the rst trial hepatitis B injections as newborns in the early 1990s.
As the hepatitis B compliance rate in newborns has gone up in their commu-
nity, so has the percentage of damaged children."372 Moreover, these nurses
have asserted that while remaining constant in all preceding years, the census
of ill children observed in health rooms has increased by 300% in the last four
years. Their school district's condential health statistics indicate that at least
20% of their children have signicant neurological damage and/or some form of
chronic illness and that the numbers of children with developmental disorders
have steeply increased, as well.373
Championing the vaccine's possible side eects and the inadequate
studies which have been conducted to assess them
Realistically, before public health ocials stop HBV immunization, which
could save many lives per year and a proper evaluation of the vaccine's bene-
ts and risks can be made, strong evidence is needed that the vaccine causes
signicant side eects. However, before public health ocials initiate a nation-
ally mandated vaccination policy for any vaccine, they should have adequate
long-term clinical trials and even stronger evidence that the vaccine has no sig-
nicant severe side eects in any population, and especially in those in which it
372Nurse Letter, supra note 365.
373Id.
125is mandated. To date, few studies have been carried out to determine the causes
of the serious adverse events allegedly associated with the hepatitis B vaccine.
Since the IOM report, none of the recommended studies have been funded by
any of the drug companies and none have been reported in the literature.374
While documentations in medical literature and patient reports do not \prove"
that the vaccine is causally related to the adverse reactions reported following
its administration, a plausible etiologic link warranting further study is strongly
supported, at the very least, by the close temporal relationship between hepB
vaccination and the onset of similar symptoms reported in vaccinated patients,
the resemblance between the serious reactions to the hepatitis B vaccine and the
extrahepatic manifestations of hepatitis B infection, and the possible immune
complex mechanism driving the immune response to the vaccine and the virus.
Among others, Dr. Dunbar is determined to investigate the possible etiologic
link of adverse reactions reported as being caused by the hepB vaccine and her
commitment to this endeavor must be applauded. Clearly, in order to establish
the immune mediated nature of these phenomena, immune complexes contain-
ing HBsAg and antibodies must be identied and studied in recently vaccinated
individuals of appropriate genetic and age populations. Dr. Dunbar is studying
the immune responses to HBsAg in dierent individuals developing autoimmune
responses, in part to test her hypothesis that subsets of patients having adverse
reactions to the vaccine have similar and predictable gene sequences. Addition-
ally, as a researcher and expert in cellular and molecular biology, Dr. Dunbar
374Computer searches conducted by Dunbar of the literature from 1966 to present; personal
communication received by Dr. Dunbar from other scientists.
126is investigating the possibility that molecular mimicry or other autoimmune
mechanisms may be the means by which the genetically engineered hepatitis B
vaccine \tricks" the immune systems of genetically susceptible individuals into
attacking their own bodies so as to consequently cause debilitating autoimmune
disorders. She hopes that in researching the long term prognosis for patients
having adverse reactions to the vaccine, she will be able to develop a prophy-
lactic strategy for identifying those likely to react adversely as well as specic
therapeutic strategies for those who have already responded adversely to the
hepB vaccine.375
A critic of the molecular mimicry hypothesis, Dr. Marrack has challenged any-
one \to take T cells from a live person and show that they react to both self
proteins and to a pathogen that mimics self," because \[t]hen you'd know that
pathogen started that disease in that person. You'd catch the gun pointing at
the right person." So far, according to Dr. Marrack \that experiment has not
been done."376 To meet Dr. Marrack's challenge and in furtherance and in
need of her goals, Dr. Dunbar has applied to the National Institute of Health
(NIH) for funding. Specically, she requested that the NIH support her eort
to investigate the scientic basis and genetic role of the adverse reactions being
attributed to the vaccine, similar to those manifesting in HBV infected individ-
uals. Consistent with the rhetoric professed by several federal health authorities
in refutation of the vaccine's potential for harm, 377 the NIH has denied her pro-
375Personal Communication from Dr. Dunbar; Dunbar's Proposal to the NIH, supra note 6.
376Times, supra note 269.
377CDC Fact Sheets, supra note 51; see Margolis' Testimony, supra note 12; AMA Fact
Sheet, supra note 11.
127posal twice for lack of \epidemiological data" that the adverse reactions being
reported are causally associated with the vaccine.378 Dr. Marrack's comment,
the NIH's refusal to fund Dr. Dunbar's studies, and federal health authori-
ties' staunch reliance on the abyss of scientic knowledge insulating this vaccine
from censure can all be perceived as casting doubt on the possible causal rela-
tionship between the vaccine and the reactions reported thereto or the possible
mechanism by which the adverse reactions may be induced. Although poten-
tially debilitating, these responses, however, only fortify and empower the case
against the safety of the hepatitis B vaccine by pointing to the powerful catch-
22 that pervades and lies at this controversy's core. Scientic evidence has not
yet demonstrated a causal relationship between the vaccine and the induction
of its reported side eects because no studies have been done to detect such a
relationship. No studies have been done because federal health authorities and
some scientists still do not believe or will not allow themselves to believe that
such a relationship can exist.
In light of this catch-22, it is not surprising that government funds are not be-
ing allocated to study adverse reactions possibly caused by this vaccine as it
relates to the genetics of those infected with the HBV virus and injected with
the vaccine.379 Moreover, at the recent Institute of Health meeting held at the
National Academy of Sciences, it was apparent to Dr. Dunbar that the CDC
and the FDA still did not have information pertaining to the role genetics can
play in the adverse responses which are believed to be induced by the vaccine.
378Personal communication with Dr. Dunbar.
379Skinner Report, supra note 26.
128Dr. Dunbar nds this absolutely remarkable, if not imaginable as a scientist,
in light of the long established belief held by the scientic community that the
immunological reactions to the hepatitis B virus and to HBsAg, as used in the
vaccine, have great genetic variability.380
Although the AMA, the CDC, WHO, and other federal agencies continue to
assert that no scientic evidence to date supports a causal association between
hepatitis B vaccination and demyelinating diseases so as to warrant further
study, interestingly, studies are nevertheless being organized in the Vaccine
Safety Datalink project at the CDC because of \public concern" about the
issue and the insucient research on this specic topic.381 Computerized med-
ical records on approximately 5 million or 2% of the U.S. population are being
used in this study. Results will probably be available in a year.382 There are
also at least six research projects underway attempting to examine whether
a causal relationship exists between the hepatitis B vaccine and MS, at least
two of which are funded by vaccine manufacturers.383 Results will also become
available soon. Despite their potential for great informational benets, the ex-
perimental designs of these studies, like those which have preceded them, have
been seriously questioned. It is apparent to Dr. Dunbar that new studies being
done will not take genetic variability, of paramount importance, into account.
The CDC study will be conducted in California, where investigators will not be
able to ask about race. Dr. Dunbar has also been told that clinical trials will
380Personal Communication with Dr. Dunbar.
381CDC Fact Sheet, supra note 51.
382Margolis' Testimony, supra note 12.
383AMA Fact Sheet, supra note 11; Shadow Falls, supra note 273.
129exclude anyone who has or has a family history of an autoimmune disease. This
is especially worrisome because states are increasingly mandating that all chil-
dren receive this vaccine when scientists are not performing appropriate studies
to evaluate vaccine associated risks for those with a genetic predisposition to
such diseases.384 Surely, no one would agree that such genetically susceptible
individuals are less worthy of protection or should be sacriced in the crusade
against halting HBV transmission among drug abusing or sexually promiscuous
adults.
Clearly, one cannot evaluate the risk-benet issue for each population exam-
ined unless there is, at the very least, a sucient and forthcoming exchange
of information with respect to the safety of this vaccine or adequate clinical
investigations into what initially appears to be potential problems associated
with a vaccine that later manifests in the lives of many individuals. Involuntary
public human experiments do not suce. The CDC's study, and others being
conducted, must address not only \public" concerns, but also the concerns of
physicians, immunologists, epidemiologists, and other basic scientists, such as
those of the IOM and those participating in the study group on hepatitis B
vaccines.385 Moreover, such studies should consider as seriously the thousands
of \anecdotal reports" of adverse events reported as a consequence of HepB vac-
cination as the CDC has done in comparing \anecdotal" reports of HBV and
HIV transmission related events.386 Furthermore, these studies should be car-
ried out to determine the long-term prognosis for patients experiencing adverse
384Personal communication with Dr. Dunbar.
385Response Sheet, supra note 10.
386Id.
130reactions to the vaccine so that a prophylactic strategy for identifying those
likely to react adversely and therapeutic strategies for those who have already
done so can be developed. Individuals who may have a family history of a disease
must be included, so that risks can be evaluated for those with possible genetic
predispositions. At the very least, such investigations could warn those popu-
lations who might have a greater risk for responding adversely to the vaccine.
Immunologists and vaccinologists who have the ability to investigate the origins
and mechanisms of such adverse events should be funded and allowed to do so.
Just as we would not ask nor expect the tobacco industry to conduct unbiased
investigation and research into the potential causal relationship between lung
cancer and smoking, it is imperative that only individuals not aliated with or
receiving compensation from any of the vaccine manufacturers be involved in
these studies. It is clear that the Institute of Medicine is in agreement with the
points highlighted and summarized here. In its report, it published that \more
research could be done on potential long term adverse eects from vaccines
as well as the potential of vaccines to induce or worsen immune disorders."387
Moreover, it asserted that \[t]he use of larger and better designed clinical trials
conducted both before and after a vaccine's licensure for general use could also
be considered to improve the rate of detection of rare adverse events" as well as
\vaccine recall procedures." 388
Consistent with the IOM's recommendations, Dr. Dunbar and other scientists
are challenging the catch-22 which so powerfully pervades our public health pol-
387Dunbar's Letter to Kane, supra note 181.
388Id.
131icy. She has obtained limited funding from private sources and will nevertheless
undertake her proposed studies in collaboration with an immunogeneticist and
a hepatitis virus expert at the University of Oklahoma. She and her collabo-
rators have well-equipped laboratories for state of the art immunological and
biochemical analyses and they have already collected blood samples throughout
the country from those reporting adverse reactions to the vaccine. Although
inadequate funding has slowed the progress of the unique studies which she has
initiated, her eorts will persist. Clearly, her studies are critical to understand-
ing the nature and cause of the adverse events being reported as following the
hepatitis B vaccine's administration. This and other studies should be carried
out to evaluate reports of severe adverse eects as a consequence of vaccina-
tion before this vaccine is used universally, if not mandated, in immunologically
fragile infants who may not otherwise be at a signicant risk for contracting or
transmitting the HBV virus. In addition to Dr. Dunbar's study, laboratories
not associated with drug companies are in the process of investigating etiologic
links between the vaccine and rheumatoid arthritis.389 Epidemiological studies
specically aimed at testing the existence of a relationship between the vaccine
and the inducement or exacerbation of autoimmune disorders are being planned,
as well.390 In France, 150 physicians have petitioned the French Academy of
Sciences to commission a study by investigators not connected to manufactur-
ers of the vaccine. The Academy endorsed the call for a survey.391 Scientists
389Skinner Report, supra note 26.
390Dr. Bonnie Dunbar, Dept.Cell. Biology, Baylor College of Medicine ( personal communi-
cation).
391Skinner Report, supra note 26.
132planning and carrying out these studies (both in the U.S. and abroad) report
receiving two and three communications per day (via email, fax, letter, or tele-
phone) from patients and medical personnel asking to contribute their own or
their patients' data to the studies.392 It looks like the quest for scientic truth
is underway.
392Id.
133ROLE OF THE VACCINE ADVERSE EVENT REPORTING SYSTEM IN ASSESSING THE VACCINE'S SAFETY
THE VAERS SYSTEM
Until new scientic research is conducted and results are released, the Na-
tional Childhood Vaccine Injury Act of 1986, specically the Vaccine Adverse
Event Reporting System (VAERS) which it created, will continue to play an
important role in assessing the safety of this vaccine. This national system was
designed to collect, manage and evaluate reports of possible adverse events re-
lated to vaccination. Initiated in 1990 and jointly managed by the CDC and
FDA, VAERS has been instrumental in meaningfully assessing vaccine risks.
Considered to be the \front line" of national vaccine safety supervision,393 it
is the only surveillance system that covers the entire U.S. population. Though
potentially comprehensive, VAERS is a passive surveillance system, whose suc-
cess relies on the contributions of physicians, health care providers, parents and
vaccine manufacturers to submit reports of adverse reactions that occur dur-
ing a period following vaccination. VAERS data are available to the public
through the National Technical Information Service and also through requests
made to the FDA's Freedom of Information oce.394 The criteria for reporting
to VAERS are non-restrictive in that the VAERS system will accept and include
393Ellenberg, supra note 239.
394General Information and the VAERS form itself are available on the VAERS Internet
web-site. The address is: http://www.fda/gov/cber/vaers.html.
134any report, if submitted.
Vaccine manufacturers are required to report every potential adverse event of
which they learn; however, they are not penalized for not doing so. Even if
reported, documentations of adverse events following vaccination cannot con-
clusively establish causation, without an extensive follow-up of each serious
event and death report made. Careful review, however, of such reports during
months following a vaccine's licensure can uncover previously unexpected events
or potential problems, only detectable when a vaccine is used in a more diverse
population group than originally studied in clinical trials. Thus, this type of
system is essential to the discovery of potential adverse consequences because
as Dr. Ellenberg notes,
It is the only surveillance system which covers the entire U.S. population
and includes the largest number of case reports of events temporally associ-
ated with vaccination in the U.S. It provides timely availability of data from
a geographically diverse population, allowing rapid detection of possible new,
unusual or rare adverse events. Such detection generates hypotheses that may
then be tested in other databases.395
Moreover, as an open forum of information for public purview and contri-
bution, the VAERS system has tremendous potential to provide for a greater
in-depth understanding of the nature and scope of vaccine associated adverse
events. Despite its virtues, noble intentions and potential for success, VAERS
is not without criticism. The VAERS system is perforated with problems and
leaves much room for improvement. Supporters of the mass vaccination program
criticize the VAERS system as being over-inclusive, while critics assert that it
is under-inclusive of adverse events possibly induced by the hepB vaccine.
395Ellenberg, supra note 239.
135PERSPECTIVES OF PUBLIC HEALTH AUTHORITIES
Supporters of the federal mass vaccination program do not believe that the
number of side eects reported to VAERS establish a sucient justication for
questioning the administration of the hepB vaccine or its safety. The CDC lists
at least three major limitations of relying upon VAERS data. First, VAERS
accepts all reports of adverse health events which follow vaccination, regardless
of the cause. Second, the same case may be reported to VAERS more than
once when dierent people le the same report. For instance, a health care
provider, a parent, and a manufacturer may all send VAERS the same report so
as to result in several entries of the same case into the database. Additionally,
the same report may also be led separately for dierent vaccines administered
at the same time. Third, the details and diagnosis of a given report may be
incomplete or inaccurate depending on a person's access to complete clinical
information.396 Consistent with the stance taken by the CDC, Dr. Margolis be-
lieves that case reports of serious adverse events obtained through VAERS often
do not represent true consequences of vaccination. While reports to VAERS,
jointly managed by the FDA and the CDC, can provide valuable information
about serious adverse events that may be associated with a vaccine, he believes
that such data can only be used to generate hypotheses, rather than to de-
termine whether a vaccine could actually cause an adverse event. While some
patients may develop symptoms of illness subsequent to vaccination, Dr. Mar-
396CDC Fact Sheet, supra note 51.
136golis relegates these symptoms to chance or the recognition of a patient's earlier
illness that does not increase the overall risk of that illness occurring.397 Sim-
ilarly, Susan Ellenberg, director of the Biostatistics & Epidemiology Division
of the Center for Biologics Evaluation and Research at the FDA, believes that
\with virtually universal childhood immunization, beginning at birth or shortly
thereafter, any adverse medical event in a child will `follow' vaccination, and
some of these will coincidentally follow within a few days of vaccination."398
As indicated previously, Dr. Susan Ellenberg, of the FDA, would more readily
attribute causality to an adverse reaction reported to an event, such as the ad-
ministration of the hepB vaccine, if:
1) the event conforms to a specic clinical syndrome whose association
with vaccination has strong biological plausibility ( e.g. anaphylaxis) ;
2) a laboratory result conrms association (e.g., isolation of vaccine strain
varicella vaccine from skin lesions of a patient with rash);
3) the event recurs on re-administration of vaccine (positive rechallenge); and
4) a controlled clinical trial or well-designed epidemiological study shows
greater risk of adverse events occurring among vaccinated unvaccinated (control)
groups.399
Dr. Ellenberg believes that few of the serious adverse events reported to
VAERS meet any of the rst three criteria and that any clinical trials conducted
are almost always too small to provide useful information on causality for most
rare events. Consistent with the opinions of many federal health authorities,
Dr. Satcher, assistant secretary for the Health and Surgeon General ( of the
U.S. Public Health Service Department of Health and Human Services) believes
397Dr. Margolis' testimony, supra note 12.
398Ellenberg, supra note 239.
399Id.
137that it \takes other studies to determine whether or not" reported data are
indeed due to vaccines.400 Nevertheless, he concedes that spontaneous report
based surveillance programs, such as VAERS, perform \a critical function by
generating signals of potential problems that may warrant further, more detailed
investigation" (emphasis mine). 401
VACCINE CRITICS CRITICIZE THE VAERS
Critics of the mass hepB vaccination mandates for children are not using
VAERS data to conclusively establish a causal relationship between the hepB
vaccine and adverse events reported as following its administration. Nor do
they use such data as the only link of condemnation. Consonant with the views
espoused by several federal vaccine advocates, the NVIC concedes that VAERS
reports are simply reports of adverse events which occurred after vaccination.
Without full medical record documentation and follow-up of each report, it is
impossible to conclusively determine causation.402
However, despite such limitations, such reports can be helpful, as even vaccine
advocates suggest, in determining the etiologic link of events reported. Critics of
the federal vaccine policy are indeed, in Dr. Margolis' words, using VAERS data
to \generate hypotheses"403 and are asking that such data be appreciated for
their signicance as \generating signals" that \warrant detail investigation,"
400Satcher, supra note 208.
401Id.
402NVIC Press Release, supra note 280.
403Margolis' Testimony, supra note 12.
138as Dr. Satcher has recommended.404 As previously explained, many reports
to VAERS of hepatitis B vaccine related adverse events contain similar symp-
toms that include fevers, rashes, vision problems, joint pain, muscle weakness,
seizures and other autoimmune and neurological dysfunctions. Moreover, many
of the deaths listed as SIDS cannot easily be written o as such since they in-
clude clinical manifestations that question the accuracy of the SIDS diagnosis.
Such data has provoked scientists and physicians to delve deeper and determine
whether some deaths and reactions may have been vaccine related. Addition-
ally, the NVIC asserts that while children usually receive multiple vaccines on
one day, such has not been the case with the administration of the hepatitis B
vaccine. To temper causality complexities, many adults and children have only
received the hepatitis B vaccine at the time of their hepB vaccination; there-
fore, many VAERS reports represent children who only received the hepatitis
B vaccine prior to their reported hospitalization, injury or death. Thus, rather
than relying on VAERS to provide a link of causal condemnation, NVIC and
its supporters merely ask, as Dr. Ellenberg recommended, that \other types of
studies" 405 be appropriately performed to determine whether or not the ad-
verse events being reported are related to the vaccine.
As demonstrated in the preceding section of this paper, scientic research has
proposed a \biologically plausible" mechanism by which the vaccine may in-
duce adverse reactions in vaccinated patients ( e.g., molecular mimicry). Addi-
tionally, reports of adverse events following vaccination allude to the existence
404Satcher, supra note 208.
405Ellenberg, supra note 239.
139of \positive rechallenges," among those receiving the hepB vaccine, especially
when one considers the rarity of such disorders in the general population and
the cluster of such cases documented in those vaccinated. As adults, in addition
to infants and children, continue to suddenly exhibit immune and neurologi-
cal dysfunction following vaccination, it will be more dicult to convince such
patients that they had an underlying genetic or metabolic disorder waiting to
be expressed and whose manifestation happened to coincidentally coincide with
the administration of the hepB vaccine. As a national sentinel system, VAERS
should be used to warn practitioners, government ocials and patients that a
vaccine may be associated with some health problems, especially when many
of the vaccine-related adverse event reports contain similar symptoms { as is
the case with the hepatitis B vaccine. More importantly, federal ocials should
proceed with extra caution before requiring that individuals subject themselves
to protocols lighted by possibly portentous signs that danger lies ahead.
Though supportive of VAERS for its enormous informational potential, critics of
the federal vaccination policy are not without criticism of the VAERS system.
The VAERS system, as currently structured, is highly inadequate to provide
the necessary scientic information for which it was created. In analyzing raw
computer data generated from VAERS, the NVIC has found that most of the
hopes and expectations for increased reporting, better education and prevention
of vaccine injuries have not been realized through this system. Specically, the
NVIC has found (1) that most health care providers fail to report such reac-
tions; (2) a lag time exists between the onset of adverse events and the ling of
140reports to document them; (3) reports are often lled with data entry errors;
(4) reports are duplicated; (5) government ocials fail to adequately follow-up
reported serious injuries and deaths; (6) some vaccines are still on the market,
despite their association with high numbers of adverse event reports.406 Given
these problems, critics of the mass administration of the vaccine believe that the
adverse events reported only represent a small percentage of adverse reactions
actually occurring in the U.S. as a consequence of the hepB vaccine, namely less
than 10%.407
While VAERS permits physicians to report an adverse event as long as there is
mere \suspicion" that the drug or vaccine may be related to an adverse eect,
many have and do not. The success of the VAERS system and other similar pas-
sive programs depend on health care professionals' surveillance and voluntary
reporting of adverse events following vaccination. Such surveillance, in turn,
depends on pediatricians' variable levels of awareness and index of suspicion
for such events|levels which have been shown to be decient in many regards.
David Kessler has provided several reasons why physicians do not report serious
events to the FDA or the vaccine manufacturer following the administration of a
vaccine shot. For example, when confronted with an unexpected outcome from
treatment or the administration of a vaccine, many physicians do not consider
the reaction to be vaccine induced, but rather consider the event to be related to
some other factor or the biology of the vaccine recipient's make-up. Health care
practitioner dismissal of possible vaccine related events may be a consequence
406Information distributed by the NVIC.
407NVIC Press Release, supra note 280.
141of limited training in therapeutic decision making and clinical pharmacology.
Additionally, physicians are not culturally inclined to notify the FDA about ad-
verse events or product problems. Nor do they readily consider drug or device
induced disease when confronted with unexpected outcomes; instead, they con-
sider such reactions to be related to the course of the disease. Finally, physicians
may be unclear as to what adverse reactions should be reported to the FDA.408
The FDA has even conceded to the fact that the VAERS system is highly under-
representative of the number of adverse events of which vaccine recipients ac-
tually suer. FDA statistics indicate that the majority of VAERS reports are
made by doctors. However, in 1993, a former FDA commissioner wrote in the
Journal of the American Medical Association that one study showed that \only
about 1 percent of serious events" attributable to drug reactions are reported to
the FDA,409 and other studies have estimated that physicians only report ap-
proximately 10% of events related to a vaccine's administration.410 Moreover,
the NVIC presents additional support for the proposition that reports made by
doctors to VAERS represent only a small fraction of the vaccine-related injuries
and deaths occurring in the U.S. every year. A 1994 NVIC study of 159 doctor
oces in seven states found that only 28 out of 159 doctors ( 18%) surveyed
indicated that they submit reports to the government (to any federal agency,
such as the FDA, CDC or any health department) when a child suers a seri-
ous health problem following their hepB immunization. In New York, only one
408David Kessler, M.D., Introducing MEDWatch, JAMA June 2, 1993, vol. 269, no.21, at
2765-2768.
409NVIC Press Release, supra note 280.
410Fisher Statement, supra note 2.
142doctor out of 40 surveyed reported vaccine related adverse events to any govern-
mental agency. This nding suggests that 97.5% of vaccine related deaths and
disabilities go unreported in this greatly populated and vaccinated state. As
found in New York, data obtained from the six other states surveyed revealed
that few physicians, if at all, report, to any federal agency, whether it be the
FDA, CDC, or a local health department.411
State Doctors Reporting
Arkansas 23 7
California 11 3
Georgia 21 9
Illinois 24 4
Maryland 26 2
New York 40 1
Texas 14 2
A survey of pediatric clinics in Arkansas further illustrates that the prob-
lems associated with physician reporting of vaccine related adverse events are
not unique to these seven states and probably run rampantly nationwide. Many
of the nurses surveyed in Arkansas had indicated that the doctors for whom they
worked did not report adverse reactions to proper authorities, if at all, follow-
ing a patient's vaccination. While a few did believe that adverse events were
reported to a health department, a follow-up revealed that most state health
department ocers did not pass reports of adverse events received to the CDC
or any other federal agency.412 Although fewer than ten percent of all doctors
obey the law and report serious health problems experienced by patients follow-
ing their HepB vaccination, the federal government still receives between 12,000
and 14,000 reports of related hospitalizations, injuries and deaths every year.
If this estimation represents less than 10% of what is actually occurring, then
the number of adverse events occurring annually as a consequence of the hepB
vaccine may exceed 100,000 cases. Thus, the 12,000 to 14,000 annual reports of
hepB vaccine related injuries and deaths, often dismissed by federal health au-
thorities as being rare occurrences, may be just the \tip of the iceberg," of what
is awaiting to be unearthed by responsible investigation. Clearly, determining
411VAERS information obtained from the NVIC (1994 study results) ( If the oce indicated
they report to any federal agency i.e. FDA, CDC, or health department, the report was
counted).
412Survey obtained from the NVIC of nurses working in health clinics in Little Rock,
Arkansas.
143what fraction of these unreported events lead or have lead to permanent injury
or death cannot be properly assessed without improvements in reporting eorts
by health care practitioners.
Sadly, many physicians and medical students have not yet appreciated their
instrumental role in maximizing the informational resource potential of the
VAERS system. Indeed, many physicians have asked Dr. Dunbar \why should
they look at it [the vaccine] or discuss it with their [patient's] parents," since it is
recommended and mandated by government ocials.413 Others have said that
their colleagues do not report adverse incidences related to hepB immunization
because they \don't want to get involved."414 They further tell her that they
have been informed that this vaccine is the safest ever developed because it is a
recombinant DNA vaccine and \therefore you can't get the disease."415 Unfor-
tunately, these health practitioners either misinterpreted or missed a signicant
aspect of immunology. As explained before, any peptide ( a limited sequence
of amino acids of a protein) or a full length or truncated protein (produced by
purication from a biological source or using recombinant technology) when in-
troduced into the body will be processed by the immune system, and depending
on the nature of that protein, could result in long-term autoimmune reactions.
Unfortunately, Dr. Dunbar believes that such details of immunology are not
taught in medical schools. A senior member of a national health committee,
involved in recommending school mandates for childhood vaccines, approached
her after a speech she had given to the Institute of Medicine at the National
Academy of Sciences. It was apparent that even he needed some brushing up
on the basics of immunology, as he commended her on her speech and asked
her for some guidance with respect to this aspect of immunology. Thus, it is
essential that before we are able to tap into the wellspring of information which
lies at VAERS' core and detect adverse events associated with the hepB vac-
cine, physicians must be better educated on the potential risks associated with
this vaccine, its possible interactions with other vaccines and the increased risks
that hepB vaccination could impose on already sick or genetically susceptible
children.
Insucient reporting eorts by health care professionals is far from being the
only problem plaguing the VAERS system. Scientists attempting to delve deeper
into what adverse events are actually reported face a daunting task. Dr. Dun-
bar rst encountered VAERS, after observing two individuals in her laboratory
develop serious medical problems following their hepB vaccination. These prob-
lems were similar, if not identical in nature, to those listed in the Physician's
Desk Reference text as reported reactions to this vaccine and within a time
frame predictable for consequential immunological reactions. After paying to
obtain reports of similar adverse reactions from the FDA, under the Freedom
of Information Act, Dr. Dunbar found herself buried by thousand of pages of
documents listing thousands of hundreds of reports identical to those which she
had led. Despite the inadequacies of these reports, the information contained
413Dunbar's Testimony, supra note 4.
414Id.
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144within them did demonstrate a unifying theme. The responses reported neu-
rological damage, arthritis- like symptoms, and other immunological disorders
which were not only similar to each other, but also similar, if not identical, to
those alluded to in dozens of published medical journals warning of the vaccine's
possible ability to cause severe immunological reactions. Although invited and
incited by this correspondence to delve deeper into the reactions reported, it
seemed as though Dr. Dunbar had extended her welcome. Finding enough
information to warrant an extensive follow-up investigation of a causal rela-
tionship, her eorts to understand the nature of the events reported and their
possible association to the vaccine were severely hampered by the limited data
contained within the reports. 416
While providing a plethora of data, Dr. Dunbar found these lists to be inade-
quate for the purposes for which they were admitted to the VAERS. Although
a pioneering scientist in contraceptive vaccine development, she could not study
the mechanisms by which the reported reactions could have occurred. The re-
ports did not and still do not provide essential medical details (e.g., patient
identity, genetic background, family history of autoimmune diseases, etc). Nor
do they enable one to contact the physicians who reported these reactions.
Moreover, there did not seem to be any follow-up action taken on the reactions
which she attempted to examine. Consistently, no one had contacted her in
response to the reactions she had herself led. Overall, she found that the in-
formation provided by VAERS to be \inadequate and not accessible to those of
us who are studying the serious adverse reaction events apparently related to
this vaccine."417
Physicians and Scientists have not been able to maximize the potential of the
VAERS system. Moreover, manufacturers have wielded it to their advantage.
Though required to report adverse reactions attributed to their vaccines, man-
ufacturers are not penalized for not doing so. As a consequence, VAERS's po-
tential for success has been left in the grasp of parents who wish they had never
entrusted their children's care in the hands of health care providers. Surely,
parental reporting to VAERS can help compensate for so many of the inadequa-
cies associated with physician reporting and record documentation. However,
in order to be eective, parental eorts and strides must be taken seriously and
sympathetically. Public condence in health care systems, especially VAERS,
has already been greatly compromised by the failure of public health authorities
to appreciate parental contribution to the detection of adverse events following
the vaccine's administration.
Feelings of bureaucratic incompetency overwhelm parents like Michael Belkin,
who is left wondering how many other children died during the same time period
when his ve week old daughter, Lyla Rose, died. Though the world to him,
Lyla's death was apparently not signicant enough to be counted as a statistic
by the FDA. The New York City Coroner called the VAERS to report Lyla's
hepatitis B vaccine related infant death, but no one returned his phone call.
416Id.
417Id.
145If such a reporting system does not return the calls of the N.Y. City Medical
Examiner, one can only imagine how many other reports are ignored, as well. If
the VAERS is supposed to be the emergency 911 number for disasters of tainted
lots of vaccine that could poison thousands of other babies, then children may
be in grave danger. Michael Belkin's experience and skepticism of the vaccine's
safety is not unique. Several other parents, who similarly believe that their
children were injured by the hepB vaccine, are questioning whether the VAERS
provides a legitimate sample of data from which conclusions about the safety of
the larger population can be made.418
Parents, like Mr. Belkin, or the public more broadly, are learning from experi-
ence and disappointment that they cannot rely on purportedly reassuring stud-
ies or statistics presented by the FDA or other governmental health authorities,
which rely on the VAERS. For example, in a hepatitis B vaccine workshop at
the National Academy of Sciences (NAS), which Mr. Belkin attended recently,
the FDA declared that there were only 19 neonatal deaths reported to VAERS
since 1991 allegedly related to the hepatitis B vaccine. He, like many other
parents, have deemed the FDA and the \VAERS study data to be completely
deceptive."419 The fact that the \VAERS doesn't return coroner's calls" has
led him to believe that \deaths and adverse eects from vaccination are woe-
fully under-reported" and thus, to \conclude that the hepatitis B vaccine is safe
because VAERS only reports 19 deaths is scientic fraud."420 Pursuant to the
forum, Mr. Belkin personally obtained raw data from the VAERS system and
found 54 cases of SIDS to have been reported following the Hepatitis B vaccine
in just the 18 months from January 1996 to May 1997, alone. Indeed, Michael
left the NAS workshop with the impression that
Merck and the CDC didn't know and didn't really want to know how many
babies are being killed or injured by Hepatitis B vaccination. This is a bureau-
cratic vaccination program that is on auto-pilot ying into a mountain. The
CDC bureaucrats have a vested interest in the status quo. If there were 17,000
reports of a dangerous disease in an 18 month period, the CDC would be all
over the case. But when there are 17,000 reports of adverse reactions to a vac-
cine ( as there were in the 1996-1997 data alone) the CDC advocates for `public
health'{ the CDC dismisses it as a coincidence. 421
Michael Belkin's opinions are representative of the views which are cur-
rently pervading the public conscience. A recent letter testimony submitted to
Congress by a school nurse concerned about the safety of the hepatitis B vaccine
similarly expressed the feelings that the
418Belkin, supra note 3.
419Id.
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146CDC and FDA have no idea what the long term eects will be on the newly
developing neurological and immune systems of infants who are injected with
this vaccine. They seem to be only concerned with denying the connection
between these damaged children and the hepatitis B shot they received within
a few hours of birth. 422
If these voices echo the pain being felt in the hearts of many parents and
more broadly, the public, then surely the critics of the federal vaccine policy
are not to blame for the deteriorating public condence in the vaccine or more
generally, our public health systems. Time and time again, the public is pointing
to the government as the culprit, as they repeatedly nd it \red handed" with
negligence.
IMPROVING THE VAERS SYSTEM AND THE REPORTING
OF ADVERSE EVENTS
Underlying VAERS' unrealized success is a staunch presumption maintained
by government ocials and vaccine providers that the case reports of deaths and
injuries following vaccination are only temporally, not causally related to hepB
vaccination and that true vaccine adverse events are rare. By assuming rather
than proving that a vaccine did not play a role in causing injuries, causation
cannot be conclusively determined or even alluded to so as to warrant further
investigation. In being driven by this presumption, Barbara Fisher believes that
the Department of Health and Human Services has sadly contributed to the suf-
fering of many vaccine victims through the federal compensation system in order
to protect the status quo. In 1996, the Department proposed to add the hepati-
tis B vaccine to the Vaccine Injury Table (a table listing reactions to vaccines
422Nurse's Letter, supra note 365.
147for which vaccine victims will be compensated). However, it cited \anaphylaxis
within four hours" as the only adverse event presumed to be caused by the
hepatitis B vaccine, in spite of IOM's conclusion that no scientic studies have
ever been conducted to evaluate continuing reports and studies suggesting that
the hepatitis B vaccine can cause arthritis, SIDS, GBS, myoptic neuritis, MS,
transverse myelitis or other central demyelinating diseases. As a result of this
non-causality presumption, health ocials, much like those comprising DHHS,
fail to fully investigate reports of hospitalizations, injuries and deaths following
vaccination and have a standard, or at least release it to the public, for recalling
lots of vaccines which are associated with high numbers of hospitalization, in-
jury and death reports. Therefore, it is not surprising that several federal health
authorities continue to aver that there is no need to conduct full investigations
into individual reports of vaccine induced side eects or be concerned when high
numbers of hospitalizations, injuries and deaths are connected to any one lot.
As long as this presumption underlies the VAERS system, VAERS will not
enable public health authorities to realize the goals for which it was created,
namely adequately monitoring adverse events related to vaccination, gaining
knowledge about the nature, frequency, and severity of events following vacci-
nation or being able to adequately recall vaccine lots which may be more reactive
than others. 423
The ramications of this federally held presumption resonate beyond the ac-
423Barbara Loe Fisher, Statement on HHS Proposed Changes in the Vaccine Injury Table
and Qualied Aids and Interpretation of the National Childhood Vaccine Injury Act, National
Vaccine Information Center, May 1996, available upon request from the NVIC.
148tual VAERS system and contribute to and exacerbate the problems associated
with physician reporting, medical record documentation and follow-up investi-
gations for each adverse event reported. As a result of this presumption, no
publicity is generated by the government to inform the public that a federal
vaccine injury compensation system exists. As a consequence, many doctors do
not know about federal compensation programs, are afraid of costly lawsuits
and thus, fail to report hepB vaccine related adverse events. Many American
doctors who may be aware of the system still do not know that there is a Vaccine
Adverse Event Reporting System; those that do are not likely to believe that a
child's health problem reported by a parent following their child's vaccination
could have been caused by the vaccine which the physician had just adminis-
tered to the child. Thus, given that this presumption strings all the way through
the U.S. health care system, it surely is not surprising that, at most, only 10 %
of physicians ever report adverse events, and when they do, they report little,
if any, vaccine related information patient's medical records.
Contemporaneous with such inadequacies, an unknown number of chil-
dren are reacting poorly to vaccines. Many are suering permanent injuries
or even confronting death. Because their parents may never be told about the
VAERS program by the government or by their physicians and their doctors
may never recognize or do not want to admit that the vaccine they have admin-
istered is causally related to an adverse event of which a child complains, the
cause and nature of the child's health problem is often misdiagnosed. Hence,
the presumption initiated at the federal level does not halt at the health care
149practitioner level either. As a consequence of its eect on physician ideology
and concomitant ramication on their reporting and detection abilities, parents
are not informed as to how they can identify whether their child has responded
adversely to a vaccine or how they can monitor their child's health subsequent
to vaccination. Most parents would not even suspect that a vaccine could have
caused their child's sudden epileptic episode or death from \SIDS." Nor would
they be culturally or intuitively receptive to investigating or questioning the
safety of what their health care provider is administering to their child to pro-
tect their wellbeing. Moreover, the minority of parents who have actually taken
the initiative to question and challenge the safety of the hepB vaccine, before it
is administered to their child, are often treated with disrespect and hostility; as
a reward for their courage, their emotions are only traumatized even more.424
As this presumption nds reinforcement, many parents educated through the
tribulations of experience, like Michael Belkin, are stamped with the impres-
sion that \the Drug Company/CDC/FDA alliance has really pulled the wool
over the medical profession's eyes with the hepatitis B vaccine"425 and per-
haps, more broadly, over the public at large. Unless the thousands of reports
424In her testimony before the Government Reform Committee Hearing on Aug. 3, 1999,
Tonya Nelson describes her traumatic experience when her newborn daughter died shortly
following the hepB vaccination. The coroner and police treated her \like I [Tonya] had com-
mitted a crime...they questioned me over and over. It was not the kind of situation a mother
should be in when her child had just died." Tonya was called 2 months later and told by the
coroner that the cause of her daughter's death was the hepatitis B virus { which she could
have only gotten from the vaccine. Sixteen weeks later, she received the death certicate in
the mail and the cause of death was noted as \natural causes," otherwise known as \SIDS."
When she called the coroner in shock, she had found out that he was asked to resign. A
pathologist she was told to call told her to stop trying to nd others to place the blame on
and to go on with her life. Her doctor told her that she could not help her because malpractice
insurance is too expensive. Her phone call messages left with the CDC were never returned.
Many like Tonya continue to suer, with gaping open wounds.
425Belkin, supra note 3.
150of hospitalizations, injuries and deaths following vaccination are taken seriously
by vaccine regulators, policymakers, and vaccine manufacturers, the casualties
of mass vaccination policies will continue to grow and concomitantly feed into
the public mistrust of our public health structures. If public apprehension and
suspicion are engrained deep enough within the public conscience, the decay
of trust in the American public health landscape may inltrate other federal
health policies so as to spoil legitimate and well warranted ones.
In sum, most of the hopes and dreams for increased reporting, better educa-
tion, and prevention of vaccine deaths which fueled the creation of the VAERS
system have not been realized, despite governmental, scientic, physician and
parental eorts. VAERS has raised the red ag, warning us that patterns of
similar health problems are occurring following the administration of one vac-
cine or a combination of vaccines. Such signals must be followed with rigorous
scientic investigation. As the IOM concluded, there are \many gaps and lim-
itations in knowledge bearing directly or indirectly on the safety of vaccines."
426 What is clear and cannot be denied is that there is a vacuum of scientic
knowledge about how or whether the hepatitis B vaccine causes the adverse
reactions reported thereto. This information gap makes \it far too easy for
health ocials to minimize vaccine risks and write o health problems following
vaccination as simply `coincidentally' occurring at the same time of vaccination
or to suggest, without any empirical evidence whatsoever, that the child who
426Fisher Statement, supra note 2.
151reacts is genetically defective."427
Indeed, adverse reporting and data collection systems will continue to be awed
as long as the presumption is maintained that case reports of deaths and injuries
following hepB vaccination are only temporally, not causally, related to its ad-
ministration. As Barbara Loe Fisher demonstrates, \ if you don't believe they
occur or occur only rarely, you wont look for them. If you don't look for them,
you won't nd them."428 Clearly, \the success of detection methodologies are
entirely dependent upon the willingness of those doing the detecting to believe
in the plausibility of cause and eect and explore all possibilities."429
Those who oppose the mandatory hepB vaccination schedule for children are not
asking that every adverse report be regarded as a causal consequence of hepB
vaccination. However, they do believe that to further a goal of detecting actual
adverse events rather than dismissing them, we must fundamentally transgure
the presumption which underlies our public health system. It may probably
be better to prove that a vaccine did not play a role in an adverse event than
to conveniently assume it did not. This change is especially signicant where
vaccination is mandated for otherwise healthy children. A proper functioning
reporting and data collection system will require that this transformed presump-
tion be carried at every step along the way of our public health system, from
pre-licensing to post-marketing surveillance of vaccine related injury and from
427Id.
428Opening Statement by Barbara Loe Fisher, Institute of Medicine Vaccine Safety Forum,
Workshop on \Detecting and Responding to Adverse Events Following Vaccination," Nov.
6,1995. Available upon request from the National Vaccine Information Center [hereinafter
Detecting and Responding].
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152federal health authority ideology to parental responsivity. A \new or old vaccine
should be recognized as having the potential to cause health problems that have
not yet been detected because of the limits of human intelligence, technology
and funding." 430
As previously explained, the detection of vaccine induced adverse reactions is in-
extricably linked to the acceptance of causal relationships by both reporters and
data collectors. Consequently, ecient detection of adverse events depends on
a high reporting rate by private physicians, public health clinics and emergency
rooms of adverse events occurring within thirty days of vaccination. Medical
schools should integrate into their curriculums courses on vaccine risks, ben-
ets and side eects as well as ways in which physicians can act as partners
with parents in preventing or responding to vaccine induced reactions. Edu-
cation campaigns should be promoted to emphasize and inform physicians and
the public about the importance of screening children at risk for responding
adversely to the hepB vaccine, monitoring children after vaccination, seeking
medical attention for vaccinees if vaccine related reactions do occur, and report-
ing adverse events following vaccination to the government. Moreover, health
care practitioners must become more amenable to reporting such adverse events
to VAERS, rather than merely dismissing them as coincidences. Perhaps physi-
cians should be mandated to report vaccine adverse events and be penalized
for not adhering to their responsibilities, much like the mandatory vaccination
laws which exclude children from school if they do not comply. Clearly, we
430Id.
153will never be able to detect and understand vaccine related adverse events if
health care providers continue to erroneously determine or dismiss causality at
the reporting level.
Once death, hospitalization or injury is reported following the administra-
tion of a vaccine, data collectors and federal health ocials must also be ready
to accept the possibility of a cause and eect relationship. According to Fisher,
there should be a forty-eight hour on- site follow-up and investigation of the
report. Adult patients should be interviewed, while parents of children patients
should be questioned. Deaths labeled as SIDS, especially occurring when the in-
fant is less than a month of age, should be considered \suspect" and thoroughly
investigated. Additionally, a mechanism should be developed to monitor the
outcome of possibly related vaccine serious events, such as seizures, with long
term follow-ups being conducted after six months, a year and two years, to
gather data on permanent damage { the type which is being reported as a
consequence of this vaccine.431 The mechanisms for detecting adverse events
which occur within thirty days of vaccination are dierent from those which
must be set up to detect health problems which have more subtle or delayed on-
sets; learning disabilities, for example, do not become measurable until children
are old enough to attend school. Improved detection of reactions with delayed
onsets will require retrospective evaluation of historical data as well as the cre-
ation of prospective studies which compare unvaccinated controls to vaccinated
individuals over a period of ten to twenty years. While such studies would be
431Id.
154expensive and logistically dicult, they may be necessary if we are to determine
which vaccines are contributing to the development of immune and neurological
damage in young children, often not becoming apparent until later in life.432
Since today's children are our country's future, the expenditure of such eorts
and resources are well worth the cost.
In addition to improving reporting and follow-up methodologies for adverse
events which are possibly vaccine induced, federal health authorities must rec-
ognize and appreciate the value of the VAERS system as being another source of
signicant information for adequately detecting adverse events. Data obtained
from the VAERS system are not only valuable for identifying patterns of classic
vaccine reactions which warrant further investigation, but are also instrumental
for identifying categories of children who should be screened out of mass vacci-
nation programs and who may, otherwise, painfully pay for the politics which
gamble with their lives.
432Id.
155FRANCE HALTS THEIR HEPB VACCINATION MANDATE WHEN ALLEGED VICTIMS OF THE HEPB VACCINE SUE:
In October 1998, France became the rst country to suspend a government
mandate requiring that school children receive the hepatitis B vaccine protocol.
Faced with a potential public health disaster, this halt was taken in response
to a plethora of reports of chronic arthritis, neurological disorders, symptoms
resembling multiple sclerosis, autoimmune and other serious health problems
following the administration of the hepB vaccine. One French physician has re-
portedly collected data on more than 600 people suering from serious immune
and neurological dysfunctions, many resembling multiple sclerosis, alleged to
be induced by the hepB vaccine.433 Consistent with a 1998 Canadian study
published in The Journal of Rheumatology ( 1998:25:1687-93) by Pope et. Al.,
French data released in 1998 at the 62nd Annual meeting of the American Col-
lege of Rheumatology linked the vaccine to the development of autoimmune
rheumatoid diseases, such as lupus and rheumatoid arthritis, in genetically sus-
ceptible individuals.434
Perhaps it was the force of lawsuits against vaccine manufacturers and the
French government that spurred this sudden halt to the heretofore mandated
childhood vaccine, rather than a over due concession to what was hypothesized
and denied for years. Most interesting and perhaps, instrumental, in France's
suspension of the vaccine's administration is the class action litigation currently
occurring in France. As of July 1998, French attorneys representing 15,000
433NVIC, Hep B Vaccine Victims in France Sue; France Suspends Hep B Vaccine Mandate,
available at < http: // www.909shot.com/hepbfrance.html>.
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156French citizens and at least fteen associations led a lawsuit against the French
government \accusing it of understating the vaccine's risks and exaggerating the
benets for the average person."435 These plaintis are bringing suit against
the entities they believe are responsible for the adverse reactions they have ex-
perienced following the receipt of the hepB vaccine. As a consequence of the
mass hepatitis B vaccination campaign organized by the Minister of Health and
vaccine producers, more than 20 million people have been vaccinated in France
since 1994, either because they were obliged to do so or because, as the plaintis
in this class action contend, they were \pressed into accepting the vaccination
(either for themselves or for their children)."436 Increasingly, these individuals
have learned that the vaccine is not without serious risk, the magnitude of which
is not yet known. Moreover, the plaintis in this class action, including private
and public entities as well as physicians, believe that they have been victimized
by government health authorities and pharmaceutical companies. Specically,
these plaintis assert that the defendants in this class action deliberately dra-
matized the prevalence of HBV in France by propagating false information on
its mode of transmission and real magnitude. In addition, they assert that they
were not told at the time they or their children were vaccinated, and still have
not been informed, of the vaccine's possible serious side eects. Furthermore,
these individuals allege that the vaccine has subjected them to and continues
435Id.
436This section of the paper is based from and recounts the facts and allegations contained in
the complaint led by the National League for Liberty in July 1998 against the French govern-
ment and vaccine manufacturers for the administration of the hepB vaccine; this document is
available at, < http://www.ctanet.fr/vaccination-information/plainte.html>. Citations
have been omitted.
157to expose them to physical threats that could have otherwise been avoided.
The history of the vaccine's recommendation, promulgation and nal halt in
France, as recounted in these plaintis' complaint, and from which this section
is based, is interesting for its striking resemblance to the chronology of events
currently culminating in a controversy outbreak in the United States. Being one
step ahead of the U.S., the chronology of events which took place in France is not
only signicant for its evidentiary value with respect to the vaccine's potential
to harm, but also for its symbolic import of what may result and what is now
gaining momentum throughout the U.S. as states and the federal government
continue to urge, if not mandate, that children and newborns be vaccinated.437
THE PREVALENCE OF HEPATITIS B IN FRANCE
France is one of the countries of the world least aected by the Hepatitis
B virus, with an incidence rate of approximately ve to ten cases per 100,000
inhabitants. Moreover, there are only an estimated 100,000 chronic carriers and
8,000 new cases led in France per year. The prevalence of the virus in France is
100 to 200 times less than in the regions most aected by the HBV disease, such
as the Far East or Tropical Africa. The risk of a French individual acquiring a
serious hepatitis B infection is about one in 50 million and as in the U.S., the
disease is cured without sequelae in approximately 95% of cases. Furthermore,
437Id. The rest of this section is based on the plaintis' complaint. Footnotes to this
complaint will no longer be cited.
158it is estimated that there are only four to ve deaths, seventy active chronic
hepatitis cases, twenty-ve cirrhosis cases and four liver cancers per year in
all of France from serious cases of HBV. Additionally, it is estimated that the
number of HBV related cases would be ten to fty times lower if cited statistics
focused on individuals for whom no risk factor prevails. Thus, as in the U.S.,
the risk of Hepatitis B in France is low for all and approaches a risk of \zero for
children."
DECISION TO PROMOTE THE MASS VACCINATION POLICY
IN FRANCE
Until 1994, the promulgation of the vaccine was targeted towards only those
at risk for contracting the virus. Based on the recommendations of the WHO,
Monsieur Douste { Blazy, the Minister of Health, launched a national vaccina-
tion campaign which propagated gures, claiming that there were 40,000 new
cases of HBV infection each year and 300,000 chronic carriers of the virus in
France. Similarly, Professor Jean-Francois Girard, Director General of Health,
declared that, \We are seeing a slight increase in the prevalence of hepatitis
B in France. This disease represents a major health problem." Plaintis in
the class action believe that these gures were unfounded. Ocial sources of
information in France, such as the Sentinel Network and the Courly Network,
indicated that the incidence of hepatitis B in France between 1990 and 1994 was
clearly abating. In charge of Sentinel Network, Dr. Antoine Flaugault stated in
1996 that \[t]he data do not reect a current increase in the incidence of acute
hepatitis B in the general population." Similarly, Professor Maurice Sepetjan
159of the Lyon-Nord Faculty of Medicine noted that, \[w]e observe a very clear
regression in cases of hepatitis B during the last 15 years."
Despite the especially low incidence of Hepatitis B in France and its appar-
ent decline in 1994, French health authorities, nevertheless, instituted massive
publicity campaigns to reinforce their recommendation that all newborns and
adolescents be vaccinated. For example, a national vaccination campaign was
launched in September of 1994, whereby reimbursement by social security was
oered. In 1995, adolescents and infants became the object of a recommen-
dation in the 1995 vaccination calendar drawn by the Vaccinations Technical
Committee of the Senior Council of Public Hygiene in France. This recommen-
dation was made despite the fact that only babies born to mothers with specic
antigens are at risk for developing the disease and that screening mothers in the
sixth month of pregnancy for specic hepatitis B antigens had been obligatory
since 1992. The plaintis in this lawsuit contend that these campaigns marked
\the passage from a policy of selective vaccination of individuals at risk to a
policy of mass vaccination" for those who were not.
The timing of the mass vaccination campaign was signicant in light of the seri-
ous side eects recorded years before the widespread vaccination call. In 1982,
the CDC, the FDA and Merck Sharp and Dohme had created a surveillance
committee for investigating possible side eects associated with the hepatitis B
vaccination schedule. They found forty-one recorded cases of neurological side
eects, of which nine were GBS and four myelitis, from a sample of 850,000 in-
dividuals vaccinated between June 1982 and May 1989. Additionally, believing
160that a case of acute myelitis could be causally linked to the vaccine, Presse Med-
icale reported in December of 1993 that \[t]he possibility of an antigenic cross-
reaction between the vaccine protein and a component of the nervous system has
been suspected, the immunity system conict becoming evident with repeated
antigenic provocation. This could explain the numerous cases of neurological
problems observed in unwell recipients of previous injections..." Moreover, a
team headed by Professor Lyon-Caen, neurologist at Pitie Salpetriere Hospital,
reported a dozen cases of multiple sclerosis or central nervous system demyeli-
nating reactions in young adult patients weeks after they were injected with the
vaccine. Consequently, Professors Lyon-Caen and other researchers explicitly
warned physicians in medical journals not to immunize anyone with the hepB
vaccine if they had MS or similar diseases. In a recent letter to patients, dated
Jan. 28, 1995, Dr. Pertuiset, of the American Hospital in Paris, also warned
that \[r]ecent observations have shown that in some cases there is a worrying
chronological relationship between hepatitis B vaccination and the eruption of
multiple sclerosis...." When questioned in April of 1996 about whether the
hepatitis B vaccine could cause possible neurological eects, Professor Autret
of the Tours University Hospital Centre responded, stating that \there is a suf-
cient temporal relationship for linking the advent of the demyelising attack
on the administration of vaccines." Other medical journals also documented
the possibility, if not likelihood, that the vaccine causes autoimmune diseases
and pointed to the surface antigen of the virus used in the vaccine as being im-
plicated. These warnings, contained in medical journals and similarly asserted
161by medical practitioners and researchers, strongly suggested that demyelinating
attacks, particularly auto-immune in nature, could be triggered in certain ge-
netically predisposed patients following their hepB vaccination. As a sample of
evidence pointing to a possibly dangerous specimen, further investigation into
and caution with respect to administering the hepB vaccine should have been
exercised.
PUBLIC CAMPAIGNS AND PROMULGATION OF THE
VACCINE IN FRANCE
The possible alarm signals familiar to public authorities and pharmaceutical
companies were left unheeded, or rather squelched by a perpetuating and an
overpowering series of public campaigns, rst initiated by Monsieur Philippe
Doute-Blazy, and continued by his two successors at the Ministry of Health,
which sirened the need for the country to be vaccinated against the HBV dis-
ease. As a means to spur French citizens into vaccinating themselves and their
children, much of the publicity went so far so as to fuel misleading beliefs among
the public. The pharmaceutical companies rst directed their campaign at easy
medical targets | mothers, individuals who would do anything for the safety
of their child. In persuading them to vaccinate their children, pharmaceutical
companies dramatized an increasing incidence of the hepB disease and made
erroneous statements as to its possible modes of transmission. In furtherance of
this eort, physicians were reminded of their powerful role in enforcing the gov-
ernment's recommendations, namely in their inuence over patients' decisions
to vaccinate themselves or their children. For instance, in 1995, the Minister
162of Works and Social Aairs, associated with Social Security and the French
Health Education Committee, spoke of \30,000 to 100,000 new cases" of HBV
and emphasized that \[I]f doctors are widely in favour of hepatitis B vaccina-
tion its introduction into the system will counter public reluctance, particularly
where adolescents are concerned. The purpose of the campaign is vaccination of
adolescents and of infants from two months of age." These calls to physicians,
though, need not have been heeded for the campaign to be eective. Publicity
promulgating the need that everyone be vaccinated against HBV ran rampantly
across the country. The importance of childhood vaccination was heard on nu-
merous television and radio shows and could have been read on the 200,000
posters plastered around the country, two million hand outs administered to
the general public or in instructive guides written for teachers and physicians.
In 1995, the French government spent fteen million francs publicizing the hepB
vaccination campaign.
In particular, one of the most misleading statements propagated by this publicity
campaign was that \hepatitis B is transmitted by saliva," a common miscon-
ception still heard in the U.S. today and which continues to play an inuential
role in the decisions of parents to vaccinate their children. This assertion, prop-
agated by inuential educational and health authorities, did and continues to
encourage the mass vaccination of children by invoking fear in the hearts of
parents that that their children can be infected through casual physical contact
with others. In 1993, the French Health Education Committee and the Ministry
of Health similarly fostered such ungrounded beliefs in asserting that \hepatitis
163B is transmitted though blood, sexual secretions, saliva... in fact, the virus is
present in all bodily uids of an infected individual." Similarly, the High Seine
General Council circulated a tract in 1994 and 1995, warning that \[h]epatitis B
can be contracted from saliva." This statement was broadcasted on Fun Radio
and the French Committee for Adolescents has eagerly promoted it. Moreover,
the leaets of vaccine manufacturers SmithKline Beecham (SKB) and Pasteur-
Merieux (P-M) stated that \saliva [w]as a major vector for transmission of the
virus." Knowing of the possible inuence a physician may have on mothers
decisions to vaccinate their children, SKB further warned in literature intended
for doctors that hepatitis B is transmitted by tears, sweat, saliva and mother's
milk.
It is surprising that health authorities and vaccine manufacturers continue to
assert that saliva is a vector for transmitting and spreading the disease, despite
strong evidence to the contrary. As early as 1995, a Guide to Vaccinations lim-
ited infective vectors to blood and sexual relations. In 1997, an INSERM report
indicated that if there was any virus in the saliva it was at a level 1,000 times
less than in the blood. Moreover, in 1998 Pasteur-Merieux and others admitted
that the disease cannot be transmitted by the transferal of saliva alone, without
skin abrasions or mucus. Furthermore, at a press conference on Jan.21,1998,
Monsieur Kouchner, current public health minister, publicly armed the long
held scientic belief that the hepatitis B virus is not transmitted through saliva.
In light of contrary scientic evidence, plaintis in the class action assert that
the government's aforementioned publicity disseminated misleading information
164into the public. Consequently, they demand that public health ocials and vac-
cine manufacturers be held responsible for ensuing vaccinations that resulted in
injury. Plainti's nd further support for culpability in the fact that Professor
Bader, in charge of publicity at the Drug Agency in France, has not yet inter-
vened to restate the facts. In creating a sense of obligation upon its citizens of
what was really only recommended, plaintis in the class action allege that such
publicity misguided its audience as to the necessity of vaccination and continues
to do a great disservice to the public health it is obliged to promote.
To further propagate the mass vaccination campaign, vaccine producers system-
atically misinformed practitioners and the public, alike, as to the undesirable re-
actions possibly caused or induced by the hepB vaccine. Vaccine manufacturers
shirked a duty owed to the public by strategically intensifying their vaccination
campaign while cowardly refusing to bring to the playing eld important and
relevant information needed by parents for the careful balancing and weighing
of factors comprising their decision to vaccinate themselves or their children.
For example, as early as 1995 and 1996, side eects arising from the SKB and
P-M vaccines were reported in the practitioner VIDAL, while no similar men-
tion was found in the family 1998 VIDAL. School vaccination programs have
also contributed to the public's ignorance with respect to the vaccine's safety
or potential to be a health hazard. School health ocials have failed to inform
parents as to possible side eects resulting from the vaccine's administration.
Moreover, French children are re-vaccinated every six years, without a follow-up
evaluation being performed upon them to determine whether such children may
165have responded adversely to the vaccine in the past. Furthermore, some teachers
who have taken the initiative to provide parents with details of secondary eects
possibly linked to the vaccine, perhaps so that they could look for them or make
a more informed decision, have been severely penalized. Ironically, despite the
potential for tremendous informational benets, these public campaign eorts
have attempted to keep parents uneducated, misinformed and in the dark.
As perhaps the only alternate source of reliable information, patients have en-
trusted the well-being of their children to the care of physicians, asking for
meaningful and reliable guidance and advice with respect to this vaccine. How-
ever, being themselves misguided or unaware of signicant facts, physicians have
only exacerbated and perpetuated the public ignorance which plagues much of
France. Despite noble intentions or as a result of ignorance, physicians may have
also unwittingly placed themselves at risk for liability, or possibly reproach, for
having endangered their patients lives. Until 1995, all the hepatitis B vaccines
were represented as being completely harmless. The physician's VIDAL only
mentioned the possibility of local reactions or of benign or short lived eects
caused by the vaccine. More importantly, pharmaceutical companies professed
a double standard by incongruously denying that risks could be caused by the
vaccine while advising physicians administering the vaccine to exercise great
caution. For example, on February 10, 1992, Dr. Marie Therese Nutini of In-
stitute Pasteur Vaccines responded to a physician who had inquired about the
correlation between ankylosing spondyarthritis and the hepatitis B vaccination,
stating that
166it is now admitted that stimulation of the immune system in any way cannot
give rise to an auto-immune malady but it can reveal it or provoke an eruption.
Here are the current recommendations in this type of pathology: contraindi-
cate living vaccine viruses as far as possible; administer only those vaccines
strictly necessary; after an eruption of the ailment wait a year/18 months be-
fore vaccinating. It is evident that: the risks/benets of the vaccination should
be carefully weighed; where it is possible check on existing antibody level may
permit reduced vaccination; post vaccination checks will enable the response to
the vaccine to be determined.
Despite the signicance and usefulness of such advice, only one
doctor was privileged with such information, after expressing con-
cern and explicitly seeking guidance. Many wonder why the same
was not sent to each practitioner to invite caution with respect to
administering the vaccine. Moreover, the Vidal, the medical refer-
ence lying in every competent doctor's right hand, failed to mention
any side eects for the Pasteur-Merieux vaccine until 1996. One can
infer from Dr. Nutini's statements made in 1992, as well as from
other evidence previously mentioned, that such adverse eects were
clearly known or at least suggested to by clinical trials or physician
reports before 1996. Similar to Dr. Nutini's response, Dr. Duterte
of Smith-Kline Beecham responded to a physician's letter on Jan.
24, 1997, acknowledging that \[m]ultiple Sclerosis is one of the rare
but possible undesirable eects of the hepatitis B vaccination men-
tioned in the VIDAL dictionary and in the instructions intended for
patients attached to the packaging." But again, no attempt was made
to publicize this information to all physicians administering the vac-
cine. This assertion is quite interesting, given that two months later,
167this same company published an advertisement, accompanying an ar-
ticle entitled, \ Doubt dispelled: vaccination programmes should be
maintained." Finally, in 1998, Dr. Hamelin, Medical Director at
Smith-Kline Beecham, did send a letter to all doctors, rather than
just one seeking guidance; however, this time to allay fears rather
than to urge caution. It read in part, \Neither in France nor in the
rest of the world has any causal link been shown between hepatitis-B
vaccination and the onset of demyelising diseases (multiple sclerosis
, etc...) or other auto-immune diseases." Pasteur-Merieux sent a
similar letter to all doctors as well. Contrary to what these compa-
nies have informed all physicians, doubts as to the vaccine's safety
persist, especially as scientic evidence mounts to rebut what was
distributed to dispel fears.
With the resurgence of \accidents" associated with the vaccine, the
French Medicines Agency has launched a pharmacological inquiry
into the possible undesirable eects attributed to the vaccine since
its advent to the health market. In its rst report on Dec. 15, 1994,
the Agency indicated that it found 241 cases of undesirable neurolog-
ical eects, approximately twenty-ve of which were of the multiple
sclerosis type. The National Pharmacovigilance Commission and the
Medicines Agency, however, declared that this degree of risk did not
exceed that which was expected to occur in the population studied.
The French League for Liberty in Vaccination, however, believes that
168this assertion is fallacious for the same reason similar studies con-
ducted in the U.S. have been rejected. This study had compared the
number of adverse reactions in non-vaccinated children over a fty-
two week span to children who had been vaccinated within a ve week
period, when problems associated with vaccination would probably
not yet have manifested. Despite the inadequacy of this study, Pro-
fessor Alexandre, director of the Medicines Agency, sent a letter in
November of 1995 to every doctor asserting the theoretical impossibil-
ity of zero risk for any vaccine or drug and that any stimulation of the
immune system necessarily entails the risk of inducing an eruption of
adverse eects, such as multiple sclerosis in vaccinated patients who
already have the disease. However, this letter failed to mention that
in a report devoted to neurological accidents associated with the hep-
atitis B vaccine, his own Medicines Agency admitted to \demyelising
attacks being capable of evoking a rst eruption of multiple sclerosis"
in individuals who did not suer from such attacks previously. Like
the Medicines Agency, the Department of the Director-General at
the Ministry of Health was also optimistic about the vaccine's safety;
on Dec. 13, 1996, it concluded that \[i]nvestigation of the neurologi-
cal eects notied does not allow any new scientic considerations to
be brought to bear on the causal link between the hepatitis B vacci-
nation and multiple sclerosis... In the present state of knowledge the
hepatitis-B vaccination remains of great importance and justies the
169continuance of vaccination programmes."
Several French public authorities have based their conclusions of non-
causality on results obtained from a compilation of voluntary notica-
tions made by practitioners to the French pharmacovigilance system,
a system much like the U.S. VAERS system, since the vaccine was
rst commercialized in 1994. Given public ignorance as to the hepB
vaccine's possible side eects and the aforementioned misleading pub-
licity campaigns, one would not expect many health professionals to
have made an association between the hepB vaccination and the onset
of certain symptoms so as to report them as following or being caused
by vaccination. Indeed, as in the U.S., reports actually made have
been thought to only scratch the surface, representing only 10% of
adverse events related to the vaccine. Many more reports are likely
to be uncovered and detected as reliable scientic information is dis-
seminated into the public, or at least among health practitioners.
Despite the abnegations by French health ocials as to the vaccine's
potential threat, several French authorities have recognized the lim-
ited and under-representative nature of this pharmacovigilance in-
quiry. As a consequence, some have concluded that it would be inap-
propriate to rely on physician reports of adverse events as evidence
of non-causality.
Following in this perspective, Monsieur Bernard Kouchner, current
Secretary of State at the Ministry of Health, underscored in Le Gen-
170eraliste Review on March 17, 1998, that \If the known gures do
not allow us to agree a relationship between the vaccination and the
nervous system problems, neither do they allow us to dismiss any
connection absolutely...if only because of our notications which are
voluntary, can never be regarded as exhaustive." As an example
of an opinion probably held widely among the scientic community,
the Medicines Agency urged the National Pharmacovigilance Com-
mission to modify the list of undesirable eects associated with and
the precautions to be used in the administration of all hepatitis B
vaccines. As a result, the Agency stated,
Exceptionally, cases of peripheral neuropathy, optic neuritis, or demyelising
attack on the central nervous system have been reported in the week following
vaccination, without causal link being established... In consequence, for those
with multiple sclerosis, where the serology shows absence of immuni[z]ation
against HBV, the benet of this vaccination should be evaluated in relation to
exposure to the virus and the risk of undesirable neurological eects.
Despite the implications of his own statement made one month earlier and
the admissions made by other health authorities, Monsieur Kouchner announced
that he would follow the advice of the Vaccinations Technical Committee and
not challenge the vaccination campaign for young children. The timing of this
pronouncement was interesting. At about the same time, the government had
set forth the law which would compensate health care personnel adversely af-
fected by the mandatory hepatitis B vaccine. By compensating individuals
for hepB vaccine injury, this law and Kouchner's initial statement implicitly
acknowledged that the vaccine could be responsible for the adverse eects re-
ported thereto. The signicance of this implication was shielded, however, by
171a more forceful proposition suggested by the law and reinforced by Kouchner's
later pronouncement that health is compensable, and thus, risk is justiable.
Notwithstanding the complications cited in the physician's VIDAL, implicitly
and sometimes expressly alluded to by the vaccine manufacturers' own state-
ments, neither the pharmaceutical companies nor public authorities halted the
marketing or administration of the vaccine. Such inaction is especially surpris-
ing in light of the suggestion that populations low at risk for contracting the
hepB virus could face a 300 times greater risk of suering from a vaccine induced
injury.
The scales of justice, on the other hand, are being implemented to carefully
balance the benets and risks of this vaccine. This system of mandating that
some use a product, while simultaneously attaching no liability for its conse-
quences has threateningly perpetuated what is already a grossly misinformed
or rather uninformed system. Vaccine manufacturers have attempted to usurp
the legal system to their advantage, as they have done with the public health
conscience. In wielding \gag orders" as a leverage tool in vaccine damage legal
settlements, vaccine manufacturers have attempted to prevent disclosure of in-
formation to the public about hepB vaccine health dangers. The Tribunals in
France, however, have taken a step in demonstrating that they, and the public
more broadly, will no longer allow pharmaceutical companies to maintain a cap-
tive market and be \immune" from accountability for the consequences of their
products. Some courts have already announced decisions recognizing the link
between hepB vaccination and the onset of pathology. For example, Nanterre
172TGI held on April 4, 1997 that Pasteur's vaccines were entirely responsible for
the plainti's ailments based on a medical certicate which read \Post- vacci-
nation Guillain-Barre Syndrome admitted for rehabilitation." In June of 1998,
a Nanterre court ruled that there was sucient evidence to conclude that the
Smith-Kline Beecham vaccine was associated with the manifestation of multi-
ple sclerosis in two vaccinated individuals. The British drug maker SmithKline
Beecham has appealed the ruling and a court order to pay roughly $23,000.
Another ruling is pending in a case against French vaccine manufacturer P-M.
Now, Kouchner has halted the mandatory law requiring that all children obtain
the vaccine. Instead of relying on the lack of conclusive scientic data in or-
der to dismiss causality, as many U.S. health authorities have done, Kouchner
asserts that \it cannot be excluded that the vaccination might reveal or facili-
tate" central nervous system problems.438 Despite the World Health Organiza-
tion's assurance of the vaccine's \outstanding record of safety and eciency,"439
Kouchner's decision represents a new cautious approach to public health policy,
consistent with an earlier statement he had made in 1998 as well as with the
belief espoused in this paper, namely that we must transform the presumptions
that underlie our public health infrastructure.
Perhaps Kouchner's regained faith in the art of strong possibilities was rekin-
dled and is fueled by powerful reminders of what other scandals had in store
for authorities similar to him in position. A former prime minister, Laurent
Fabius and two other ministers are to stand trial for their roles in the scandal
438Article obtained from the NVIC, titled France Suspends Hepatitis B Inoculations, supra
note 433.
439Id.
173that left more than 500 people dead, when health ocials knowingly provided
AIDS tainted blood products to hemophiliacs. In 1997, authorities began inves-
tigating the role other health ocials played in distributing potentially tainted
growth hormones that may have killed 40 children aicted with dwarsm in the
mid-1980s. Although Kouchner's new rened attitude seems to be a move in the
right direction, the WHO feared its ramications. In October of 1998, the WHO
expressed its concern that France's decision to halt the vaccine's obligatory ad-
ministration would undermine WHO's 100-country inoculation program as well
as the public condence in this vaccine. Moreover, WHO fears that France's
action, or rather the suggestion of causality which this country's rened view
fosters, would induce other countries to suspend or delay the vaccine's introduc-
tion into mandatory immunization schedules.440 As WHO feared, the French
are teaching America what the threat of liability can do against those who have
acted irresponsibly.
440Id.
174CLOSING
WHAT DO AMERICANS WANT AND WHAT CAN WE
EXPECT?
The fears of the World Health Organization are currently being realized in
the U.S.. The legal revolt against the hepB vaccine in France is empowering,
showing Americans what the dissemination of information can do to transform
the preconceived biases percolating through the layers of our public health in-
frastructure and potentially contaminating the validity of and attitudes towards
public health policy with respect to the safety of the hepB vaccine. Perhaps ig-
nited by the \restorm" of French lawsuits, the American public is making it
clear that they want the government to \know we will no longer blindly follow
their dictates. We will ask questions and use the legal system if we feel the need
to be heard."441
Interestingly, the rst boards of health consisted of volunteer citizen groups,
composed of ordinary people, much like the parents who are concerned and
expressing such views today. Immunization practice and essentially all public
health laws in the U.S. have their historic roots in the 18th and 19th centuries,
when unpredictable epidemics of highly contagious, dangerous diseases, such
as yellow fever, typhoid, and smallpox, swept through a city and caused high
441Leah Janzen, Parents Fight Needles, WINNIPEG NEWS, Nov.7, 1998, at A1-A2 ( ob-
tained from the NVIC) [hereinafter Janzen]
175mortality rates. Since port cities were hit especially hard when European immi-
grants disembarked from ships carrying smallpox into crowded cities, volunteer
citizen communities were formed to quarantine such boats until those disem-
barking were certied to be free from contagious and infectious diseases.442
At the turn of this century, the rst mandatory vaccination regime was enacted
to control small pox. Doctors usurped control over these citizen communities
and funding from taxes planted the seeds for what would soon grow to be a
massive public health infrastructure. It was not long before quarantine laws,
initially established to protect society from infected individuals, expanded to
include within their exclusive embrace citizens who were neither vaccinated or
infectious. In 1918, an Illinois court upheld the right of a local board of health
to exclude children from school for a period of two weeks during a smallpox
epidemic, unless they already had smallpox or had been vaccinated. In 1922, a
case involving the quarantine laws was brought before the Supreme Court. In
response, the Supreme court said,
while the powers given to health authorities are broad and far-reaching,
they are not without their limitations. As we have said, while the courts will
not pass upon the wisdom of the means adopted to restrict and suppress the
spread of contagious and infectious diseases, they will interfere if the regulations
are arbitrary and unreasonable. A person cannot be quarantined upon mere
suspicion that he may have a contagious and infectious disease but the health
authorities must have reliable information on which they have reasonable ground
to believe that the public health will be endangered by permitting the person to
be at large. Where danger of an epidemic actually exists, health and quarantine
regulations will always be sustained by the courts, but the health regulations are
all sustained on the law of necessity...Health authorities cannot promulgate and
enforce rules which merely have a tendency to prevent the spread of contagious
and infectious diseases, which are not founded upon an existing condition or
upon a well-founded belief that a condition is threatened which will endanger
442Fisher Statement, supra note 2.
176the public health (emphasis mine).
The signicance of this decision is further amplied by the disease context in
which it was professed. Hepatitis B is not like smallpox, a disease which could
be transmitted as easily as by breathing the air of one's neighbor. There are not
many young children or infants directly exchanging bodily uids in the U.S., as
is necessary to transmit the HBV disease. By mandating hepB vaccination as
a pre-requisite for school entrance, state ocials may be quarantining children
on the mere suspicion that such children have the hepB disease - a conjecture
that is highly suspect, unfounded and unreasonable. This disease is not highly
contagious in this age group and the U.S. is not facing an HBV epidemic, either.
Therefore, states are trying to promulgate and enforce rules that at most merely
have a tendency to prevent the spread of contagious and infectious diseases. Not
clearly grounded in necessity, this public health policy seems quite arbitrary and
unreasonable.
The promulgation of traditional public health measures, such as education cam-
paigns, may be more eective in protecting children from engaging in high risk
behaviors than is vaccinating young children who will probably need to be vac-
cinated again when their behavior could actually put them at risk for contract-
ing hepB. Moreover, improving methods of educating and screening pregnant
women, IV drug users and prostitutes for vaccination could more eectively
combat transmission among those really at risk, if that is our goal. If such ef-
forts have been ineectual in the past, care should be taken to alter strategies,
not target groups.
177One wonders why states have not mandated that every pregnant mother be
tested for hepatitis B upon delivering her baby. While the civil rights of these
women may be a concern, the civil rights of innocent babies who are not at risk
for contracting the disease must not be asked to yield in sanction. This paper
in no way denigrates programs attempting to reduce hepatitis B in populations
of high risk, both in the U.S. and abroad. Nor does it suggest that we abruptly
halt current vaccination programs in the U.S. However, it does ask that we
enliven, and resuscitate the sacred principles of informed consent and personal
choice, founding our Country's democracy and which have been cast aside, if
not relegated to the subterranean of our current public health landscape and
conscience. This request appears particularly reasonable in areas of the U.S. in
which the incidence of hepatitis B is very low and for population groups who are
not at risk for contracting or transmitting the disease. If our goal is to protect
the public health, especially against the transmission of the disease, we must
consider why we are subjecting millions of innocent newborns and children, not
signicantly endangered by the HBV disease, to a vaccine that may not only
not protect them, but may also actually kill or handicap them.
In the last decade, many parents have stood on the sidelines in silence,
helplessly and passively watching their children be victimized by what they think
their health care system, and specically the vaccine, induced. Out of necessity,
many parents became investigators overnight as they sought to understand why
their healthy child had needlessly become so sick. As their hope and faith
178in the government and political process deteriorates in this trying search, so
has the fortress which had once shielded their innermost voices and doubts
from outward expression. With this new found freedom, parents have rallied a
forceful cry against the only law in American \requiring a citizen to risk his life
for his country"443 since the repeal of the military draft in the 1970's. Unlike
the eighteen year old men who were required to risk their lives, these eight hour
or eight week old infants are incapable of voicing or formulating objections. So
America is speaking for them, asking for a choice in this decision.
Recently, hepatitis B vaccine victims have asked Congress for improved
health agency investigation and informed consent protections. In November
of 1998, parents concerned about the safety of the hepatitis B vaccine asked
a judge to shut down a voluntary program that would inoculate more than
18,000 Manitoba school children. Cynthia Devine, the attorney representing
this group of parents, said that she would ask the judge to \suspend the pro-
gram until more information about the situation in France can be distributed to
parents."444 Because the information provided to parents \didn't contain any
balanced scientic evidence," she requested that the court \declare the existing
forms null and void because they do not represent full and informed consent."445
Apparently similar to the materials used to promulgate the vaccine in France,
the consent form suggested that the program was obligatory rather than volun-
443NVIC, Opening Statement by Barbara Loe Fisher, Institute of Medicine Vaccine Safety
Forum, Workshop on Risk Communication and Vaccination. Statement obtained from the
NVIC.
444Janzen, supra note 442.
445Id.
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More recently, a national poll of 1000 registered voters, taken by the Polling
Company, revealed that two out of three (68%) Americans want the right to
make informed, voluntary decisions about whether to subject heir children to
hepB vaccination.446 A plurality of Americans (45%) oppose state laws requir-
ing that all ve year olds receive the hepB vaccine as a pre-requisite for ad-
mission into kindergarten. When given information about risks associated with
the hepatitis B vaccine, 59% of respondents were less likely to support manda-
tory vaccination laws. Moreover, only 25% of Americans believe that people,
after receiving information about the risks and benets of medical procedures,
including the administration of drugs or vaccines, should then be required to fol-
low the orders of their doctors or public health ocials.447 Barbara Fisher, of
the NVIC, powerfully captured the sentiment of contemporary public opinion;
in her statement to Congress last May, she asserted that \the lack of informed
consent protections in mass vaccination programs is leading to fear and mistrust
of the whole vaccination system. What we hear parents saying is: show us the
science and give us a choice."448 Indeed, Americans are demanding that they
be given the right to balance the lofty risks and benets of this vaccine and
ultimately decide which preventative health care protocols will govern the lives
of their children. Clearly, parents will no longer stand on the sidelines, entrust-
446NVIC Press Release, supra note 280.
447Id. Since the poll's margin of error was +/- 3.1% at the 95% condence level , the same
survey would probably lead to the same results if administered to a similar population in
roughly 19 out of 20 cases.
448Testimony of Barbara Loe Fisher, Hearing of the Criminal Justice, Drug Policy and
Human Resources Subcommittee of the House Government Reform, May 18, 1999 [hereinafter
Fisher's Testimony].
180ing this careful balance and the concomitant search for truth in the hands of
health ocials who have already decided the issue. By mandating that children
be vaccinated without conducting adequate safety studies prior to the vaccine's
administration, public health authorities have in eect forced parents to partic-
ipate in a potentially dangerous national experiment in which their children are
involuntary subjects.
The issue of personal choice is not only important for protecting the individual
liberties upon which our democracy was founded. In demanding choice and in
giving voice to the stories of their children, parents have taken the rst step in
transforming the issue of vaccine safety into a politically correct subject. By
creating a climate for the free exchange of knowledge and information, parents
are fostering public discussion about the vaccine's safety, instrumental for chal-
lenging the faulty presumptions which underlie our public health policies, retard
the advancement of science, and undermine the public's condence in a system
designed to protect them. As Barbara Fisher asserts,
If the universal a priori presumption continues to be that the children and
adults who have died or suered health problems following vaccination would
have died, been brain injured, or become immune compromised even if no viral
or bacterial antigen had been administered, then there will continue to be no
incentive for clinicians and public health ocials to spend any real time, money
or energy detecting and responding to reports of deaths and injuries following
vaccination. There will be no incentive for politicians to provide funding or
government executives to make it a budget priority. There will be no incentive
for researchers to commit the time and eort to conduct serious scientic in-
vestigations. There will be no answers because, it the name of disease control
through mandatory vaccination, the hard questions about vaccine safety will
be dismissed without serious examination. And we will continue to be bound
by chains of ignorance { an ignorance that may come with a price so stagger-
ing that it could literally eventually compromise the biological integrity of the
181human race.449
Without a human face and without a public voice, it is easy to dismiss
the role of science in public policy. As Barbara Fisher powerfully puts it,
when parents take the state mandated vaccine risk and it turns out that the
risk for their child is 100%, everyone has been carefully pre-conditioned to accept
the idea that the vaccine is not responsible. The doctor is not responsible. The
vaccine manufacturer is not responsible. The government is not responsible.
The genetically defective child is responsible.450
By challenging mandatory vaccination laws, parents are demonstrating their
unwillingness to accept this attribution of responsibility or the casualties of our
most precious resource. Beyond every vaccine adverse event statistic is a real
child with real parents, emboldened to express their concern.
Despite the noble eorts of some courageous parents, many are still waiting
to tell the public and health authorities of their story, which may provide the
necessary answers to the questions we have been long asking. While critical
to the advancement of science, their contribution will not propel its progres-
sion unless their voices are heard, and more importantly, respected. As Albert
Einstein once wrote,
The progress of science presupposes the possibility of unrestricted commu-
nication in all results and judgments|freedom of expression and instruction in
all realms of intellectual endeavor. By freedom I understand social conditions
of such a kind that the expression of opinions and assertions about general and
particular matters of knowledge will not involve dangers or serious disadvantages
for him who expresses them. This freedom of communication is indispensable
for the development and extension of scientic knowledge.451
449Opening Statement of Barbara Loe Fisher, Institute of Medicine Vaccine Safety Forum,
Workshop on Risk Communication and vaccination, May 13, 1996.
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182Thus, science will remain at a standstill if the views of parents, scientists
and organizations like the NVIC, are continually ignored and denigrated. The
potential for growth in scientic understanding will continue to be stunted when
parents who have contacted the NVIC are too traumatized by what has hap-
pened to their children or are too frightened by threats from state health and
welfare ocials to express their views. Some parents charged with child neglect
have been told that their children will be taken away if they do not comply with
the state mandated vaccine. In fear of public authorities, some physicians have
expressed their reluctance to report adverse events as a consequence of the hepB
vaccine or give a medical exemption for children they thought needed it. Some
patients have been forced to go forward with the hepatitis B vaccine, even after
they have experienced fevers, skin lesions, joint pain and other autoimmune and
neurological symptoms. Many of these individuals are members of a single fam-
ily.452 Given the likely genetic predisposition in patients suering from vaccine
adverse events, public health authorities may be demanding that parents not
only sacrice one, but multiple family members in this crusade against hep-
atitis B. Thus, in Einstein's words, the \expression of opinions and assertions
about general and particular matters of knowledge" regarding the public health
and this vaccine have become of the type which \involve dangers or serious
disadvantages for him who expresses them."453 In an eort to protect the pub-
lic health, many of the state mandated vaccine laws and the actions taken to
enforce them have actually disrespected the individual human life and the invi-
452Fisher Statement, supra note 2.
453Opening Statement of Barbara Loe Fisher, Institute of Medicine Vaccine Safety Forum,
Workshop on Risk Communication and vaccination, May 13, 1996.
183olable rights of parents to listen to their hearts and conscience in order to make
a valuable, rational voluntary decision. The essence of informed consent as it
is applied throughout American health policy is based on the ethical principle
that the person who must live with the consequences of a decision should make
it. This ethical tenet is especially signicant in this context, where parents will
be the ones who will have to bear the burden when their child becomes another
adversely aected vaccine statistic, sacriced for the purported public good.
Clearly, public health policy requires participation by the public. The public
would be more amenable to having their children vaccinated if more research on
risk factors had been and will be visibly performed. Thus, parents are asking
for more than that they be given the personal choice to balance the weights
which may decide the lives of their children. They are asking that they be given
the weights { that their consent be truly informed. The disclosure of necessary
information preceding a child's vaccination must not only include identifying
adverse events that might be causally associated with the hepB vaccine, but
also detecting any predisposition that children in particular families may have
that may heighten their risk for responding adversely to the vaccine. Even if
remote, the real risks of serious diseases that may attend vaccinations must be
scrupulously and comprehensively explained to the parents of such children.
This type of disclosure will require a fundamental transformation and renovation
of our public health policy system. Progress in scientic research will require a
concerted eort by public health ocials and the public, alike, to dismantle the
decrepit and faulty presumptions which constitute the foundation of our public
184health infrastructure. As indicated several times in this paper, \no conrmed
reactions" has become the unied, standard rhetoric given by governmental
and health ocials in response to assertions that the vaccine may cause adverse
reactions. Of course, there are no conrmed reactions; the kind of scientic
studies that could reveal the link have not yet been done. The studies have not
been conducted because the pleas of parents have been ignored, suppressed and
depreciated. The success of detecting adverse events rests on the willingness
of those to believe in the plausibility of nding a cause and eect relationship
because \[i]f you don't believe they occur or occur only rarely, you won't look
for them. If you don't look for them, you won't nd them."454 Thus, consonant
with Kouchner's new found attitude, it may be better \to prove the vaccine
did not play a role rather than to conveniently assume the vaccine did not play
a role."455 Moreover, causal relationships between vaccines and temporary or
permanent debilitating health problems will remain unsolved unless molecular
biologists and neuroimmunologists are given the chance and are encouraged to
precisely dene the biological mechanisms for responding to vaccinations. In-
adequate long-term studies and the failure of scientists to study genetic and
racial diversity among infants and children enrolled in vaccination schedules
only exacerbates the vacuum of knowledge clogging our understanding of these
mechanisms, as does the growing introduction of obligatory vaccines to an al-
ready crowded mandatory vaccination schedule.
454Opening Statement of Barbara Loe Fisher, Institute of Medicine Vaccine Safety Forum
Workshop on Detecting and Responding to Adverse Events Following Vaccination, Nov. 6,
1995.
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185As an ocial public health policy, results and implications drawn from future
studies must be appreciated for their signicant value. This building block will
require that we strip our nations' tenacious intellectual, bureaucratic and eco-
nomic commitment to vaccination as the only method for eradicating illness and
the media's propagation of fear used to enforce it. The renovation of our public
health edice will require improved education for medical students, physicians
and the public as to the possible risks associated with hepB vaccination as well
as of the importance of screening children with high risk factors for responding
adversely, monitoring children after vaccination and reporting related adverse
events to the government. Obviously, physicians cannot warn patients with what
they do not know. Few medical students have reason to question or right to
choose what information they are taught. This attitude is reinforced when they
begin their practice and have little time for continued education. In a sense,
physicians have become captive by a system, much like their patients, which
discourages them from independently acquiring information and forming their
own opinions. Only better educated physicians can properly advise patients and
their parents on how they can recognize and react to negative changes in their
children's physical, mental, and emotional health following hepB vaccination. If
causality continues to be erroneously determined by providers at the reporting
level, vaccine adverse events will never be detected or understood.
Improving reporting protocols for adverse events will not suciently treat the
malaise from which our public health policy suers. The information contained
within these reports must be adequately and appropriately evaluated for their
186potential signicance. A valuable database of vaccine adverse reported events
should be created to retrospectively evaluate common denominators among
cases reported. Such action would not only enable us to better identify high risk
children, but also point us in new directions for vaccine adverse event research,
particularly for the pathological proles of vaccine injury and death.456
Once reported and adequately studied, data obtained from adverse reports and
scientic research must be accepted, rather than readily dismissed for their
cause-eect potential by the leading architects supervising and advising the re-
construction and maintenance of our public health policy infrastructure. Such
top government and health care ocials must demonstrate a commitment to
making positive changes that will help vaccine injured children or rather pre-
vent future children from being injured. The failure of researchers, vaccine
manufacturers and health care ocials to communicate what medical science
does and does not know about vaccine risks has been perceived to be a funda-
mental betrayal of the public's trust, the pillars upon which our public health
system relies.
Therefore, if public health authorities begin to acknowledge what parents have
known for years in their hearts and which they are now expressing, parents
will work with, rather than against, public health ocials in remodeling and
repairing our public health policy infrastructure. Otherwise, the integrity of the
health system, which public health authorities have undeniably worked so hard
to build, will only further erode. While doctors and scientists may deny a causal
456Id.
187association, the mothers and fathers of our country will not, \[a]nd that simple
fact will continue to haunt the mass vaccination program until the basic science
research is done, credible vaccine safety evaluation systems are put in place,
and parents believe that physicians are acting as caring partners with them in
helping to prevent vaccine reactions."457 Thus, public health authorities can be
sure that organizations, like the NVIC, will enlist the help of parents of vaccine
damaged children, or those not wanting their children to become vaccine statis-
tics, in battling the politics of science. Americans have been placed in the dark
for too long and now refuse to follow blindly. They ask for a glimmer of hope
that the government is lighting the way in the search for scientic truth. If they
do not nd this spark, eorts to promulgate public health protocols will backre
as the public dares to start a holocaust of obstinence and revolt against public
health policy. Indeed, their bonre has already ignited a rampantly spreading
blaze.
457Statement by Barbara Loe Fisher, National Institutes of Health Pertussis Conference,
June 3-5, 1996, obtained from the NVIC.
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Amino acid: a class of organic molecules containing an amino group that
can combine in linear arrays to form proteins in living organisms. They are the
key components in all living organisms from which proteins are synthesized by
the formation of peptide bonds. There are also several important amino acids
that have no relation to proteins.
Anaphylaxis: a system or treatment that leads to damaging eects on
the organism. Now reserved for inammatory reactions and for what results
in acute allergic reactions marked by shortness of breath, rash, wheezing, and
hypotension.
Antibody: an immunoglobulin molecule that has a specic amino acid se-
quence by virtue of which it interacts only with the antigen that induced its
synthesis in cells of the lymphoid series ( especially plasma cells) or with anti-
gen closely related to it. They are classied according to their ode of action.
Antigens: substances which are capable, under appropriate conditions, of
inducing a specic immune response and of reacting with the products of that re-
sponse, that is, with specic antibodies, or specically sensitized T-lymphocytes,
or both. Antigens may be soluble substances, such as toxins and foreign pro-
teins, or particulates, such as bacteria and tissue cells; however, only the portion
of the protein or polysaccharide molecule known as the antigenic determinant
(epitope(s)) combines with antibody or a specic receptor on a lymphocyte.
Arthralgia: mild or severe pain in the joint(s).
Arthritis: inammation of a joint(s) with swelling, redness, stiness, ten-
derness, and pain, especially during movement. Chronic inammation of the
joints that occurs with chronic arthritis can eventually lead to crippling of the
body including fusion of the joints, deformed bones, compression of the spinal
cord, the inability to move and severe, constant pain.
Autoimmunity: a condition in which an individual's immune system reacts
against his or her own tissues.
Bell's Palsy: Facial paralysis which occurs suddenly and is thought to
involve swelling of the nerves. Although the precise cause is unknown, it is
thought to be caused by a viral infection or immune system problem. Symptoms
may begin with pain behind the ear followed by facial weakness and, within
hours, can lead to partial or complete facial paralysis. Complete recovery within
a few months occurs in many cases but some victims are left with permanent
nerve damage including partial paralysis.
Chronic hepatitis B: an inammatory disease of the liver caused by hep-
atitis B virus and lasting six months or more.
Chronic Fatigue Syndrome (CFS): a syndrome characterized by a wide
range of immune and neurological system dysfunction including profound, chronic
458For denitions of other terms, one can refer to the on-line medical dictionary, available at
<http://www.graylab.ac.uk/cgi-bin/omd?hepatitis+B>.
189fatigue that can be disabling; joint and muscle pain and weakness; vision, bal-
ance and physical coordination problems; severe, chronic headaches; gastroin-
testinal symptoms; heart palpitations; inability to concentrate; loss of memory;
deterioration of intellectual abilities; and personality changes. Some suerers
have abnormal immune system functioning or brain lesions. The cause of chronic
fatigue syndrome is unknown, although some scientists theorize that it is caused
by an infectious virus that attacks the immune system and the brain. The more
than 70,000 Gulf War veterans who are reported to be suering from \Gulf War
Syndrome" are exhibiting symptoms identical to CFS. It is known that Gulf
War veterans were given 17 dierent viral and bacterial vaccines, including ones
that were experimental, before being exposed to environmental toxins in the
Gulf.
Cirrhosis: sometimes used to refer to the chronic interstitial inammation
of any organ.
Dane particle: as the complete infective virion of hepatitis B, it is a 42nm
spherical particle, containing a 27nm core antigen.
Demyelination: The myelin that sheaths many nerve bers helps transmit
neural impulses. If the myelin sheath is damaged through traumatic injury,
metabolic disorders, toxic insult, viral or bacteria infection or vaccination, it can
cause degeneration or demyelination. Two well known demyelinating diseases
are multiple sclerosis and Guillain-Barre Syndrome. Demyelination is often
irreversible, leading to permanent brain dysfunction or death.
Fulminant hepatitis: a severe and rapidly progressive form of hepatitis B
accompanied by hepatocellular death and the signs and symptoms of hepatic
failure. May be a complication of hepatitis B, C or D.
Glycosylation: the process of adding sugar units, such as by adding proteins.
Guillain Barre Syndrome (GBS): a rapidly progressing form of polyneuropa-
thy that can be caused by infections, surgery or vaccination. It is thought to
be the most frequently acquired inammatory demyelinating neuropathy and
the weight of evidence suggests that most cases are immune mediated. GBS is
characterized by muscle weakness, numbness, pain and paralysis.
Hepatitis B:
a form of viral hepatitis, known as serum hepatitis, because it is commonly
spread through contact with infected blood products (transfusion). May also
be spread sexually or from mother to infant. Hepatitis B can cause much more
severe infection than Hepatitis A. Infection with can result in an asymptomatic
carrier state, a chronic infection or in the cirrhosis of the liver.
The virus is 42nm in diameter, with an outer sheath enclosing an inner 27nm
core particle, containing the circular viral DNA. Aggregates of the envelope
proteins are found in plasma and are referred to as hepatitis B surface antigen
(HBsAg).
Hepatitis B antibodies: antibodies to the hepatitis b antigens, including
antibodies to the surface and core of the dane particle and other antigens.
Hepatitis B antigens: antigens of the virion of the hepatitis b virus or
the dane particle, its surface, its core and other associated antigens.
Hepatitis B immunization: the hepatitis B (hepB) vaccine is used to oer
190protection against HBV infection, with 3 shots administered over the course of
a half year. In the U.S., all infants receive the hepB vaccine. Two vaccines are
available in the U.S. (engerix-b and recombivax-hb). The rst dose of hepB is
frequently given while the newborn is still in the hospital or when the infant rst
visits a doctor following birth. The second dose is given about 30 days after the
initial dose. A booster dose is performed approximately six months later. Babies
born to mothers testing positive for hepB receive hbig (hepB immune globulin),
in addition, for prompt protection. Older children (11-12 years) are advised
to receive a hepB booster, as are adults in high risk situations for contracting
HBV.
Hepatitis B surface antigen (HBsAg): a serologic marker on the surface
of the hepatitis B virus. The body will normally produce antibodies to the
surface antigen as part of the normal immune response to infection. It is the
presence of antibodies to the hepatitis B surface antigen that are detected in a
positive hepatitis B blood test.
Hepatitis B virus: The type species of the genus Orthohepadnavirus that
causes human hepatitis B and is also apparently a causal agent in human hep-
atocellular carcinoma. The dane particle is an intact hepatitis virion, named
after its discoverer. Non-infectious, spherical and tubular particles are also seen
in the serum.
Histocompatibility antigens: a group of antigens that includes both the
major and minor histocompatibility antigens. The former are genetically deter-
mined by the major histocompatibility complex.
Homologous: corresponding in structure, position, or origin, such as an
antigen and its specic antibody or the feathers of a bird.
Human leukocyte antigen: a genetic ngerprint on white blood cells and
platelets, composed of proteins, that play a critical role in activating the body's
immune system for responding to foreign organisms.
Immune system: the body system, made up of many organs and cells,
that defends the body against infection, disease and foreign substances. Usually
stimulated in specic ways.
Immunoglobulin: a specic protein substance that is produced by plasma
cells to aid in ghting infection. Some proteins take part in various immune
responses of the body to bacteria or foreign substances.
Immune complex: multimolecular antibody antigen complexes that may
be soluble or insoluble depending upon their size and whether or not comple-
ments are present.
Immunogenetics: a subeld of genetics that uses both genetic and
immunological analyses to study the genetics behind antibody forma-
tion and the immune response.
Inoculation: introduction of a material (usually a vaccine) into the tissues.
It is also used to refer to a mode of entry for bacteria into the body.
Jaundice: Yellowing of the skin (and the white of the eyes) by a bile pig-
ment. Frequently caused by a liver problem.
Lupus: An inammatory connective tissue disorder that occurs predomi-
nantly in young women, but also occurs in children. Its precise cause is unknown,
191but it is thought to be an autoimmune disorder. Symptoms include: fatigue,
nausea, weight loss, arthritis, skin and mucous membrane lesions, sensitivity to
light, headaches, epilepsy, lung, kidney and heart disorders.
Major Histocompatibility Complex (MHC): the set of gene loci spec-
ifying major histocompatibility antigens, for example, HLA in man.
Major histocompatibility antigen: a set of plasmalemmal glycoprotein
antigens involved in rapid graft rejection and other immune phenomena.
Molecular Mimicry: a process in which structural properties of an intro-
duced molecule imitate or stimulate molecules of the host.
Multiple Sclerosis (MS): a chronic demyelinating disease which is thought
to be immune mediated or caused by an infection, but a denitive cause remains
unknown. It is characterized by the breakdown of myelin and lesions throughout
the brain.
Myalgia: pain in a muscle or muscles.
Myelin: the material making up the sheath that surrounds the nerve axons
and by which transmission of signals throughout the body occurs.
Neuritis: inammation of a nerve or noninammatory lesions of the periph-
eral nervous system.
Neuropathy: Any functional disturbance or pathological change in the pe-
ripheral nervous system characterized by pain, weakness, and numbness, causing
loss of sensation, muscle weakness, atrophy( wasting/shrinking) and paralysis.
Optic Neuritis: characterized by a rapid loss of vision over hours or days
in one or both eyes caused by demyelination of the optic nerve bers.
Pathogenesis: The origin and development of disease.
Peptide: a compound of two or more amino acids.
Rheumatoid arthritis: Chronic inammatory disease in which there is
destruction of the joints. Considered by some to be an autoimmune disorder in
which immune complexes are formed in joints to excite inammatory response.
Sequelae: a condition following as a consequence of a disease.
Transverse Myelitis: This is a clinical syndrome characterized by a sudden
onset of signs of spinal cord disease and involves demyelination of the spinal cord.
It can be associated with multiple sclerosis. It has been associated with viral
infection, IV drug use and vaccination, but no denitive cause has been found.
Symptoms begin with sudden local back pain, followed over several days by
pain and weakness starting in the feet and moving upward. Bladder and bowel
dysfunction and partial paralysis often follow. There is no treatment and many
victims are left with signicant disabilities.
Virion: a single virus particle, complete with coat.
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